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Articular cartilage lesions cause pain, morbidity and may progress to osteoarthritis, 
which in terms of medical care, has been approximated to cost 1-2.5% of the gross 
national product of USA, UK, France and other countries. Current repair strategies 
have considerable limitations and have prompted the development of cartilage 
tissue engineering (CTE) approaches. One of the challenges of CTE is the expansion 
and differentiation of adult stem cells in vitro, into functional articular chondrocytes 
whilst avoiding hypertrophy.  Hypoxia is an important environmental factor required 
for cartilage development, for stimulating articular chondrogenesis and ECM 
formation. There remains, however, a number of questions regarding the in vitro role 
of hypoxia and HIF stabilization in the development of CTE strategies. These include: 
a) the appropriate level of hypoxia required for chondrogenesis, b) determining if 
artificial HIF stimulation has advantages over physiological hypoxia, c) which of the 
commonly-used HIF-stimulating compounds most potently induces HIF-mediated 
articular chondrogenesis and d) if there exists a relationship between 
mechanostransduction and HIF during chondrogenesis. Compared to normoxia, 
hypoxia (2%O2 and 5%O2) induced the expression HIF target genes (including VEGFA, 
PGK1 and EGLN) but only 5% inhibited hypertrophic collagen type X expression. 
Artificial stimulation of HIF-1a by DMOG induced greater expression of HIF 
chondrogenic targets (SOX9 and collagen-modifying enzymes) than other 
compounds used (CoCl2 and DFX) and physiological hypoxia. DMOG also reduced 
collagen type X at the mRNA level compared to the other HIF stabilising compounds. 
In terms of the effect of hypoxia on mechano-signalling during chondrogenesis, 
exposure to 2%O2 induced ROCK activity, actin re-organisation and SOX9 expression 
during BM-MSC chondrogenesis on soft polyacrylamide gels. No such changes were 
induced on stiff substrates. This suggests the existence of specific crosstalk between 
HIF and stiffness-sensing pathways, which may inform CTE strategies in which 
hypoxia-mediated chondrogenesis of BM-MSCs is conducted within biomaterial 
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Hydrochloric Acid (HCL) 
Double-Stranded DNA (dsDNA) 
Cadmium Chloride (CdCl2) 
Sodium Dodecyl Sulfate (SDS) 
Deionised Water (dH2O) 
Bicinchoninic Acid (BCA) 
Bovine Serum Albumin (BSA) 
Polyacrylamide Gel Electrophoresis (PAGE) 
Polyvinylidene difluoride (PVDF) 
Non-fat milk (NFM) 
Molecular Weight (MW) 
Moloney Murine Leukemia Virus Reverse Transcriptase (MLV-RT) 
Polymerase Chain Reaction (PCR) 
Quantitative Polymerase Chain Reaction (qPCR) 
Nation Centre for Biotechnology Information (NCBI) 
4',6-diamidino-2-phenylindole (DAPI) 
Poly(ɛ-Caprolactone) (PE) 
Phosphoglycerate Kinase (PGK1)    
Gremlin1 (GREM1)  
Dickkopf WNT Signalling Pathway Inhibitor 1 (DKK1) 
Reactive Oxygen Species (ROS) 
Insulin growth factor II (IGF2) 
Mitogen Inducible Gene 6 (MIG6) 
Inhibin Beta A Subunit (INHBA) 
Enzyme-Linked Immunosorbent Assays (ELISAs) 
Mitogen-Activated Protein Kinase (MAPK) 
Mitogen-Activated Protein Kinase Kinase (MEK) 
Extracellular Signal-Regulated Kinase (ERK) 
Activator protein 1 (AP-1) 
Unfolded Protein Response (UPR) 
N-Oxalyl-(d)-Phenylalanine (NOFD) 
Distal-less Homeobox 5/6 (Dlx5/6) 
Traction Force Microscopy (TFM) 
N-Oxaloylglycine (NOG) 







1.1. Articular Cartilage 
1.1.1. Structure & Function 
Articular or hyaline cartilage overlies the subchondral bone within articulating joints. 
It is an Extracellular Matrix (ECM)-rich tissue consisting of distinct regions from the 
articulating surface down to the underlying calcified bone, which vary in structural 
organisation, as shown in figure 1.1. Despite this heterogeneity, the constituents of 
each region are a mixture of collagens, glycosaminoglycans (GAGs), water, and a 
specialised cell type- the articular chondrocyte. These cells constitute only 
approximately 1-5% by volume of the whole tissue [2], have a low metabolic activity 
and are responsible for synthesis of cartilage ECM [3].  
The primary functions of articular cartilage are to reduce friction between opposing 
surfaces of the joint, providing resistance to the compressive and tensile forces on 
the joint during movement, and protecting the underlying subchondral bone from 
compression-induced damage [2]. The superficial layer, proximal to the synovial fluid, 
functions as an impermeable barrier for protection of the remainder of the tissue 
and enables resistance to tensile forces experienced during limb movement [4].  It 
consists of tightly arranged network of Collagen Type II and IX fibrils, parallel with the 
articulating surface of the joint, together with chondrocytes of a high aspect ratio [5, 
6]. The middle zone contains collagen fibrils of obliquely-arranged orientation, in 
addition to proteoglycans and a sparse arrangement of rounded chondrocytes. This 
region grants the articular cartilage its resistance to compressive forces. It functions 




perpendicularly to the articulating surface and the highest concentration of 
proteoglycans [3].  
Hyaline cartilage is present on the articulating surface of all diarthroidal joints, 
including the knee, hip and ankle. Despite articular cartilage being largely similar in 
composition and function between the different joints in which it is present, distinct 
differences have been identified. These are thought to be due to the varying degree 
of compressional force which each of these joints encounter. Shepherd and Seedhom 
made observations on the differences in cartilage thickness between different joint 
types and found that of the knee to be greater than that of the ankle or hip [7]. 
Moreover, this thickness appeared to correlate with the size, height and body mass 
index of the donor, with an inverse relationship identified between thickness and the 
compressive forces experienced by the joint.  
Interestingly, the susceptibility to degradation also varied between joints. Upon 
dissection from human joints, chondrocytes within the knee were found to be more 
susceptible to catabolic factors than those in the ankle, which displayed an increased 
rate of a production of GAGs required for repair [8]. This observation was similar to 
that described by Eger et al who, in explant models, demonstrated the increased 
resistance to degeneration of articular cartilage within the ankle compared to that of 
the knee [9]. It may be hypothesized that the increased load bearing on the articular 
cartilage within the knee, increases its susceptibility to degeneration. The increased 
thickness of the articular cartilage within this joint may also result in reduced 






Figure 1.1. Osteochondral Tissue Structure. A: The gross structure of an articulating 





1.1.2. The components of articular cartilage  
 
1.1.2.1. Articular chondrocytes 
 
 The low metabolic rate of the chondrocyte population within articular cartilage is a 
result of a lack of vasculature and subsequent low nutrient supply [10]. This is in part 
due to regression of vasculature at the limb bud stage of limb development [11] but 
also is due to expression of anti-angiogenic protein expression by articular 
chondrocytes [12]. Proteins such as Chondromodulin-1 inhibit endothelial cell 
growth, thereby inhibiting vessel formation [13]. If left unhindered, angiogenesis is 
inhibitory to articular chondrocyte function and is a driver of cartilage degeneration 
in osteoarthritis (OA) [14, 15]. The development of an essential anti-angiogenic 
milleu by articular chondrocytes implies that this cell population functions most 
optimally in a low metabolic state. Corresponding to their low metabolic rate, 
articular chondrocytes generate a required level of Adenosine Tri-Phosphate (ATP) 
via glycolytic pathways (Lane, 2015 #1384).  
Another advantage of the slow-metabolism and proliferation of chondrocytes is with 
regards to the stabilisation of articular cartilage ECM. The articular chondrocytes 
generally do not proliferate and remain in the ECM for a long period of time [10]. It 
is this aspect which enables them to maintain the ECM of the articular cartilage over 
the majority of an individual’s lifetime. The half-life of collagen type II is estimated to 
be 117 years [16] with proteoglycans described to reside in the ECM for 3-24 years 
[17].  
Whilst such an ECM turnover rate is benefical for maintance of articular cartilage 




movement [3, 18], it also provides a stable extracellular environment for the articular 
chondrocytes. For example, interactions with Collagen Type II is thought to inhibit 
apoptosis of articular chondrocytes via Annexin V [19]. However, despite these 
advantages of the slow turnover of articular chondrocytes and the ECM in which they 
reside, repair or acute chondral defects is a major issue as described in later sections 
of this chapter. Relatively low rates of both chondrocyte proliferation and secretion 
of new ECM components are inhibitory to endogenous repair of lesions which exceed 
the superficial layer of articular cartilage [20].  
 
1.1.2.2. The extracellular components of articular cartilage 
 
Water constitutes a large proportion of the wet weight of articular cartilage, 
approximately 80% in the superficial and 65% of the deep zone composed of water 
[2]. It functions to maintain a flow of nutrients to the residing chondrocytes and is 
integral in order for the ECM to maintain the compressive resistance of the tissue to 
external forces [3]. It is also essential in lubricating the articular surface and inhibiting 
friction between opposing bones. The other major constituents, Collagen and 
proteoglycans, each contributing to approximately 10-20% of the total cartilage wet 
weight.   
 
1.1.2.2.1. Collagen Type II 
The major collagen subtype in articular cartilage is Type II Collagen. Its synthesis by 
articular chondrocytes begins at transcription of the COL2A1 gene, which encodes 




(mRNA) molecule is then processed and spliced to generate the protein-coding 
mRNA. Two variants of mature COL2A1 mRNA have been identified and are classified 
based on the inclusion of exon 2 or not, with their differential expression 
hypothesized to alter Collagen Type II bio-synthesis [22]. Interestingly, each of these 
mRNA isoforms have also been shown to mark distinct chondrocyte populations, 
with mature chondrocytes and chondroprogenitors shown to express differential 
levels of the exon 2-containing and exon 2–free forms [23]. Inactivation of a single 
allele of COL2A1 in developing mice results in a decrease in Collagen Type II protein 
in the ECM of the cartilage overlying the humerus head [24]. A decrease in the 
formation of ordered, parallel fibrils was also observed with a softer cartilage being 
generated as a whole. Complete deletion of COL2A1 resulted in ECM disorganization 
of the developing mouse limb which resembled that observed in cases of OA. The 
importance of COL2A1 gene transcription for cartilage function was also highlighted 
by Tiller et al who identified the cause of a large spectrum of chondrodysplasias. The 
phenotypes observed were due to dominant mutations within the COL2A1 gene 
which increases the susceptibility of articular cartilage to degradation [21].  
The tertiary protein structure of Collagen Type II in cartilage ECM consists of a triple 
helix of alpha 1 collagen chains [25]. As described by Bruckner and Van der Rest [25], 
Collagen Type II is secreted as a pro-collagen molecule, linked to both its C- and N-
terminal ends by short sequences known as telopeptides. The C-terminal is important 
in determining the organisation of each pro-collagen chain and their association with 
other monomers. Simultaneous with integration into a triple helical arrangement, 
the N and C-terminal ends of the pro-collagen chain are degraded by specific 




modification during their incorporation into the ECM. Proline hydroxylation of the 
pro-collagen molecules is required for their assembly in triple helix structures [26] 
whereas lysine hydroxylation is required for the complete stability of the 
supramolecular structures formed from multiple triple-helices [27].  
Spatial organization of Collagen Type II fibrils as described by Fox et al [3], is 
dependent on the region of articular cartilage in which they reside. The superficial 
zone is composed of fibrils which are arranged in a parallel manner relative to the 
articular surface. Towards the subchondral bone of the joint, the collagen fibrils are 
arranged in arranged in progressively perpendicular orientation through the middle 
region to the deep region. To examine the organisation of collagen fibrils via a non-
invasive method, Bergholt et al utilized a technique known as Raman Spectroscopy. 
During Raman Spectroscopy, differential scattering of donor monochromatic light 
occurs due to differentially-arranged collagen fibrils which enable resolution of the 
supramolecular structure of this ECM component. Bergholt et al confirmed the 
observations made by histological methods. They observed the collagen fibrils adopt 
a parallel, oblique and perpendicular arrangement relative to the articulating surface 
in the superficial, middle and deep zones respectively [28].  
In terms of function, Collagen Type II forms a backbone for Collagen Types IX and XI 
[29] and together, these fibrillary structures function to maintain the integrity of 
cartilage in response to shear and tensile stresses.  The Collagen Type II proximally-
located to the articular chondrocytes are also integral in maintaining the viability of 
these cells. [30]. Kim and Kirsch identified a role for cartilage collagens in inhibiting 




matrix [19]. This was observed to occur via an interaction of collagen type II with cell-
surface marker- Annexin V. The interaction of Collagen Type II and Type XI also 
stabilizes the GAG network which is required for the maintenance of the mechanical 
characteristics of the cartilage ECM [18]. Collagen Type II also plays an indirect role 
in the reduction of friction between opposing articular surfaces. This function of 
Collagen Type II is mediated by Lubricin [31] which is secreted by articular 
chondrocytes in the superficial layer and also acts to inhibit chondrocyte apoptosis 
[32]. 
1.1.2.2.2. Aggrecan 
Articular cartilage contains multiple proteoglycans, and Aggrecan is the most 
abundant of these. Mutations in the gene encoding its protein core, ACAN [33] results 
in phenotypic outcomes which are grouped together into the Aggrecanopathies. For 
example a mutation within the ACAN gene has been shown to predispose patients to 
Osteochondritis Dissecans which in juvenile patients, increases the rate of 
subchondral bone lesions [34]. In the ECM, the core protein region of Aggrecan 
consists of 3 globular regions- G1, G2 and G3 [35]. The first of these functions to 
tether Aggrecan to another major cartilage ECM, Hyaluronic Acid (HA). Between each 
of globular domains is the inter-globular domain, to which are attached the 
carbohydrate portion of the proteoglycans – the GAGs, which are classified into 
chondroitin and keratin sulphates [35]. Aggrecan does not form isolated structures 
in the ECM of cartilage but rather, multiple Aggrecan molecules via the G1 domains 




HA is synthesized at the membrane region of cells by HA Synthase [35]. Following 
production, it is then secreted in the extra-cellular space and forms a coat around 
the cell where it complexes with Aggrecan molecules. This complex is formed via a 
link protein which has also plays a role in the protection of HA from HAase-mediated 
digestion. The chemical structure and ionic charge of the HA-Aggrecan complex 
enables the cartilage matrix to absorb water and swell in size accordingly [35]. The 
presence of large amounts of Aggrecan in the chondrocyte extracellular space 
increases the amount of water retained in the matrix. This results an equilibrium 
being attained between the swelling of the ECM structure and the tensional force 
created by the ability of the Collagen Fibrils to resist this swelling. The HA-Aggrecan 
complex therefore enables cartilage to maintain the viscoelastic nature of cartilage 
and provide resistance to compressive forces on the joint [35]. This equilibrium 
between the Aggrecan-induced swelling and Collagen-induced tension, also 
maintains the resistance of cartilage to fluid flow-induced deformation [36]. 
 
1.1.3. Development 
During development, articular cartilage is formed during endochondral ossification, 
a process required for formation of the appendicular skeleton [37]. The initial stage 
of limb development is the formation of a condensed population of mesenchymal 
precursors, which go on to form the initial cartilaginous anlage required for bone 
formation. Following chondrogenesis of the limb bud mesenchyme, vascular 
infiltration from the perichondrium is the signal for formation of the primary 




newly formed chondrocytes occurs, resulting in their cell death, remodeling of the 
cartilage matrix and differentiation of invading osteoblast precursors. Synchronous 
with this process is the preservation of a population of resting chondrocytes within 
the growth plate, whose phenotype are maintained and go on to form the articular 
cartilage. 
 
1.1.3.1. Limb bud specification 
At the onset of limb mesenchyme formation, the family of Hox transcription factors 
expressed in the lateral plate mesoderm [39] stimulate expression of T-Box 5/4 
(TBX5/4) [40, 41] which via Fibroblast Growth Factor (FGF) 10, stimulate subsequent 
expression of FGF8 in the Apical Ectodermal Ridge (AER) [42], a thickened epithelial 
layer at the distal tip of the prospective limb bud. This process specifies the hind- and 
forelimbs, with FGF8 initiating and propagating the proximal to distal growth of the 
pre-cartilage mesenchymal population [43]. Another signalling centre, the zone of 
polarizing activity [44] functions to specify digit formation along the anterior to 
posterior axis via Sonic Hedgehog (Shh) signalling [45]. Finally, a 3rd signalling centre- 
the non-AER limb bud ectoderm, functions to generate the dorsal to ventral polarity 
of the mesenchymal condensation, via Wnt7a and Bone Morphogenetic Protein 
(BMP) signalling [46].  
The importance of FGF signalling in limb bud formation was shown by studies such 
as that by Moon et al, who observed skeletal deformation due to a conditional 
knockdown of FGF8 in forelimb progenitor cells in addition to downregulation of SHH 




patterns of mesenchymal condensation occurs within the limb bud. These regions 
are delineated by expression of transcription factors such as Paired-Related 
Homeobox 1 (PRX1) and Msh Homeobox 1 (MSX1), required for early induction of 
chondrogenesis [48, 49].  
 
1.1.3.2. Chondrogenic commitment of limb bud progenitors 
Following formation of the limb bud, the resident mesenchymal population 
undergoes chondrogenic differentiation and further division into two sub-
populations [50].  One of these populations goes through a proliferative phase, 
followed by senescence, hypertrophic differentiation and apoptosis, prior to 
endochondral ossification. The second population enters a resting state and 
constitute the articular cartilage at the end of long bones.  
Between the mesenchymal and proliferative/articular chondrocyte stage, the 
differentiating cells go through an osteochondral progenitor phase in which the 
transcription factors SOX9 and Runt-Related Transcription Factor 2 (RUNX2) are both 
expressed [51], and play key roles in switching the cell fate between that of a 
chondrocyte or osteoblast. SOX9 has been shown to inhibit the osteoblastic factor, 
RUNX2 [52] as well as chondrocyte hypertrophy [53], and is indispensable during 
chondrogenesis, as it functions with SRY Box-5 (SOX5) SRY Box-6 (SOX6) as a 
transcription factor complex [54], inducing transcription of genes required for 
cartilage formation such as COL2A1 [55] and ACAN [56]. In addition to this complex, 
other transcription factors are a requirement during chondrogenesis including Paired 




from the limb bud stage throughout articular cartilage patterning [57] and are 
required for chondroprogenitor specification [58]. Other factors include Nkx3.1/3.2 
which are required throughout chondrogenesis, playing roles in chondro-
specification [59] and chondrocyte hypertrophy [60].  
 
1.1.3.2.1. Role of cell-cell adhesion 
The condensation of mesenchymal populations is deemed a pre-requisite for 
cartilage development. Accordingly the temporal expression and activity of cell-cell 
adhesion molecules such as Neural Cell Adhesion Molecule (NCAM) and N-cadherin 
have been shown to be indispensable during chondrogenesis [61] with their 
expression reduced following chondrocyte formation [62]. In hMSCs, N-cadherin-
mediated cell-cell adhesion has been shown to enhance membrane localization of β-
catenin [63], the transcriptional co-activator at the bottom of the canonical Wnt 
signalling pathway [64]. β-catenin has been shown to be detrimental to 
mesenchymal progenitor chondrogenesis [65], as well as inducing a bias towards 
osteoblastic differentiation and bone formation [66]. Cell-cell contact and N-
Cadherin binding is therefore integral in minimizing Wnt-induced suppression of 
chondrogenesis, a function also mirrored by SOX9 [67]. In addition, BMP-induced 
chondrogenesis was also shown to be inhibited upon blocking of N-Cadherin [68] and 
was also shown to reduce Transforming Growth Factor-Beta (TGF-β)-mediated 
chondrogenic differentiation [69]. These studies demonstrate the requirement of cell 





1.1.3.2.2. Role of the TGF-β family of growth factors 
A host of growth factor ligand-receptor bindings are required during cartilage 
development. The TGF-β family of ligands and receptors play an important role in 
this process, demonstrated by the deletion of BMP receptors or overexpression of 
BMP inhibitor, Noggin which both result in reduced chondrogenesis [70, 71]. 
Chondrocyte-specific BMP2 knockdown also reduces proliferation and survival of this 
cell population in the growth plate [72] as well as inhibiting bone regeneration in a 
murine fracture model [73]. TGF-β ligands, expressed highly in the mesenchyme and 
cartilaginous elements, have been shown to enhance initial mesenchyme 
condensation [74], chondrogenic lineage commitment [75] and arrest chondrocyte 
hypertrophy [76]. Both BMP and TGFβ ligands exert their effect on cartilage 
development via the SMAD family of proteins, which transduce the signal generated 
upon engagement of BMP/TGFβ receptors into transcriptional changes. TGF-βs bind 
the TGF receptor types 1 and 2 induce activation of SMAD2/3 and binding by SMAD4 
before their translocation to the nucleus and transcription of specific target genes. 
For example nuclear SMAD2/3 enhances SOX9-dependent transcription of 
chondrogenic genes such as COL2A1 [77]. Upon binding of a different set of receptors 
by BMPs, SMAD1/5/8 phosphorylation and activity have been shown to be essential 
in induction of chondrogenic phenotype from MSCs [78] in addition to cartilage and 
endochondral bone development [79]. 
 




Following chondrogenesis and formation of the cartilage growth plate from the 
mesenchymal limb bud, the chondrocytes then undergo a complex program of 
events to pattern the formation of mineralised bone and articular cartilage of the 
limb. From the terminal regions of the prospective long bone, along the longitudinal 
axis, chondrocytes form distinct groups, each of varying proliferative rates and 
phenotype. The end of the cartilage template consists of resting chondrocytes. These 
express genes such as SOX9, SOX5, SOX6 [80] and GDF5 [81] in a specific temporal 
program, creating an ECM rich in Collagen Type II, and XI and Aggrecan [82]. These 
articular chondrocytes also express PRG4 [83]. This encodes Lubricin which as 
described, is important in joint articulation.  
Further along the developing bone are a group of highly proliferative chondrocytes, 
the turnover of which is required for longitudinal bone growth. Further along still, 
towards the centre of the growth plate are a group of chondrocytes which have left 
the cell cycle and have begun to de-differentiate into hypertrophic chondrocytes. 
Following their completion of hypertrophy, these chondrocytes, which exhibit an 
enlarged morphology, express RUNX2 and COL10A1 [84] and secrete a Collagen Type 
X-rich ECM [85].  
The ECM surrounding hypertrophic chondrocytes is also marked by degradation of 
Collagen Type II and Aggrecan. Matrix Metalloproteinase 13 (MMP13) has been 
shown to largely govern Collagen Type II degradation prior to the onset of 
endochondral ossification [86] with Aggrecanases such as Adamts5 [87] digesting 
Aggrecan in the growth plate. The lack of a proteoglycan and Collagen Type II-rich 




hypertrophic cartilage with compared to that at the articulating surface. This is due 
to a lack of water perfusion of hypertrophic cartilage and a subsequent decrease in 
resistance to compressive forces. This was demonstrated by Sibole and Herzog who 
observed the increased deformation of hypertrophic cartilage compared to articular 
cartilage in response to a compression force on the tissue [88].Following remodeling 
of the growth plate ECM, apoptosis of the hypertrophic chondrocytes occurs [89] 
followed by osteoblastic invasion and mineralisation of the vacant space [90]. 
 
1.1.3.3.1. Control of articular cartilage patterning by Indian Hedgehog Signalling 
Indian Hedgehog (Ihh) signalling is considered the master regulator of chondrocyte 
de-differentiation during limb development. The Ihh ligand produced by pre-
hypertrophic and hypertrophic chondrocytes [91], diffuses along the longitudinal axis 
of the developing limb, to the pool of proliferative chondrocytes where it binds to 
Patch1 receptors [92]. This results in inhibition of another transmembrane protein, 
Smoothened, enabling nuclear translocation of the Gli family of transcription factors. 
This induces expression and secretion of Parathyroid Hormone Related Peptide 
(PTHrP) which upon binding to Parathyroid Hormone receptors (PTH) on neighboring 
pre-hypertrophic and immature chondrocytes, stimulates their proliferation and 
reduces hypertrophy [93].  
Chondrocytes further away from the PTHrP-producing proliferative chondrocytes, 
undergo hypertrophic differentiation due to a lack of PTHrP-PTH binding. Upon 
entering the post-mitotic hypertrophic phase these cells in turn, secrete Ihh in a 




hypertrophic role of the Sox9/5/6 complex has been shown to function through this 
IHH-PTHRP signalling loop, inducing expression of IHH/PTHRP components required 
for regulation of chondrocyte phenotype [94]. This system enables controlled rates 
of chondrocyte proliferation and de-differentiation, required for endochondral bone 
development [95].  
 
1.1.3.3.2. Control of articular cartilage patterning by Wnt signalling 
Another pathway heavily implicated in the progression of chondrocyte hypertrophy 
is the Wnt signalling pathway. The canonical Wnt pathway acts via the transcriptional 
co-activator, β-catenin. Upon binding of Frizzled receptor [96] by a canonical Wnt 
ligand, a protein complex composed of Axin, Glycogen Synthase Kinase, β-catenin 
and others is dissociated, resulting in nuclear translocation of β-catenin [97]. β-
catenin then binds to the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of 
transcription factors, resulting in transcription of target genes associated with 
canonical Wnt signalling [98].  
As with other pro-hypertrophy signals, the source of Wnt ligands during 
endochondral ossification is the surrounding perichondrium [99], with the 
hypertrophic effect of these mediated through RUNX2-dependant mechanisms 
[100]. Conversely, one of the anti-hypertrophic mechanisms of SOX9 is through 
inhibition of β-catenin-TCF/LEF [67(Topol, 2009 #217], implicating canonical Wnt 
signalling as an antagonizing mechanism to Sox9-mediated chondrogenesis. Wnt 
signalling also drives the key fate switch of mesenchymal limb bud progenitors, 




chondrogenesis [66]. Finally, antagonists of canonical Wnt signalling such as those 
which block Wnt-Frizzled binding have a protective role in OA, preventing de-
differentiation of articular chondrocytes [101]. 
 
1.2. Cartilage Regenerative Medicine 
Acute trauma/stress-related injury to the diathroidal joint may result in damage to 
the residing articular cartilage [102]. As described by Rai et al, compared to highly 
vascularized subchondral bone, articular cartilage has a reduced ability to repair itself 
following the occurrence of lesions which penetrate further than the superficial layer 
[103]. The articular cartilage is avascular as a result of regression of the blood vessels 
at the limb bud stage of development and this is coupled with formation of a vascular 
network at the primary and secondary ossifications centres [104]. The lack of vascular 
system in the articular cartilage reduces the delivery of nutrients and cells required 
for cartilage repair. Damage to articular cartilage may result in patient pain, 
immobility and constitute a large percentage of injury-cases of the diarthoidal knee 
joint. In a study conducted from 1989-2004, from 25,124 arthroscopies conducted 
due to various knee joint complications, 67% were deemed to have suffered chondral 
or osteochondral fractures, with 36% of these lesions measuring over the self-repair 
threshold in terms of defect size [105].  
In addition to symptoms of pain and reduced locomotive ability, chondral lesions may 
result in damage and remodeling to the surrounding tissue due to abnormal 
transmission of compressive forces on the joint during movement [106]. This has 




osteoarthritis if left untreated [108, 109]. The incidence rates of OA are extremely 
high, with occurrence in 19.2%-27.8% of the US population aged ≥45, and 37% of 
people aged ≥60. The management of OA also represents a significant economic 
burden on healthcare systems. As described by Hunter et al – ‘the cost of OA in the 
USA, Canada, UK, France and Australia has been estimated to account for between 
1% and 2.5% of the gross national product of these countries’ [110].  
 
1.2.1. Current reparative & restorative strategies for cartilage repair 
The pain, immobility, and potential progression to OA, emphasises the requirement 
for immediate repair of acute chondral defects. Current clinical strategies for repair 
of these defects have been deemed unsuitable for a number of reasons [111]. 
Autologous/allogeneic transplantation is not a suitable measure for acute lesions due 
to the risk of disease transmission/immune rejection, the requirement of multiple 
surgical procedures, donor site morbidity and low tissue availability [112]. 
Subchondral drilling or microfracture [113] enables access of the lesion to the 
endogenous source of mesenchymal stem cells within the bone marrow. This 
technique shows some clinical success, but in younger patients only [114]. In some 
cases following microfracture, the defect site is occupied with tissue that resembles 
fibrocartilage [115]. This is mechanically-inferior to articular cartilage, degenerates 
in the long-term [114] and as a result, may predispose the patient to OA [116].  
An improvement on microfracture [117] is Autologous Chondrocyte Implantation 
(ACI) [118] which works under the principle of implanting isolated and expanded 




requires multiple surgeries however, to harvest autologous cells and for the 
subsequent implantation, during which the donor site under the periosteal flap may 
also suffer from hypertrophy [120]. Another key hurdle with ACI is faced during 
expansion of chondrocytes prior to their implantation. In vitro culture of articular 
chondrocytes and passaging reduces expression of genes which denote the articular 
chondrocyte phenotype. This is synchronous with their hypertrophic differentiation 
[121] which reduces their suitability for repair of articular cartilage.  
 
1.2.2. Mesenchymal stem cell-based cartilage tissue engineering. 
The problems described in chapter 1.2.1 associated with conventional treatment 
methods for chondral defects may be alleviated with the use of Cartilage Tissue 
Engineering (CTE). CTE is the combination of cells, soluble factors and biomaterials 
for de novo cartilage formation, for the purpose of repairing degenerative tissue. One 
of the key questions which arises when designing a CTE strategy, is that of cell source. 
For this reason, the use of mesenchymal stem cells for CTE has been under the 
research spotlight as a genuine alternative to the use of primary chondrocytes. Their 
ability to be expanded for multiple passages without loss of phenotype [122], their 
capability for chondrogenic differentiation [123], together with their abundance 
[124], indicates their advantage to primary chondrocytes for CTE. The potential for 
BM-MSCs in CTE was demonstrated by their ability to repair chondral defects when 
implanted into a defect site within a HA hydrogel. When compared with a 




patients in the MSC-treatment group exhibited reduced pain and increased joint 
locomotion [125].  
1.2.3. Non bone marrow-derived mesenchymal stem cell types for articular 
cartilage regeneration 
 This thesis will focus on the use of BM-MSCs in CTE, however it is important to focus 
on the potential other cell types for such an application. Whilst the ease of isolation, 
multipotentcy and self-renewing ability of BM-MSCs [126, 127], denotes them as an 
appropriate cell choice for cartilage regeneration, other cell types may also be suited 
for repair of chondral defects. As pertained to, articular chondrocytes, despite their 
ability to maintain a Collagen Type 2 and GAG-rich ECM [119], are subject to de-
differentiation in culture [121, 128]. This inhibits their expansion and the generation 
of the large cell population required for adequate cartilage regeneration.  
A potential source of stem cells which are capable of restoring damaged articular 
cartilage are those from the periosteum. This tissue forms a vascularized, bone-
covering layer and contains a resident population of progenitor cells capable of rapid 
proliferation, osteogenesis and chondrogenesis [129]. The cartilage regenerative 
properties of the periosteum have been demonstrated extensively [130]. Following 
the isolation of periosteal stem cells by Fell, studies have documented the ability of 
these cells to contribute significantly to the repair of articular cartilage defects when 
implanted in vivo [131] or re-surfacing of the the entire articulating surface [132]. 
Another potential alterative to BM-MSCs, are mesenchymal stem cells derived from 
adipose tissue. These cells represent a much more abundant source than that from 




than the 100ml of bone marrow aspirate [133]. Combined with the ability of adipose-
derived MSCs for articular chondrogenesis and cartilage tissue regeneration [134, 
135], points to a potentially important reservoir of cells for development of CTE 
strategies.  
 
1.2.3.1. Bone marrow mesenchymal stem cells 
Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) residing in the stroma or 
perivascular region of the bone marrow [136, 137] are Adult Stem Cells (ASCs). ASCs 
like other stem cell subtypes, are able to self-renew [127] but unlike those types 
observed at earlier points in development, such as pluripotent embryonic stem cells 
[138], display a more limited, multipotent potential for differentiation [126]. BM-
MSCs were discovered by Friedenstein, who observed colony formation from 
adherent fibroblast-like cells with the potential for osteogenic differentiation [139]. 
These were subsequently shown to be capable of differentiation into cartilage, fat, 
muscle and neural tissue [140].  
 
1.2.3.1.1. Developmental origin 
The specification of a mesodermal population occurs as early as the epiblast stage of 
embryonic development [141] [142]. The mesodermal germ layer is formed during 
the Epithelial-to-Mesenchymal-Transition (EMT) of the epiblast epithelium as it 
migrates through the primitive streak, a process known as gastrulation [143]. More 




Lateral Plate Mesoderm (LPM) which is located between the extraembryonic and 
intermediate mesoderm [144]. The mesodermal populations in the LPM undergo a 
series of EMT and Mesenchymal-to-Epithelial Transitions (MET), one of which divides 
the LPM into the somatic and Splanchnic LPM epithelial layers [145], with the former 
generating the mesenchymal-progenitor-containing limb bud [146] and is 
hypothesized to be the tissue from which resident BM-MSCs are generated. This is 
suggested due to the similar set of markers expressed in the somatic LPM during limb 
bud development, and bone marrow mesenchymal stem cells. These markers include 
alpha-smooth muscle actin [147], Paired Related Homeobox 1 [148] and SRY Box-9 
(SOX9) [51]. 
 
1.2.3.1.2. Tri-lineage differentiation potential  
The predisposition for BM-MSCs to undergo osteogenic, chondrogenic and 
adipogenic differentiation was shown by Banfi et al. These authors observed an 
expression of genes conducive for each cell fate decision during their expansion 
period prior to their induced differentiation [149]. These authors also demonstrated 
the maintenance of the osteo-chondro differentiation potential throughout the 
continued passages of BM-MSCs. This culminated in their ability to differentiate 
following proliferative senescence, which was shown to be reached after 22-25 
population doublings following isolation from bone marrow.  
Primary BM-MSCs following their isolation, appear to retain a specific epigenetic 
profile which grants them their tri-lineage differentiation potential. Almeida et al 




term culture which was conducive for osteogenic/chondral differentiation. This pre-
disposition for cartilage and bone differentiation was greater than that exhibited of 
Adipose-derived MSCs (AMSCs) [150]. Amongst the osteogenic, chondrogenic and 
adipogenic lineages, Meyer et al demonstrated an epigenetic prolife of unstimulated 
BM-MSCs to favour that of osteogenic differentiation [151]. However upon 
adipogenic induction, these authors demonstrated a clear increase in activating 
epigenetic marks at the gene loci encoding targets of the master adipogenic 
transcription factor- Peroxisome Proliferator-Activated Receptor-γ (PPARγ). 
Herlofsen et al in BM-MSCs, also demonstrated the shift towards a specific pattern 
of histone marks which delineate activation of a chondrogenic transcriptional profile 
[152].  The primary nature of BM-MSCs was demonstrated to be key in generating 
this epigenetic profile conducive for tri-lineage differentiation. Brown et al, 
demonstrated the increased osteogenic, chondrogenic and adipogenic induction of 
primary BM-MSCs compared to that of MSC generated from in vitro differentiation 
of embryonic stem cells [153].  
 
1.2.3.1.3. Immunomodulation 
The differentiation potential of BM-MSCs therefore presents them as a useful tool 
for the study of mesenchymal tissue development in addition to a cell source for 
regenerative strategies for repair of osteochondral tissue. In addition, a unique 
characteristic of BM-MSCs are their immunomodulatory properties. Puissant et al 
demonstrated the ability of BM-MSCs to inhibit the activation of lymphocytes, with 




Mononucleocytes (PBMCs) [154]. In addition, BM-MSCs have been shown to reduce 
the activity of both CD4+ and CD8+ T-Cells which were initially activated in response 
to murine skin engraftment of the MSCs [155].  
This immunomodulatory properties of BM-MSCs has implications for regenerative 
medicine strategies. This was demonstrated for example by Reinders et al who 
intravenously-delivered autologous BM-MSCs alongside a kidney allograft which was 
previously subjected to immune-reactivity and rejection by the recipient patient 
[156]. The delivered BM-MSCs appeared to generate a systemic immunomodulatory 
milieu which compared to transplantation without BM-MSC treatment, reduced 
fibrosis and atrophy of the tubular structures in the transplanted kidney. 
Administration of the BM-MSCs in this study reduced PBMC proliferation and 
circulating immune-stimulatory cytokine levels such as interferon-γ. 
 
1.2.3.1.4. Isolation and characterisation 
In addition to the MSCs, the bone marrow compartment is comprised of multiple 
cells types including hematopoietic stem cells [157], osteoblasts [158] and 
lymphocytes [159]. Therefore prior to any study utilising BM-MSCs, including for CTE, 
it is required to separate these cells from the other contaminating populations. Aside 
from demonstration of tri-lineage differentiation potential, a primitive selection 
factor for BM-MSCs is their ability for adherent culture in vitro. This separates MSCs 
from cells of the hematopoietic origin and thus demonstrates a simple method to 




Another major criterion which distinguishes BM-MSCs from other cell types is the 
expression of specific cell-surface markers. These were originally defined by The 
International Society for Cellular Therapy (ISCT) [161].  The three markers which are 
deemed by these guidelines to identify BM-MSCs are Cluster of Differentiation (CD) 
105 (CD105)[162], 73 (CD73)[163] and 90 (CD90) [161]. These are involved in 
transduction of TGF–β signalling during chondrogenesis [162], MSC migration [164] 
as well as their adhesion to other cells [165] and the surrounding stroma [163]. On 
their own however or in combination, these markers do not delineate a BM-MSC. 
Indeed, expression of CD105 and CD73 have been shown to select for both 
endothelial cells [166] and skin fibroblasts [167]. Fibroblasts have a reduced capacity 
for colony formation and multi-lineage differentiation compared to MSCs, despite 
similar morphological characteristics [167]. Therefore, to further separate these 
stromal stem cells from the hematopoietic compartment of the bone marrow, the 
absence of expression CD11b or CD14, CD19 or CD79a, CD34, CD45, and Human 
Leukocyte Antigen-DR, together with the positive expression of CD105, 73 and 90 are 
required.  
Despite the existence of the ISCT guidelines described above, debate exists over the 
phenotypic markers which distinguish BM-MSCs. For example, CD271 and 
Mesenchymal Stem Cell Antigen-1 have also been reported to delineate BM-derived 
cells capable of osteogenesis, chondrogenesis and adipogenesis [168, 169]. Stro-1 
was also demonstrated as a marker of BM-MSCs but reports of Erythrocytes also 
expressing this antigen have prompted the requirement for examining Stro-1 
expression in conjunction with other bona fide BM-MSC antigens [170]. The ability of 




of a complex set of phenotypic criteria which mark BM-MSCs, beyond that required 
by ISCT. Cells which are selected based on the ISCT criteria may therefore omit 
specific subsets of BM-MSCs which are capable of tri-lineage differentiation and 
represent viable cells for study of mesenchymal development or tissue engineering. 
 
1.2.3.2. Scaffolds for cartilage tissue engineering 
A primitive example of CTE is Matrix-Assisted ACI (MACI) in which, akin to ACI, cells 
are expanded following isolation from the patient. However, unlike ACI, 
chondrocytes are then seeded onto Collagen Type I/III scaffolds to facilitate 
proliferation and stabilisation of their phenotype [171]. Despite increasing cartilage 
regeneration compared to techniques such as microfracture [172], an improvement 
of clinical success due to MACI was not observed in a direct comparison with ACI 
[173]. This is also is compounded with MACI also requiring multiple surgical 
procedures and the time-consuming process of in vitro expansion. MACI did 
however, demonstrate the potential of ECM scaffolds for improving cartilage repair. 
The use of scaffolds for CTE is demonstrated by the field of mechanotransduction. 
Research. Mechanotransduction is the mechanism behind cell response to 
mechanical stimuli in the cell microenvironment. Studies in this field have 
demonstrated the need for CTE strategies which provide the correct physical cues for 
tissue repair [174], as described in section 1.4. 
 




The choice of scaffold is important due to their ability to dictate cell survival, 
phenotype and host tissue integration following in vivo implantation. Artificial 
polymers such as Polylactic Acid (PLLA) were utilised in one of the earliest attempts 
at osteochondral tissue engineering, and was shown to enable survival of implanted 
rib perichondrial cells into a rabbit defect model, despite promoting formation of 
fibrous Collagen Type I [175]. Such polymers can be highly customized in terms of 
attachment of bioactive moieties, are able to be expanded up to production on an 
industrial scale to meet clinical standards. For example Poly(Vinyl Alcohol)-
Polycaprolactone (PVA/CL) nanofiber scaffolds demonstrated great promise when 
seeded with rabbit-derived mesenchymal stem cells and implanted into a full-
thickness defect of a rabbit medial condyle. Repaired tissue showed increased 
staining for GAGs and Collagen Type II compared to non-treated controls and 
improved MSC proliferation and differentiation during in vitro, preliminary assays 
[176]. 
 
1.2.3.2.2. Natural scaffolds for cartilage tissue engineering  
Natural scaffolds offer a host of advantages compared to artificial polymers. One of 
these is their increased bioactivity due to the presence of specific sequences within 
their structure which guides cell growth and tissue formation during development. 
HA is an example of such a material. It functions as a backbone of articular cartilage 
ECM, linking Collagen Type II fibrils with proteoglycans and has been shown to be key 
during limb morphogenesis and formation of the cartilage growth plate. HA synthase 




cell adhesion in the pre-cartilage condensation of the limb bud [178]. HA-based 
scaffolds have demonstrated much promise for CTE with their chondrogenic effect 
on encapsulated human MSCs have been observed compared to that of inert 
Polyethelene Glycol (PEG)-based scaffolds [179].  
HA was shown to aid the cartilage-forming ability of co-cultured adipose-derived 
MSCs and human chondrocytes, enhancing GAG synthesis from such cultures whilst 
inhibiting Collagen Type X production [180]. The translational properties of HA are 
demonstrated by its use in the clinically-tested product Hyalograft-C which is a 
combination of autologous chondrocytes and HA-derived matrix. Implantation with 
Hyalograft-C has been shown to result in a positive outcome for patients with 
articular cartilage lesions following 3 years post-surgery [181]. Other natural 
polymers has also shown the potential for their use in CTE. For example, collagen-
based hydrogels seeded with human MSCs from the illac crest of donors were shown 
to enhance chondrogenesis and provide a bias for chondrocyte induction over 
osteogenesis [182].  
 
1.2.3.3. Supplements for inducing cartilage ECM formation 
The continued optimization of BM-MSC chondrogenesis demonstrates the reliance 
on these cells for CTE strategies. As described below, the role of supplements which 
stimulate the post-translational processing and secretion of pro-collagen 
polypeptides have been demonstrated. This is in conjunction with the use of growth 
factors which induce a transcriptional program within MSCs that is conducive for 




Ascorbic acid is important in the collagen synthesis and maintenance of collagen 
triple helices. One the initial studies which examined this mechanism behind this 
phenomenon was that by Murad et al in 1981. These authors built upon previous 
observation of the increased growth of avian long bones cultured in a Ascorbate-rich 
medium [183]. Murad et al observed the increase in Collagen biosynthesis in human 
skin fibroblasts due to Ascorbic acid treatment, with an induction also in the activity 
of both Lysyl and Prolyl hydroxylases [184]. Corresponding to this, a study by Myllyla 
et al demonstrated the role of Ascorbic Acid in reducing the oxidized Fe3+ ion which 
is created as a by-product during proline hydroxylation. Following conversion back to 
the reduced, divalent form of iron (Fe2+), re-activation of the prolyl hydroxylase 
occurs. This therefore implicates Ascorbate in maintaining hydroxylation of Collagen, 
thereby maintaining its formation of triple helices and structural integrity of the 
entire ECM [185]. This role as a potential supplement was shown by studies such as 
by Temu et al who observed an increase in Collagen Type II protein produced by 
chondrogenically-induced ATDC5 cells in the presence of Ascorbic Acid [186]. 
Interestingly, these authors also demonstrated the ability of ascorbate to increase 
levels of COL2A1 mRNA and GAG production, indicating the general pro-
chondrogenic effect of Ascorbic Acid.   
A role for other supplements was also shown in terms of BM-MSC chondrogenesis 
and cartilage ECM formation. For example, hydroxylated proline residues in Collagen 
triple helix formation is suggestive of a role for L-Proline in chondrogenic media, to 
provide the necessary building blocks for Collagen polypeptide biosynthesis [187]. 
Another major supplement routinely used as an inducer of cartilage formation from 




dependent effect on formation of GAG-rich nodules from mouse BM-MSCs [140]. 
This in vitro chondrogenic effect of Dexamethasone was also demonstrated to 
specifically occur in the presence of TGF-β1-treated bovine BM-MSCs. In this study, 
an upregulation of chondrogenic genes was observed, however no such change 
occurred when Dexamethasone was utilised in conjunction with BMP2 [188].  
 
1.2.3.4. The TGF-β family of growth factors in cartilage tissue engineering 
The family TGF-β growth factors are of particular focus due to the role of TGF-β1/3 
and BMP ligands in both cartilage development [189] and regeneration [190]. For 
example, a TGF-β1 and BMP-6-supplmented medium was shown to induce a 
transcriptional program within hBM-MSC pellet cultures that resembles that which 
occurs during developmental chondrogenesis. This includes specific peaks in the 
levels of mRNA encoding SOX5, SOX6 and SOX9 and progressive increases in COL2A1 
and ACAN expression throughout the chondrogenic differentiating period [191].  
Regarding application for CTE, Bian observed an increase in COL2A1 and ACAN 
expression and increase in GAG production of hBM-MSCs within a HA scaffold loaded 
with alginate-encapsulated TGF-β3. This was observed at 4 weeks following 
subcutaneous implantation of the HA hydrogels, compared to that in which the 
alginate beads contained no TGF-β3 [192]. Diao et al. also demonstrated the ability of 
scaffolds seeded with TGF-β1-positive plasmids for gene delivery of this growth factor 
to BM-MSCs [193]. The authors observed an increase in chondrogenesis and cartilage 
ECM formation upon scaffold-implantation into a rabbit-defect model This was 




plasmid-containing scaffold as the control conditions. The cartilage ECM also was 
observed to remain stable following a 10-week post-operative time period. Pagnotto 
et al also observed an increase in cartilage regeneration due to ectopic TGF-β1 
expression in human MSCs implanted as pellets within a rat knee defect site. Again, 
this was compared to hMSCs transduced with GFP Complementary Deoxyribonucleic 
Acid (cDNA) [194].  
The potential of a combinatorial therapy with TGF-β3 and BMP2 was demonstrated 
by Tomas et al, who delivered plasmids encoding these two growth factors to BM-
MSCs within alginate hydrogels. Following a 28-day in vitro differentiating period, a 
combination of TGF-β3 and BMP2 compared to treatment of either factor alone, 
induced formation of ECM which was indicative of articular cartilage [195]. These 
authors also observed a reduction hypertrophic cartilage and ossified matrix due to 
the combination therapy.  
 
1.2.4. The risks of chondrocyte hypertrophy in current cartilage tissue engineering 
strategies 
Despite the pro-chondrogenic effect propagated by the TGF-β family of growth 
factors, their potential to induce chondrocyte hypertrophy in a tissue engineering 
context has also been demonstrated. For example, TGF-β3-induced chondrogenesis 
of BM-MSCs in Poly(ɛ-Caprolactone) (PE) scaffolds resulted in formation of 
mineralised tissue consisting of increased calcium content and Alkaline Phosphatase 
activity [196]. This enzyme is required for mineralisation of tissue following 




was also demonstrated by Ichinose et al, who observed the development of a 
fibroblastic phenotype from BM-MSCs within Alginate capsules, following their 
chondrogenic induction [198]. This was also accompanied by the presence of 
Collagen Type X within the ECM. 
One mechanism behind these observed cases of hypertrophy may be due to the 
supraphysiological levels of TGF-β growth factors present in standard chondro-
induction protocols. Overexpression of TGF-β1 in the murine knee results in 
progression of OA and joint fibrosis, implicating its potential danger in CTE [199]. 
Gene therapy with DNA encoding BMP-2 or ectopic treatment of the BMP-2 ligand, 
despite increasing GAGs and Collagen Type II during hBM-MSC chondrogenesis, also 
produced extensive staining for Collagen Type X and ALP activity [200] [201]. This 
suggests the hypertrophy of these cultures which is unsuitable due to the contrasting 
mechanical properties of articular and hypertrophic [202].  
The inappropriate hypertrophy and ossification due to such growth factors could 
perhaps be predicted due to the specific temporal and spatial pattern of their 
expression and activity during native cartilage development in which hypertrophy is 
tightly regulated. The TGF-β1 receptor, ALK5 and BMP receptors ALK3 and ALK6 have 
been shown to be differentially expressed during embryogenesis with their mRNA 
levels at a peak during pre-cartilage mesenchymal condensation [203]. This 
corresponds to experiments in which a severe phenotype was observed due to 
knockout of the TGF-β1/3 receptor in pre-cartilage mesenchymal condensations [204]. 
This contrasts with the milder phenotype observed due to knockdown of these 




expression of TGF-β1 and TGF-β3 in proliferative and hypertrophic chondrocytes 
compared to resting, articular chondrocytes [206, 207]. This is suggestive of a 
temporal role of these growth factors during the transition of immature growth plate 
chondrocytes into either chondrocytes which contribute to endochondral 
ossification or articular cartilage, the latter of which being the preferred final product 
for CTE strategies.  
The potential for TGF-β to potently induce a chondrogenic differentiation program 
but also cause hypertrophy of implanted cartilage grafts, suggests a requirement for 
additional factors which suppress the negative effect of TGF-β supplements. As 
described below, one developmental cue which is integral in articular cartilage 
morphogenesis, is that of hypoxia and its downstream signalling pathways. 
 
1.3. Hypoxia in cell biology – a result of vertebrate evolution 
Oxygen (O2) is integral in biological systems due to its role as an electron vehicle in 
the final stages of oxidative phosphorylation which is required for ATP)synthesis. 
Hypoxia, which is defined as the diminished availability of oxygen relative to 
atmospheric conditions, arose as a result of higher-order metazoan evolution. 
Oxygen was introduced into our atmosphere approximately 2.5 billion years ago. 
Accordingly, lesser-evolved species of the metazoan kingdom are able to absorb 
atmospheric oxygen to such an extent as to supplement all cells in the organism. This 
includes the Caenorhabditis elegans in which oxygen is able to freely diffuse into all 
cells [208] and in Drosophila melanogaster in which the simple gas-perfusion 




complex, multi-organ vertebrates in which larger diffusion distances for gases exist, 
abundant oxygen availability is restricted to certain tissues. Accordingly, the 
evolution of complex transport systems brought about the introduction of oxygen to 
organs which would normally be devoid of such a molecule [210].  
Despite the mechanisms which serve to increase supply of oxygen to tissues which 
are not easily perfused by O2, sub-par levels relative to that of atmospheric 
conditions are still experienced by multiple organs [211]. This is due to a lack of 
vasculature in these tissues. This  avascularity arises due to specific developmental 
programs which dictate patterning and regression of the vasculature following early 
embryogenesis [11]. For example, Iwagaki et al observed a regression of cochlear 
blood vessels at the onset of development [212]. Accordingly, such tissues have 
adapted to develop and maintain themselves in hypoxic conditions.  
 
1.3.1. The functions of hypoxia 
Hypoxia stimulates signal transduction pathways which result in upregulation of 
protein such as Erythropoietin and Vascular Endothelial Growth Factor (VEGF) [213, 
214]. These are integral for erythropoiesis and angiogenesis respectively and 
together, increased neovascularization and blood flow to ischemic tissues. Genes 
upregulated also include those involved in glycolysis, enabling sufficient ATP 
production in anaerobic conditions [215], as well as those which increase efficiency 




In addition to enabling metabolic adaptation, hypoxia has a role in tissue 
development, stimulating proliferation and cell fate changes to enable the correct 
architecture and function of the tissue. For example, at 8-10 weeks of human 
gestation, extravillous trophoblasts are thought to exist in a hypoxic environment 
due to the occlusion of maternal blood [217]. This is thought to promote their 
differentiation as they are invade the endometrium [218]. The proliferation of villous 
trophoblasts is also thought to be induced by hypoxia, enabling formation of a 
population of Syncytiotrophoblasts which is essential for nutrient circulation 
between the mother and placenta. In heart development, the switch from single to 
double circulation is in part mediated by hypoxia. The apoptosis of a specific 
population of cardiomyocytes in the embryonic outflow track is mediated by hypoxic 
signalling, and this is a pre-requisite for the remodeling-induced switch in circulation 
[219].  
The role of hypoxic signalling in enabling an adaptive response to low-oxygen 
conditions is also essential in tumour progression. As cancer cells proliferate 
uncontrollably, they create a mass or tumour that is devoid of vasculature. This 
creates a subsequent hypoxic microenvironment [220] which in turn upregulates 
high rates of ATP production via glycolysis, a phenomenon known as the Warburg 
Effect [221]. There is also an upregulation of angiogenic factors such as VEGFA. This 
results in formation of a vascular bed within the malignant growth which enables the 






1.3.2. Hypoxia Inducible Factor – the transducer of hypoxia-mediated transcription 
The Hypoxia Inducible Factor [223] complex transduces physiological hypoxia into 
gene transcriptional changes. This was first discovered by Semenza et al, who 
observed the increase in expression of erythropoietin by a protein, the levels of 
which were increased in hypoxic conditions [213]. HIF is a transcriptional complex, 
principally composed of an alpha subunit, either HIF-1α/HIF-2α and the HIF-1β 
subunit [224]. Other co-binding partners required for its transcription, include CREB-
Binding Protein/p300 (CBP/p300) [225] and the metabolic enzyme Pyruvate Kinase 
(PKM) 2 [226]. Both HIF-1/2α and HIF-1β contain DNA-binding domains, which 
recognise a specific sequence of bases in the promoter regions of target genes [227]. 
This consensus sequence is known as the HIF-Response Elements (HRE) and is also 
represented in reverse by the HIF Ancillary Sequence (HAS)[213, 228]. When the 
HREs/HASs are bound by HIF-1/2-HIF-1β dimer, transcription of the corresponding 
genomic coding to which the promoter belongs, is induced. This induction of 
transcription occurs via the N- and C-terminal transactivation domains (N-TAD and C-
TAD) of HIF-1α [229].  
The spatial distribution of HIF-1α and HIF-2α vary, with HIF-1α expressed 
ubiquitously and HIF-2α expressed in specific tissues such as endothelial cells and 
lungs during development [230]. There exists a large number of transcriptional 
targets of the HIF complex, with each HIF-1/2α-containing HIF complexes inducing 
transcription of a differing subset of genes. HIF-1α induces transcription of genes 
involved in angiogenesis [213, 214], metabolism [215], cell survival [231], migration 




as HIF-1, does not induce glycolytic enzyme synthesis [234]. A third alpha subunit- 
HIF-3α does not contain a C-TAD, and as such induces transcription to a weaker 
extent relative to that mediated by HIF-1/2α [235] [236]. Another implicated role of 
HIF-3α is that of a negative-regulator of HIF-1α, via competition with HIF-1β and 
inhibition of a functional HIF complex. 
 
1.3.3. Regulation of Hypoxia Inducible Factor-1/2α 
 
1.3.3.1. Protein stability 
The rate of HIF-mediated transcription is dependent on the stability of HIF-1/2α and 
not that of HIF-1β. This is due to the susceptibility of HIF-1/2α to hydroxylation, 
ubiquitination and degradation by the Prolyl Hydroxylase 2 (PHD2)-Von Hippel–
Lindau Tumor Suppressor (VHL) pathway, whilst HIF-1β is constitutively present [237] 
(Figure 1.2). PHD2, a proline-hydroxylating enzyme, requires oxygen, ascorbic acid, 
Fe2+ and 2-Oxoglutarate (2-OG) as substrates for its function [238]. At normoxia in 
which local oxygen molecules are in abundance, PHD2 is activated and it hydroxylates 
specific residues (Proline402/564) on the oxygen-dependent degradation domain 
(ODDD) of HIF-1α [239]. The newly formed hydroxylated residues of HIF1α then serve 
as recognition motifs by VHL which is part of an E3 ubiquitin ligase complex [240]. 
VHL binds and causes the ubiquitination of the hydroxylated proline residues of HIF-





In hypoxic conditions, the lack of oxygen available for PHD2 activity results in the 
downregulation of its HIF-1α-hydroxylating ability, thereby enabling HIF-1α cytosolic 
accumulation, nuclear translocation and expression of its target genes in the HIF 
heterodimeric complex. Interestingly, expression of the gene encoding PHD2- EGLN, 
is induced by excessive HIF-1α stabilization. This results in a negative feedback loop 
to prevent hyper-activation of HIF-mediated transcription [243]. Other pathways 
central to regulating HIF-1α degradation are The Receptor for Activated C Kinase 1 
(RACK1) and Heat Shock Protein90 (HSP90) as demonstrated by Liu et al. RACK1 has 
been demonstrated to compete with HSP90 in binding to HIF-1α and in doing so, 
recruits the identical ubiquitinating complex utilised by VHL, thereby resulting in HIF-
1α degradation [244]. Conversely, HSP90 functions by binding HIF-1α and blocking 
RACK1-HIF-1α binding and degradation [245]. RACK1-dependant degradation of HIF-
1α is independent of PHD2 function. Liu et al therefore suggest the role of HSP90 and 
RACK1 and their relative binding affinities for HIF-1α, are to determine the basal, 
steady state levels of HIF function in different cell types [244]. Calcium signalling has 
also been shown play a role in the regulation of HIF-1α stability. Liu et al identified 
the ability of Calcineurin to abolish RACK1-mediated ubiquitination and proteasomal 
degradation of HIF-1α [246]. Calcineurin is stimulated by increased intracellular Ca2+ 
and calmodulin activity [246].  
 
1.3.3.2. Co-factor binding 
Essential for the conformational changes in the HIF-1α-HIF-1β dimer [247] which are 




promoters, is the recruitment of p300/CBP (Figure 1.2). Structural crystallography 
studies of HIF-1α binding to these co-factors have revealed the necessity of this 
interaction for activation of the CTAD of HIF-1α [247]. This process is required to act 
synergistically with activity of the NTAD to stimulate HIF-target gene expression, due 
to the relatively weak ability of NTAD alone in stimulating transcription.  
One of the key residues involved in the binding between HIF-1α and p300/CBP is 
Asparagine-803 (Asn-803) of HIF-1α. This amino acid is a target of another 
hydroxylase enzyme, Factor Inhibiting HIF (FIH) which regulates HIF transcriptional 
activity independent of the protein stability of HIF-1/2α [248]. FIH-meidated 
hydroxylation of Asn-803 of HIF-1α inhibits the binding of p300/CBP to HIF-1α and 
therefore disrupts formation of the HIF-transcriptional complex [247]. As with PHD2, 
FIH utilizes oxygen, ascorbic acid, Fe2+ and 2-OG [249]. Correspondingly, FIH is 







Figure 1.2. Regulation of HIF-mediated transcription by HIF-1α stability and co-
factor binding. In response to molecular oxygen from local vasculature for example, 
FIH and PHD2 each hydroxylate a specific amino acid residue of HIF-1α. A: FIH-
mediated hydroxylation results in the blocking of the co-factors, CBP/p300 from 
binding to HIF-1α, thereby reducing HIF transcriptional activity. B: PHD2-mediated 
hydroxylation results in ubiquitination of the ODDD domain of HIF-1α by the VHL 
component of an E3 ubiquitin ligase, thus promoting the proteasomal degradation 
of HIF-1α and significantly reducing HIF transcriptional activity. C: In hypoxic 
conditions, PHD2 and FIH remain inactivate, thus enabling HIF-1α to translocate and 
accumulate in the nucleus, where it activates expression of HIF target genes as part 
of a transcriptional complex with HIF-1β, CBP/p300 and other co-factors. A negative 

















Control of proteasomal degradation and transcriptional co-factor binding, represent 
the major mechanisms of HIF-1α regulation. However, regulation of HIF-1α protein 
translation also contributes to the overall rate of HIF-mediated transcription. Growth 
factor signalling has been heavily implicated in HIF-1α translation both in normoxic 
and hypoxic conditions. Phosphatidylinositol 3-kinase-protein kinase B (PKB) and 
mammalian target of rapamycin (mTOR) have together, been shown to stimulate HIF-
1α translation and HIF-mediated gene expression [250]. mTOR-mediated translation 
of HIF-1α is thought to occur through phosphorylation of S6 kinase and 4E-BP1 which 
results in cap-dependent initiation of translation. Calcium signalling has also been 
implicated in enhancing HIF-1α translation. Inceased intracellular Ca2+ levels result in 
upregulation of Protein Kinase C, which causes a subsequent induction of mTOR 
activity and HIF-1α translation [251].  
 
1.3.3.4. Transcription 
The contribution of HIF1A mRNA to overall HIF-1α levels and HIF-mediated 
transcription appears to dependant on the cell and tissue type in which it is 
expressed. For example in Hep3B hepatoma cells, no changes in HIF1A mRNA was 
observed due to hypoxic incubation, despite increases observed in HIF-1α binding of 
the VEGFA promoter [252]. Similar, post-transcriptional regulation of HIF-1α was also 
observed in lung epithelial cells [253]. These studies are suggestive of the redundancy 




contrasted with that observed by Page et al. These authors demonstrated an increase 
in mRNA encoding HIF-1α in Vascular Smooth Muscle Cells, not in response to culture 
at 1%O2, but by treatment of vasodilative proteins Angiogenin II and Thrombin [254]. 
HIF1A transcription was subsequently shown to occur via Protein Kinase C and PI3K-
mediated mechanisms. This demonstrates the HIF-inductive mechanisms required in 
response to an ischemic microenvironment which increase angiogenic factor 
expression and tissue blood perfusion [252].  
Despite this evidence of hypoxia-independent upregulation of HIF1A mRNA, cells 
incubated at low oxygen levels were shown to induce HIF1A expression by Turcotte 
et al in Renal Cell Carcinoma cells. This was mediated by RhoA-dependent 
mechanisms [255]. Hypoxia-mediated transcription of HIF1A was also demonstrated 
by BelAida et al who demonstrated an increase in HIF1A mRNA due PI3K/PKB-
dependent mechanisms in response to hypoxic incubation. A dependence of HIF1A 
transcription was also observed on the activity of the transcription factor; Nuclear 
Factor kappa-Light-Chain-Enhancer of Activated B cells (NF-κB). Together, these 
studies demonstrate that transcriptional control of HIF-1α is unlike PHD2/VHL-
mediated control of HIF-1α stability which is a conserved mechanism. Instead, the 
contribution of HIF1A mRNA to hypoxia-induced HIF activity is highly context 
dependent.  
In the context of articular cartilage, hypoxia upregulates HIF1A mRNA levels during 
chondrogenesis of cartilage endplate cells [256]. Adult articular chondrocytes have 
been shown to upregulate HIF1A mRNA in response to inflammatory/OA-inducing 




hypoxia-induced HIF activity via HIF1A transcription is not a conserved mechanism 
across different tissue types and developmental stages. 
 
1.3.4. The role of hypoxia in osteochondral development  
Specific morphogen gradients such as that of Wnt and BMP ligands, exist across 
developing and adult osteochondral tissue and are essential in the formation and 
maintenance of distinct regions of cartilage and bone [258]. Another such gradient 
between vascularised subchondral bone and avascular cartilage, is that of oxygen 
[259]. This gradient which also exists in the mesenchymal condensations of the limb 
bud, has been shown to play key roles in the formation and maintenance of the 
distinct regions of osteochondral tissue.  
The oxygen concentrations in adult human articular cartilage are reported to be 
between 1-6% with that of subchndral bone reaching up to 21% [260].  and as 
described by Maes et al, the early limb bud and cartilage growth plate are also subject 
to a hypoxic microenvironment. This is due to the regression of embryonic 
vasculature [261]. This has been shown in studies by Schipani and Provot who also 
demonstrated the requirement of HIF-1α-mediated hypoxic signalling for 
chondrogenesis of the limb bud mesenchymal population, cartilage ECM formation 
and subsequent survival of the chondrocyte population within the growth plate [259, 
262].  
The studies by Schipani and Provot are suggestive of an essential role for HIF in 




at low oxygen levels [263]. This effect is reversed in regions of higher O2 
concentration due to downregulation HIF activity, which would result in a bias 








           
Figure 1.3. The oxygen and HIF gradients present across development and adult 
osteochondral tissue. Diagrammatic representation of oxygen and result HIF activity 
gradients present across the mesenchymal limb bud (A) and growth plate (B) stages 
of limb development. C: Oxygen resulting HIF-1α protein gradients across adult 
osteochondral tissue with Blue gradients = Proteins upregulated by HIF, Red 

















































































1.3.5. The role of hypoxia in osteochondral tissue engineering  
Previous efforts of osteochondral tissue engineering (OCTE) via development of two 
independent bone and cartilage grafts before their attachment by suture or fibrin 
glue (Fig. 1.4A)[264], have been shown to fail due to shearing of the graft by 
mechanical movement of the joint [265]. Therefore for treatment of such cases, it is 
advantageous to achieve synchronous regeneration of both the bone and cartilage 
on the same continuous biomaterial scaffold (Fig. 1.4B).  
An advantage of osteochondral regeneration within a continuous scaffold is the 
mimicry of synchronous in vivo development of native articular cartilage and 
subchondral bone. Following formation of the growth plate from the limb bud 
mesenchymal condensations, the fate of the highly proliferative chondrocytes is that 
of either hypertrophy or senescence. These two paths which contribute to formation 
of ossified bone and articular cartilage respectively, occur simultaneously with the 
fate of growth plate chondrocytes subject to influence by gradients of signals such 
that of Indian Hedgehog or HIF [91, 266]. This synchronous development of articular 
cartilage and subchondral is required for the communication of forces between the 
chondral and bone layers which are applied on the joint during movement.  
A case-study in which such a strategy was employed for osteochondral regeneration 
was conducted by Mohan et al. Within a single biomaterial scaffold, these authors 
created two opposing gradients of chondrogenic and osteogenic factors respectively 
which were incorporated within PLGA microspheres [267]. The region of the scaffold 
that was abundant in the pro-chondrogenic signal (TGF-β3) with the opposing area 




formation of cartilage and bone. As identified by Magnetic Resonance Imaging and 
histological analysis, these scaffolds when implanted into a rabbit osteochondral 
defect model also resulted in regeneration of distinct cartilage and bone phases in 
vivo.  
Aricular cartilage and subchondral bone require differing levels of oxygen for their 
development and maintenance [259], as decribed in figure 1.3. Together with the 
the pro-chondrogenic and anti-hypertrophic/osteogenic effects of HIF, this suggests 
the potential HIF for OCTE in which a continuous biomaterial scaffold is utilised. 
Controlling the spatial organisation of physiological hypoxia however, may be 
logistically impossible. Therefore it may be advantageous to spatially control 
chemical agents which stimulate the HIF pathway as an alternative [268].  
Agents which act to stabilise the HIF-1α subunit of the HIF transcriptional complex, 
would therefore enable spatial control of HIF-mediated transcription when 
themselves deposited in a graded manner on a biomaterial scaffold with seeded cells. 
It could be envisaged that within a region of graded scaffold that is rich in a HIF-
stimulating compound, chondrogenesis would represent the preferred lineage 
commitment of the scaffold-seeded hBM-MSCs (Fig. 1.4C). This would be 
accompanied by a suppression of with osteoblast differentiation and hypertrophy. 
This would contrast to regions of the scaffold which are depleted for the HIF-
stimulating compound and in which HIF activity is relatively lower. In such a region, 
there may be a bias for osteoblastic differentiation of the hBM-MSCs when cultured 
in an osteogenic-chondrogenic co-induction media. This would be due to the lack of 




but also due to the bias of BM-MSCs for osteogenesis relative to that for other 




















(*61) Figure 1.4. Biphasic, Continuous and HIF-graded Scaffolds. A: Biphasic 
osteochondral graft, generated via attachment of pre-differentiated cartilage and 
bone tissue engineered grafts B: Continuous scaffolds, enabling synchronous 
development of cartilage and bone regions from one biomaterial and one cell 
population with a gradual transition from one phase to another, synthesised via 
incorporation of a graded microenvironment on the scaffold. C: HIF-graded scaffold. 
D: MSC-seeded biomaterial scaffold containing a gradient of a HIF-stabilising agent. 
E: During osteochondrogenic co-induction of the scaffold-seeded MSCs, the 
differential levels of the HIF-activating agent across the scaffold may promote the 
pro-chondrogenic, anti-hypertrophic and anti-osteoblastic function of HIF in the 
region of high concentration, whereas this would not occur in the region of low 
concentration. F: The potential continuous osteochondral graft generated using the 
HIF-regulating scaffold, containing spatially restricted regions of articular cartilage 







1.3.6. The role of hypoxia and HIF-1α in articular cartilage development and 
maintenance. 
 
1.3.6.1. Mesenchymal progenitor differentiation 
In 2007, Provot et al highlighted the role of HIF-1α in promoting the activity of SOX9, 
the master chondrogenic transcription factor, in mesenchymal precursors of the limb 
bud condensations which give rise to the growth plate [262] (Figure 1.5). This group 
showed that upon conditional knockout (CKO) of HIF-1α, expression of the SOX9 
target; COL2A1, was reduced. HIF-1α CKO also resulted in a disorganised morphology 
of the resulting cartilage ECM. Concurrent with this study, Amarilio et al 
demonstrated the role of HIF-1α in stimulating SOX9 expression in pre-chondrogenic 
precursors during mouse limb development. These authors observed the reduced 
expression of SOX9 and its downstream targets COL2A1 and ACAN upon HIF-1α CKO 
(Figure 1.5). They also observed a decrease in mRNA encoding SOX6 [263].  
From an in vitro perspective, HIF has been shown to upregulate SOX9 mRNA and the 
downstream chondrogenic targets of SOX9 in a BM-MSC line. Following induction of 
chondrogenesis, reduced SOX9-linked luciferase activity was observed upon deletion 
of HREs from the SOX9 promoter. This was relative to cells in which the HREs were 
left intact [269]. Moreover, in rat MSCs, Kanichai et al demonstrated the upregulation 
of HIF-1α due to hypoxia. This effect was mediated by PKB and p38 mitogen-activated 
protein kinase resulting in expression of chondrogenic factors [270]. Further 
cementing the role of HIF in chondrogenesis, adenovirally-delivered HIF-1α was 




of HIF-1α in chondrogenesis of BM-MSCs within alginate beads was also observed. 
This was demonstrated by a lack of SOX9, SOX5, SOX6, ACAN and COL2A1 mRNA 
upregulation in differentiating conditions in response to treatment of cells with a 
double-negative HIF-1α vector, compared to the transcriptional profile observed in 
wild type cells [272].  
The interplay between HIF-1α and chondrogenesis is also indicated by observation of 
HIF-1α upregulation during growth factor-mediated cartilage regeneration at 
normoxia. In this study, Gelse et al utilised a porcine chondral defect model 
implanted with autologous porcine BM-MSCs. Following implantation, they observed 
an increase in HIF-1α in host chondrocytes within the deep zone of the repaired 
cartilage. This was compared to that within host chondrocytes following implantation 
of the MSCs without BMP2/insulin growth factor stimulation. These authors also 
demonstrated the role of in vitro periosteal cells to upregulate HIF-1α protein in 
response to BMP2 and Insulin Growth Factor 1 treatment [275]. Correspondingly, 
McMahon et al also observed a similar effect of the TGF-β family of transcription 
factors. In human hepatoma cells, an upregulation of HIF-1α protein and HIF-
mediated transcription was observed in response to TGF-β1 treatment [273].  
  
1.3.6.2. Secretion of cartilage extra-cellular matrix  
The specific composition and architecture of the ECM surrounding articular 
chondrocytes, gives hyaline cartilage its ability to resist compressive forces and 
tension on the joint. It also enable lubrications between opposing articulating 




synthesis by cultured Human Articular Chondrocytes (HACs), relative to that seen at 
normoxic conditions [270].  Additionally, reduced oxygen concentration have been 
shown induce a more ordered morphology of collagen fibrils which is representative 
of that observed in native articular cartilage. This was observed in chondrocyte 
pellets cultured at 5%O2 compared to that at normoxia [274]. Hypoxia has also been 
shown to have a beneficial effect with regards to ECM production by chondrocytes 
embedded in biomaterial scaffolds.  Coyle et al observed an increase of a GAG and 
Collagen Type II-rich ECM due to culture of bovine articular chondrocytes at 2%O2, 
following embedding of the chondrocytes in alginate capsules [275]. A similar pattern 
of ECM formation was also induced by hypoxic incubation of hypertrophic 
chondrocytes within a Poly(Lactic-co-Glycolic Acid) (PLGA) scaffold [276].   
HIF-1α has been implicated in this hypoxic-induction of cartilage ECM production. 
Conditional knockdown of HIF-1α in developing murine limbs result in abnormal ECM 
morphology. Growth plate chondrocytes isolated from HIF-1α-CKO mice also exhibit 
reduced cartilage proteoglycan and collagen type II production compared to mice in 
which in which HIF1A was left intact [262, 277]. Chemical induction of HIF-1α was 
shown to also significantly raise Collagen Type II protein levels secreted by HAC’s 
[278] as well as that of Aggrecan, and this effect was abolished in HACs in which HIF-
1α was knocked down [279].  
In addition to the effect in chondrocytes, HIF has also been shown to increase 
cartilage ECM in the cultures of various MSC types when induced towards a 
chondrogenic lineage [270, 272] (Figure 1.5). One of the main mechanisms by which 




subsequent COL2A1 and ACAN mRNA [262, 272]. HIF has also been proposed to play 
a role in the post-translational modification of pro-collagen type II chains which as 
previously described, is required for stabilisation and function of Collagen Type II 
within the cartilage ECM. This occurs via upregulation of mRNA encoding Collagen 
Prolyl Hydroxylase (CP4HA1) which is required for the addition of 4-hydroxyproline 
residues to single collagen fibrils to enable formation of collagen triple helices [280]. 
Additionally, HIF induces expression of Lysyl Oxidase (LOX) which is an enzyme whose 
activity is required for the crosslinking of collagen triple helices. Makris et al observed 
an increase in expression of LOX in response to 2%O2 culture of bovine articular 
cartilage explants [285].  They went on to demonstrate the effect of hypoxia in 
increasing formation of pyridinoline cross-links between collagen fibres, together 
with an increase in the mechanical stiffness of the explant. These increases were 
reduced by treatment of the explants with the LOX inhibitor- beta-
aminopropionitrile. Together, the findings by Makris et al suggest a role for hypoxia 
in maintaining a stable articular cartilage ECM via collagen post-translational 
modification. This crosslinking is required to maintain the overall ECM tensile and 
compressive strength in response to forces experienced by the joint during 
locomotion [281]. 
 
1.3.6.3. Inhibition of chondrocyte hypertrophy 
Signalling gradients such as that of Ihh exist to retain populations of chondrocytes in 
their non-hypertrophic form, priming them for a permanent, articular chondrocyte 




to limit chondrocyte hypertrophy, with HIF playing a key role in this process (Figure 
1.5). HIF subunits have been shown to be expressed in human adult chondrocytes 
[282] and Lafont et al also showed the role of these in maintaining SOX9 expression 
in articular chondrocytes. This was subsequently shown to be crucial for expression 
of the downstream transcriptional targets of SOX9 which are required for 
stabilization of the articular chondrocyte phenotype [283]. This role of HIF was also 
shown to occur via SOX9-independent pathways [284]. HIF has been shown to 
downregulate the expression of hypertrophic fibroblast-like markers such as collagen 
type X, and cartilage degrading enzymes in hypertrophic chondrocytes [279]. In 
addition to inhibiting hypertrophic factors, hypoxia has also been shown  to 
upregulate chondro-protective proteins such as MMP inhibitors [285] and other anti-
catabolic factors  [286]. This is also supported by the observation that HIF-1α CKO in 
developing murine cartilage reduces mRNA expression of articular chondrocyte-
specific markers such as Growth Differentiation Factor 5 [263].  
The ability of hypoxia to promote an articular chondrocyte phenotype is mediated 
via a multitude of signalling pathways. Following chondrogenesis of the growth plate, 
canonical Wnt signalling has been shown to be conducive for chondrocyte 
hypertrophy in preparation for endochondral ossification [100]. Hypoxia has been 
correspondingly shown to increase expression of Wnt antagonists during BM-MSC 
chondrogenesis. This has the downstream effect of increasing expression of articular 
chondrocyte markers and downregulating mRNA encoding hypertrophic markers. 
[287]. The Wnt-inhibitory role of hypoxia also functions through HIF-1α which binds 




induction of TCF-LEF target genes such as which are conducive for hypertrophy, such 
as MMP13 [288].  
HIF is also important in promoting a bias for chondrogenic over osteoblastic 
differentiation of mesenchymal precursors, a cell fate decision which generates the 
growth plate or intramembranous bones respectively. The hypoxia-responsive 
transcription factor via HIF-1α-stabilising compounds [271] or constituitive HIF-1α 
activation [289] has been shown in vitro to downregulate factors involved in 
osteogenic differentiation and maturation (Figure 1.5). This includes RUNX2, Alkaline 
Phosphatase [290] and Wnt signalling [291] and as such, generate a bias for 
chondrogenic differentiation over osteoblast formation, and formation of cartilage-







Figure 1.5. Induction of a transcriptional profile by HIF which favours formation of 
articular cartilage from mesenchymal precursors. A: Following hypoxia-mediated 
formation of the HIF complex and binding to the HRE of target genes, induction of 
transcription occurs. B+C: Upregulation of SOX9 transcription (B) and subsequent 
upregulation of SOX9 target gene, COL2A1 and ACAN which results in an increase in 
secretion of Aggrecan-containing proteglycans and pro-Collagen Type II by the 
differentiating cell (C). D-F: SOX9-mediated downregulation of RUNX2 activity and 
HIF-mediated reduction of RUNX2 transcription (D) together resulting in decrease in 
transcription of genes encoding osteoblastic (E) and hypertrophic factors (F). H: HIF-
mediated transcription of genes which encode anti-hypertorphic factors such as 
GREM1 and DKK1 which inhibit BMP and canonical Wnt signalling respectively. G: 
HIF-mediated upregulation of genes which encode glycolytic enzymes. Yellow arrows 












1.4. Mechanotransduction and the influence of hypoxic signalling 
Cells are able to respond to changes in the mechanical factors of immediate 
microenvironment. These mechanical changes, for example the elasticity of the 
substrate on which they reside, have been shown to influence cell behavior. One 
aspect of such behavior is chondrogenic differentiation, which has been shown to be 
heavily influenced by the mechanical properties of the stem cell extracellular space. 
Furthermore, as described below, evidence exists of the role of hypoxia in regulating 
mechanotransducive pathways that are involved in BM-MSC chondrogenesis. 
Insights into the crosstalk between hypoxia and mechanotransducive pathways ay 
inform CTE techniques where the optimal mechanical microenvironment for 
chondrogenesis is to be combined with HIF-dependent signalling. 
 
1.4.1. The tensegrity model of the cytoskeleton 
As described by Mitchison, the cytoskeleton is composed of actin microfilaments, 
intermediate filaments and microtubules composed of tubulin monomers [292]. 
Actin is an ATPase, with ATP bound in lobed structures within the polymer sequence. 
The steady-state structure of actin is that a homotypic double helix. These helices are 
unlike the microtubules, display flexibility and yielding in response to tensional 
forces. This property of actin is required during the formation of high tensed stress 
fibres which are induced upon contraction of the actin-bound Myosin Light Chain-II 
(MLC2). As described by Lutz and Lieber, MLC2 contraction is an ATP-dependent 
process. Following binding of the ‘head’ subunit of MLC2 to the Actin helix, the bound 




This subsequently induces contraction of the actin microfilament, with the sum of 
tension produced by all actin microfilaments contributing to the tension generated 
by the cytoskeleton as a whole [293].  
Donald Ingber likened the cytoskeletal tension created by MLC contraction to 
structures whose continuous tension maintains their structural integrity [294]. Such 
structures include the Buckminsterfullerene, a 60-carbon structure made by Harold 
Kroto, Robert Curl and Richard Smalley [295]. This structure resembled those 
discovered by Richard Buckminster Fuller who coined the term ‘Tensegrity’ upon 
observation of the ability of such structures to maintain their integrity by increased 
tension of the inter-carbon bonds [296]. The Buckminsterfullerene did indeed exhibit 
this same tensegrity, which was investigated due to the observation by Russel Chu 
that the structure would not be viable without secondary structures in which 
tensional forces were continuously transferred [297].  
Ingber in his comparison between Buckminsterfullerene-like structures and that of 
the cytoskeleton, suggested that the actin network also experiences changes in 
tensional forces, with an increase responsible for maintaining cell shape and 
integrity. This was based on pioneering observations of opposing forces produced by 
the actin microfilament and the microtubules [298] and of myosin-actin tension 
orientated towards the centre of the cell [299]. Correspondingly, Harris and Stopak 
observed a pulling-force by chick cardiac fibroblasts on the surrounding silicon-based 
surface on which they were seeded, as assessed by the degree of inward ‘wrinkling’ 





1.4.2. Regulation of cytoskeletal tension and cell shape by substrate stiffness 
During development, there exists a requirement of ECM which is able to resist 
deformation in response to cell attachment cell-derived tension. Banerjee et al 
demonstrated the requirement of a basal lamina during salivary gland development 
for the maintenance of  cell morphology and a specific cytoskeletal arrangement that 
are conducive for formation of the salivary gland lobular structures [301]. Upon 
enzymatic digestion of the supporting mesenchyme, these authors observed the loss 
of cell-ECM attachment, cytoskeletal disorganization and the rounding up of 
submandibular epithelial cells. Supporting this, Li and Sakaguchi identified the role of 
cell-ECM attachment during development of the retina [302]. They observed a 
disruption and ‘rounding up’ of the retinal lamina upon injection of the embryonic 
tissue with an antibody which blocked a specific cell surface receptor responsible for 
mediating cell-ECM interactions. This receptor is a member of the Integrin family 
which are integral in mediating the transmission of signals from the ECM through the 
cell. The exact molecular nature of this is described in subsequent sections of this 
chapter.  
In addition to the effect of either the presence or absence of ECM on cell behaviour, 
the magnitude of tensional force applied by the cell onto its ECM is determined by 
elasticity of the ECM. The elasticity or stiffness of a substrate on which a cell is seeded 
is defined as the extent to which it resists deformation in response to tensional forces 
produced by the cell. As pertained to, the attachment point of a cell to its ECM is 
primarily mediated by Integrin receptors, which enables formation of focal adhesion 




it is the elasticity of the ECM between these attachment points which determines the 
tension generated within the cell. A substrate of relative high stiffness will not 
deform between sites of cell attachment and adhesion formation. This will result in 
a high tensional forces generated by the cell cytoskeleton to reach an equilibrium 
with the tension generated within the ECM [303]. Morphologically, this results in cell 
spreading and observation of visible actin stress fibres [304].  
On a relative soft substrate, despite cells exhibiting lower cytoskeletal tension 
compared to those on a stiff substrate, actin-myosin contraction is present. 
Therefore when present on an ECM which undergoes deformation more readily in 
response to a pulling force, a cell generates a rounded morphology. This is due to a 
cytoskeletal tension-mediated retraction of the actin network towards the nucleus 
in a concentric manner, which occurs due to the low relative tension and binding 
affinity of cell-ECM anchors. Mih et al demonstrated the importance of myosin 
contraction in generating a rounded cell morphology by observation of fibroblast 
spreading on a soft substrate in response to Blebbistatin treatment. This was 
compared to cells without inhibitor treatment in which a round morphology was 
observed [305]. This was also observed in the study by Vishavkarma et al in which 
the cell area of murine MSC on a substrate of 3-4 Kilopascal (KPa) increased in 
response to Blebbistatin treatment [306].  
 





A study by McBeath et al observed how changes in cytoskeletal tension and cell 
shape affected MSC fate. When cultured at high density, MSCs were shown to adopt 
a rounded cell shape. This change in cell shape was shown to mediate the bias 
towards adipogenic differentiation over that of an osteoblast, despite culture of the 
MSCs in media containing factors conducive for differentiation down either lineage 
[307]. Furthermore, when MSC spreading was restricted on 1024µm2 islands, there 
was a bias for adipogenesis of seeded cells compared to an osteogenic cell fate which 
was preferred on larger, 10,000µm2 islands. In further experiments, a reduction in 
osteogenesis was observed on the large island in the presence of an inhibitor of 
myosin contraction. Also, transfection of a constitutively-active Rho-Associated 
Protein Kinase (ROCK) which functions to induce cytoskeletal tension, decreased 
adipogenesis of MSCs cultured on the smaller substrate. These observations 
demonstrate the control of lineage commitment by cell shape is dependent on 
cytoskeletal tension. 
 
1.4.4. Regulation of cytoskeletal tension-mediated lineage commitment by 
substrate stiffness 
Supplementing that observed by McBeath et al, a seminal study by Engler et al also 
demonstrated a correlation between substrate stiffness and cytoskeletal tension-
mediated lineage commitment. These authors observed, on a Collagen Type I coated 
soft Polyacrylamide surface, in non-differentiating media, thats MSCs adopted a 
relatively smaller cell shape with which a neural fate was favoured. Neural specific 




morphology observed, resembling native neurons. This is in contrast with MSCs on a 
stiff substrate on which a spread morphology and increased propensity for osteoblast 
differentiation was exhibited. This conclusion were made due to the increased 
expression of Osteocalcin and formation of a rigid ECM resembling mineralised bone 
[304]. Critically, as substrate stiffness increased, these authors observed a positive 
correlation with actin stress fibre formation, contraction of MLC2 and stiffness of the 
cells. The role of increased cytoskeletal tension in dictating the stiffness-mediated 
differentiation of the MSCs was then confirmed by use of the inhibitor of myosin 
contraction- Blebbistatin. Treatment of MSCs on all substrates with Blebbistatin 
reduced the commitment down the originally-preferred lineages. 
Guvendiren and Burdick demonstrated a similar phenomenon to Engler et al, upon 
the culture of hMSCs on soft, stiff and dynamic stiffening Polyacrylamide (PA) 
substrates [303]. They observed a round and spread cell morphology on the soft and 
stiff surfaces respectively, with a 10-fold increase in traction force generated by cells 
on the 30KPa substrate compared to those at 3KPa. MSCs on the dynamic gel 
exhibited a cell morphology and traction force indicative of culture on the soft 
substrate which transformed into that indicative of a stiff surface following in situ 
stiffening of the PA gel. Corresponding to the changes in cell shape and traction 
forces, which correlate with the tensional forces within the cytoskeleton [308], a 
predisposition for adipogenic and osteogenic differentiation was induced on the 3 
and 30KPa substrates respectively.  
Finally, Guvendiren and Burdick conducted the differentiation of cells on the 




stiffening at day 1 of the differentiating period, a clear bias for osteogenesis was 
observed. However, upon stiffening at day 7 of the culture period, MSCs within the 
culture appeared to differentiate down both lineages with an approximate 50% 
difference observed between adipo- and osteogenesis. This implies that early 
responses to substrate stiffness are integral in determining cell fate, compared to 
stiffness-mediated stimuli at latent stages of differentiation. Again, cytoskeletal 
tension mediated the switch in cell fate as observed by the abolishment of 
osteogenesis and preservation of adipogenesis in response to inhibition of myosin 
contraction. 
 
1.4.5. Mechanisms by which substrate stiffness regulates cytoskeletal tension 
 
1.4.5.1. Sensing of substrate stiffness by integrin receptors 
Cells sense the stiffness of their environment via integrin receptors which link the 
extracellular environment with the cell cytoskeleton, and different subtypes 
exhibiting affinity with different ECM proteins [309, 310]. Upon engagement of ECM 
by the extracellular domains of integrins and binding of their cytoplasmic tails by 
Talin [311] and Kindlins [312], clustering occurs of multiple integrin receptors [313]. 
This results in the formation of focal adhesion complexes. These complexes, 
consisting of proteins such as Vinculin and Paxicillin, via Focal Adhesion Kinase (FAK) 
initiate a downstream cascade of events resulting in contraction of MLC2 and 




Upon engagement of integrin receptors by ligands in the ECM and actin-myosin 
contraction, the cell generates tension if present on a non-compliant substrate which 
results in a strengthening of the integrin-ECM interaction. This induces further focal 
adhesion maturation in a positive feedback loop, enabling continued response to the 
stiffness of the cell environment which actin stress fibres [316]. If the cell is present 
on a softer substrate, it will be unable to generate tension against a more easily 
deformed ECM substrate, therefore generating relatively weak integrin-ECM 
interactions. This generates a cortical actin organisation within the cell with few 
accompanying actin stress fibres.  
 
1.4.5.2. Transduction of mechanical stiffness to the nucleus by RhoA and ROCK  
One of the key mechanisms by which integrin-ECM binding is transduced into 
cytoskeletal tension, is via modulation of the Homolog Gene Family, Member A 
(RhoA)/ROCK pathway [307]. FAK is auto-phosphorylated in the focal adhesion 
complex [317], promotes the hierarchal addition of proteins to this complex [318] 
and indirectly activates RhoA [319]. RhoA is a member of the (Guanosine Tri-
Phosphatase) GTPase family of proteins which in an active conformation, hydrolyses 
its bound (Guanosine Tri-Phosphate) GTP to Guanosine Di-Phosphate (GDP) and in 
doing so becomes inactive. The re-activation of RhoA is induced by the exchange of 
GDP for GTP which itself is mediated by Guanosine Exchange Factors (GEFs). Zaidel-
Bar et al observed the ability of integrin-stimulated FAK in increasing activity of a 




Activation of ROCK by RhoA [320, 321] stimulates the dual effect of ROCK on MLC2 – 
1) direct phosphorylation of MLC2 [322] and 2) Inhibition of myosin phosphatase 
(MYP) [323] which functions to de-phosphorylate MLC2. This process is also 
simultaneous with the polymerisation of Globular Actin (G-actin) into F-actin-rich 
stress fibers [324]. This is induced by ROCK via inhibition of actin-binding protein, 
cofilin which enables polymerisation of G-Actin monomers [325, 326]. Together, 
RhoA/ROCK-mediated actin polymerization and contraction of MLC generates 
cytoskeletal tension.  
 
1.4.6. Mechanisms by which cytoskeletal tension regulates gene expression 
 
1.4.6.1. YAP/TAZ 
The precise steps between ROCK-mediated cytoskeletal tension and induction of 
specific gene expression patterns observed are poorly understood. However, one 
transcription factor complex, Yes-Associated Protein [327] [327]/Transcriptional 
Coactivator with PDZ-Binding Motif (TAZ) has been shown to be central to this 
process [327]. This complex is classically the effector of the Hippo signalling pathway. 
Upon cell-cell contact and engagement of the Fat4 receptor, specific kinases 
negatively regulate YAP by phosphorylating and targeting it for proteosomal 
degradation. Conversely when the Hippo pathway is inhibited, non-phosphorylated 
YAP translocates to the nucleus where it binds to TEA Domain (TEAD) transcription 




The ability of YAP/TAZ to respond to changes in substrate stiffness has also been 
shown, both via [329] and independently of the Hippo pathway [330]. On substrates 
of increased stiffness on which cytoskeletal stress fibre formation is induced, 
YAP/TAZ are localized to the nucleus. This was shown to be mediated by ROCK-
induced MLC contraction, by observation that treatment with Blebbistatin or ROCK 
inhibitor, Y-27632 abolished stiffness-mediated YAP translocation.  Nuclear shuttling 
of YAP also requires inhibition of Cofilin and de-repression of actin polymerization 
[331].  
On a relative stiff ECM, following YAP/TAZ translocation into the nucleus, a cell fate 
switch occurs which was previously demonstrated by MSCs on this substrate [307]. 
That is, a bias towards osteogensis at the expense of adipogenesis. Conversely, 
adipogenesis was higher in MSCs on a softer substrate, within which cytoplasmic 
YAP/TAZ was observed [330]. Small Interfering RNA (siRNA) knockdown of YAP and 
TAZ in MSCs on the stiff substrate appeared to abolish osteogenesis, whilst inducing 
adipogenesis. Correspondingly, TAZ has been shown to bind to and potentiate the 
function of the key regulator of osteogenesis, RUNX2 whilst inhibiting the key 
regulator of adipogenesis, PPAR-γ [332]. 
 
1.4.6.2. MRTF-SRF  
In addition to YAP/TAZ, other transcription factors which are regulated by 
cytoskeletal tension are the Myocardin-Related Transcription Factors (MRTFs) which 
are co-activators of Serum Response Factor (SRF)-target genes [333]. MRTF nuclear 




nuclear import requires RhoA activity, ROCK-mediated phosphorylation of Cofilin and 
G-actin polymerisation [335]. MRTF-SRF functions to maintain the mechanosensing 
ability of the cell in a positive feedback loop. Their targets include genes whose 
products are involved in actin and ECM re-organization in addition to those required 
for cell-cell adhesion [336]. TAZ mRNA and expression of YAP-TEAD targets have also 
been shown to be stimulated by MRTF-SRF activity [337]. 
 
1.4.6.3. The LINC complex and Nuclear Lamins  
Observations have been made of the effect of integrin-mediated cytoskeletal tension 
on inducing corresponding tension with the nucleus [338]. This has been shown to 
require in part, the Linker of Nucleoskeleton and Cytoskeleton [339] [339] complex. 
This complex connects the actin-myosin cytoskeleton with the nucleoskeleton [340] 
and mediates the force transmitted to the nucleus in response to cytoskeletal tension 
[341]. Nuclear YAP localization and subsequent transcription of TEAD-targets has 
been shown to depend on the LINC complex in strain-responsive cells [342], 
indicating a link between nuclear tension and changes in gene expression.  
Another class of structural components within the nucleus, the Lamins, may also play 
key roles in the transduction of mechanical signals from the cytoplasm [343]. Lamins 
regulate nuclear architecture, chromatin organization [344] and epigenetic control 
of gene expression [345]. They are localisaed to the nuclear lamina, between the LINC 
complex and chromatin bundles [346]. LaminA expression in MSCs correlates with 
tissue stiffness and has also been shown to be greater in cells exposed to stiffness-




coordinate actin dynamics of the cytoskeleton. It ensure formation of contracted 
actin bundles, and nuclear translocation of mechanoresponsive transcription factors, 
YAP [347] and Megakaryoblastic Leukemia (Translocation) 1 (MKL1) [348] [349]. 
 
1.4.7. Mechanotransduction during articular cartilage development and 
maintenance 
There is a multitude of evidence suggesting the role of mechanotransductive 
pathways during maintenance of the articular chondrocyte phenotype. Correlation 
between cell shape and stability of the articular chondrocyte phenotype has long 
been suggested, with spread articular chondrocytes compared to those of a smaller, 
polygonal shape exhibiting hypertrophic characteristics [350]. Reducing substrate 
adhesion and cell spreading enhances the cartilage ECM-producing ability of 
chondrocytes [351] and this is concomitant with that shown by Kim et al. These 
authors observed a progressively-higher susceptibility of chondrocytes to develop an 
OA-phenotype when cultured on substrates of increasing stiffness [352]. This OA-
phenotype was marked by increased mRNA expression of MMP13 and ADAMTS5, 
whilst reducing SOX9, COL2A1 and ACAN mRNA. These changes in chondrocyte 
phenotype were shown to be mediated via ROCK-induced cytoskeletal tension due 






1.4.7.1. Effect of substrate stiffness, cytoskeletal tension and actin 
organisation during chondrogenesis 
Cell shape is an influential aspect of mesenchymal progenitors in the limb bud 
condensation and the subsequent chondrogenic differentiation program. Ray et al 
demonstrated the round actin arrangement of chick limb bud mesenchymal cells 
prior to formation of the growth plate. Treatment of this ex vivo culture with 
Cytochalasin D inhibited myosin contraction and the round actin arrangement 
required for SOX9 and COL2A1 mRNA expression [353]. This implies that cortical actin 
organization is a product of cytoskeletal tension in limb bud cells and is responsible 
for their observed round morphology and downstream chondrogenesis. Gao et al 
investigated the effect of cell spreading on the chondrogenesis of hMSCs. Collagen 
Type II protein and SOX9 mRNA were increased in hMSCs which were 
chondrogenically-induced on 1024μm2 islands compared to that on 10,000μm2 
islands [354]. This study therefore directly implicates cell shape in downstream 
chondrogenic differentiation programs.  
The specific stiffnesses of cartilage and subchondral bone are important in directing 
osteochondral mesenchymal progenitors down the chondrogenic [355]/osteoblastic 
lineages [304], in addition to being required for the specific functions of each tissue. 
The elastic modulus from subchondral bone, through to articular cartilage has been 
shown to vary in the order of three magnitudes – ranging from approximately 2.3GPa 
to 2.6MPa for bone and cartilage respectively [356, 357] (Fig. 1.3) [1]. Allen et al 
utilised Collagen Type I-coated polyacrylamide gels to demonstrate stiffness 




in cell shape or area [355]. In this study, despite fewer long stress fibres and more 
cortical actin observed in hMSCs on the 0.5 Megapascal (MPa) substrate compared 
to those on the 1.1MPa, no significant change in cell morphology was observed. 
Despite this lack of shape change, hMSCs on the 0.5MPa surface upregulated 
transcription of SOX9, COL2A1 and ACAN compared to that at 1.1MPa.  
In the study by Allen et al, chondrogenesis on the 0.5MPa substrate in which a cortical 
actin arrangement was present in hMSCs, was reduced by ROCK inhibition. This same 
inhibition appeared to increase cartilage differentiation on the stiff substrate on 
which hMSCs displayed long actin stress fibres. This, suggests the importance of 
ROCK-mediated cortical actin organization for chondrogenesis, as opposed to ROCK-
mediated long stress fibre formation which is detrimental to chondrogenic induction. 
Kwon et al observed an increase in SOX9 and COL2A1 mRNA and Collagen Type II 
protein by murine BM-MSCs on a 1KPa substrate, compared to those on a 150KPa 
substrate [358]. Blebbistatin treatment was observed to reduce the increases in 
chondrogenic mRNA levels on the 1KPa substrate, implicating MLC2 contraction in 
generating the specific cortical actin organization required for chondrogenesis. 
Together these studies point to polar-opposite effect of cytoskeletal tension on 
chondrogenesis, dependent on the elasticity of the substrate on which cells are 
seeded. On a soft substrate RhoA/ROCK-mediated actin reorganization may be 
conducive for chondrogenesis by inducing cortical actin formation of differentiating 
cells. This is as opposed to cells on a stiff substrate in which ROCK induces stress fibre 





1.4.7.2. Role of RhoA/ROCK during chondrogenesis 
The role that RhoA/ROCK plays in generating and maintaining an articular 
chondrocyte phenotype is context-dependent. In micromass cultures ROCK 
inhibition abolished the early expression of SOX9 targets and transcriptional co-
activators in murine limb bud mesenchymal stem cells (Woods, 2006). This decrease 
in chondrogenesis is also induced by cytoskeletal destabilisation, whilst stimulation 
of actin polymerisation increased chondrogenesis [307]. The culture system utilized 
in this study was a high-density, micromass culture, in which a rounded/oval 
morphology has been shown to be adopted by individual cells [307]. Therefore the 
finding by Wood and Beier supports previous reports of the role of RhoA/ROCK-
mediated cortical actin organization for chondrogenesis. This is also supported by the 
observation that ROCK inhibition decreases the expression of chondrogenic genes in 
ATDC5 cells on softer substrates where fewer long stress fibres and increased cortical 
actin is displayed [355]. This is contrasted with observations on comparatively stiff 
substrates where ATDC5 stress fibre formation is increased and on which, 
chondrogenesis is enhanced by ROCK inhibition. This again indicates that ROCK is 
required to maintain both cortical organization and long stress fibre formation on 
soft and stiff substrates respectively. However ROCK is required for chondrogenesis 
only when differentiating cells take on a round morphology, for example when 
present on ECM of low stiffness or in high-density cultures.  
In addition to mediating the mechanotransducive effect on chondrogenesis, 
RhoA/ROCK is able to regulate SOX9 activity directly. The stability of SOX9 in ATDC5 




sequence [359]. In chondrosarcoma cells, Haudenschild et al identified a specific 
amino acid sequence within the SOX9 polypeptide which denotes it as a target of 
ROCK-mediated phosphorylation [360]. These authors then observed the ROCK-
mediated dose-dependent increase of SOX9 phosphorylation. Nuclear localization of 
SOX9 is required for transcription of its chondrogenic target genes [361]. Therefore 
observation of the abolishment of TGF-β1-induced nuclear SOX9 translocalisation by 
ROCK inhibition,  suggests the requirement of ROCK activity for SOX9 function during 
chondrogenesis [360]. The activity of RhoA and ROCK have also been demonstrated 
to positively-influence the TGF-β1/3-Smad2/3 pathways during chondrogenesis. Xu et 
al observed on an inhibition of TGF-β1-induced SOX9, COL2A1 and ACAN transcription 
in synovium-derived MSC, due to inhibition of RhoA or ROCK [362]. This was shown 
to be due to the requirement of RhoA-stimulated ROCK activity in the 
phosphorylation of Smad2 and Smad3.  
 
1.4.7.3. Role of YAP/TAZ during chondrogenesis 
The consensus for the role of YAP/TAZ during chondrogenesis is that of a down-
regulatory one. Deng et al observed a progressive decrease in YAP1 expression during 
the differentiation of chondro-progenitor cells into those capable of depositing a 
GAG-rich ECM [363]. This was synonymous with observations during endochondral 
bone development in which the cartilage growth plate expresses low levels of un-
phosphorylated, and therefore active YAP. This is in contrast to the increased 
expression in that of surrounding perichondrium, containing osteoblasts required for 




chondroprogenitor cells results in a significant reduction in GAG and Collagen Type II 
production and instead, halts their differentiation whilst maintaining their 
proliferative state [363]. Karystinou et al observed a reduction in YAP1 mRNA and 
protein in response to TGF-β1-mediated chondrogenic induction of synovium-derived 
MSCs [364]. These authors also observed a decrease in chondrogenesis of the MSC 
cell line, C3H10T1/2 in response to retroviral delivery of the YAP1 gene. This was 
marked by reduced SOX9 and COL2A1 mRNA expression in addition to diminished 
Alcian Blue staining of GAGs. Mechanistically, this was proposed to be via 
downregulation of BMP signalling due to observation of reduced Smad1/5/8 
phosphorylation in YAP1-delivered MSCs.  
Zhong et al observed the decrease in transcription of RUNX2 and COL1A1 in response 
to siRNA knockdown of YAP1 in rat BM-MSCs [365]. This was accompanied by an 
increase in SOX9, COL2A1 and ACAN expression. Together this demonstrated the role 
of YAP in promoting a pro-osteogenic and anti-chondrogenic transcriptional program 
in mesenchymal progenitors. The requirement of YAP downregulation for 
maintenance of the chondrocyte phenotype has also been demonstrated by 
observation that its siRNA-mediated knockdown result in increases in SOX9, COL2A1 
and ACAN mRNA [366]. This corresponded with observations in the same study of 
the downregulation of these chondrogenic transcripts in response to siRNA 
knockdown of LATS1. This gene encodes a kinase which inhibits YAP nuclear 
translocation [367]. 
 





1.4.8.1. Regulation of cytoskeletal tension and organisation by hypoxia and 
HIF 
The effect of hypoxia and HIF on formation of actin stress fibres and cytoskeletal 
tension has been extensively investigated. Overall, the evidence points to the ability 
of hypoxia to upregulate stress fibre formation in a variety of cell types. For example, 
Vogler et al demonstrated the increased spreading of L929 Fibroblasts upon 
incubation at 1%O2 compared to cells cultured in normoxic conditions [368].  This 
was associated with increased intensity of actin staining in cortical patterns around 
the nucleus in addition to a greater number of actin focal points. These structures 
denote regions where the cytoskeleton is linked with the ECM via adhesion 
complexes thereby signifying increased cytoskeletal tension [369]. Cytoskeletal 
contraction and re-arrangement also occurs due to hypoxia in many cancer cell types 
such as neuroblastoma [370], adenocarcinoma cells [371] and breast cancer cells 
[372]. In the case of the latter, incubation at 1%O2 for 24 hours increased the number 
of visible actin stress fibres in the MDA-MB-231 breast cancer cell line compared to 
culture at 20%O2. Hypoxia was also observed to increase tension within these breast 
cancer cells, as assessed by their ability to retract the Collagen Type I gel onto which 
they were seeded. This was accompanied by increased MLC2 phosphorylation 
denoting contraction of this myosin sub-type.  
The ability of hypoxia-incubated MDA-MB-231 cells to generate focal adhesions 
compared to that at normoxia was demonstrated. A group observed increased 




incubation of the breast cancer cells. This corresponded with greater levels of FAK 
phosphorylation which is indicative of downstream integrin signalling in cells of a 
high tensegrity [373]. HIF has also been shown to regulate cytoskeletal 
rearrangement in endothelial cell spheroid cultures. In this study, Weidemann et al 
observed an increase in the concentric F-Actin arrangement around the nucleus in 
response to treatment with HIF-1α stabilizing agent- Dimethyloxalylglycine (DMOG) 
[374]. Again in breast cancer cells, siRNA knockdown of HIF-1/2α abolished hypoxia-
mediated increases in cell contraction, focal adhesion formation and 
phosphorylation of FAK, similar to levels observed at normoxic conditions [372].  
Cofilin is an actin-binding protein which by performing its function, blocks G-actin 
polymerization which is required for stress fibre formation. Knockdown of PHD2, the 
oxygen-sensing hydroxylase responsible for targeting HIF-1α for degradation, was 
observed to increased stress fibre formation in HeLa cells [375]. This phenomenon is 
mediated by increased phosphorylation and inactivation of Cofilin and was replicated 
by treatment of wild type cells with DMOG.  
Another mechanism by which HIF increases focal adhesion formation and 
cytoskeletal contraction, is via transcriptional induction of genes encoding Integrin 
receptors. For example, Skuli et al observed increases in protein levels of Integrin-β5 
in response to hypoxic incubation in a glioma cell line, and this also was accompanied 
by increases in Vinculin and FAK phosphorylation [376]. siRNA knockdown of 
Integrin-β5 inhibited hypoxia-mediated increases of phosphorylated FAK. This 
suggests the requirement of increased integrin-mediated ECM adhesion in 




mRNA levels encoding Integrin-α6 in a breast cancer cell line, and this increase was 
abolished by HIF-1α knockdown [377]. Identification of a HIF-response element 
within the gene encoding this integrin subtype is suggestive of the ability of hypoxic-
induced transcription to directly upregulate integrin-mediated signalling. 
 
 
1.4.8.2. The regulation of RhoA/ROCK by hypoxia and HIF 
Corresponding to the majority of the literature which describes the positive effect of 
hypoxia on stress fibre formation, low oxygen tension has been shown to induce the 
activity levels of the both RhoA and ROCK. In breast cancer cells, Gilkes et al identified 
HIF-response elements in the promoter regions of both RHOA and ROCK1, 
demonstrating an ability of this transcription factor complex to directly upregulate 
RhoA and ROCK1 expression [372]. Indeed, these authors demonstrated an increase 
in mRNA encoding RhoA and ROCK1 in response to incubation in 1%O2 compared to 
culture at normoxia, in addition to observing increases in the corresponding proteins. 
These increases were also shown to be abolished by HIF-1/2α knockdown. Therefore 
hypoxia-induced HIF is implicated as the regulatory mechanism of RhoA/ROCK 
activity during breast cancer cytoskeletal contraction.  
González Rodríguez et al identified the hypoxia-mediated regulation of RhoA/ROCK 
in rat cardiomyocytes [378]. Interestingly, despite a lack of effect on RHOA and 
ROCK1 mRNA due to a 4-hour hypoxic incubation, an increased in RhoA and ROCK1 
protein were observed in addition to an induction of RhoA activity. Additionally, 




was present. Despite demonstrating a hypoxia-mediated induction of RhoA/ROCK 
protein, this study is suggestive of a context-dependent regulation of RHOA and 
ROCK1 transcription by HIF, despite both these genes containing HIF-response 
elements in their promoter regions. Following on from this, in colon cancer cells, 
Mizukami et al observed an increase in the active, GTP-bound form of RhoA due to 
hypoxic incubation, despite no overall increases in RhoA protein [379]. This increase 
was abolished by inhibition of phosphoinositide 3-kinases demonstrating a novel 
pathway by which hypoxia regulates RhoA activity. This effect of hypoxia on RhoA 
induction was also observed to be required for induction of the transcription of 
VEGFA, a long established HIF target [379]. This was demonstrated by hypoxia-
mediated increases in VEGFA mRNA being abolished by RhoA or ROCK inhibition. This 
indicates the potential requirement of RhoA and ROCK in mediating hypoxia-induced 
HIF signalling.  
With regards to evidence of increased ROCK activity due to hypoxia, Nakanishi et al 
demonstrated the increase of ROCK activity due to hypoxia in lung smooth muscle in 
vivo [380]. In response to incubation of a mouse in a mild hypoxia (10%O2), the 
authors observed an upregulation of MLC2 phosphorylation within smooth muscle 
cells of the lung. This was accompanied by an increase in phosphorylation of myosin 
phosphatase. These changes were abolished by ROCK inhibition with Y-27632 
thereby demonstrating the ability of hypoxia to induce activity of ROCK that is 
conducive for myosin light chain contraction. 
 




Hypoxia has been shown to influence the availability of YAP as a binding partner for 
TEAD transcription factors in a number of cancer cell types. In prostate cancer cells 
[381], hepatocellular carcinoma cells [382] and breast cancer cells [383], the nuclear 
localisation of YAP is induced by hypoxic culture. This is simultaneous with a decrease 
in the inactive, phosphorylated YAP. In the study by Ma et al, hypoxia downregulated 
the hippo pathway and increased levels of activated YAP. This increased in YAP was 
shown to be mediated via an increase in expression of Zyxin which plays a key role in 
the focal adhesion complex in response to integrin engagement [384]. The findings 
by Ma et al are therefore suggestive of a role for hypoxia in regulating the levels of 
active YAP via changes in formation of the cell adhesion complex and the 
transduction of ECM stiffness by the cell. 
 
1.5. The research aims of the thesis - utilising hypoxia and HIF signalling in BM-MSC 
chondrogenesis  
Hypoxia plays critical roles during chondrogenesis of mesenchymal progenitors and 
cartilage ECM formation, both during limb development and in vitro chondrocyte 
specification. This suggests the role that hypoxia may play in achieving a cell 
phenotype and ECM composition from BM-MSCs which mimics articular 
chondrocytes and native articular cartilage in which they reside. Generation of 
native-like articular cartilage is required for the repair of chondral defects. This may 
enable the desired mechanical properties of the regenerated cartilage which would 
enable resistance to the compressive and tensional forces on the joint during 




required to achieve optimal chondrogenesis and cartilage ECM formation, whilst 
inhibiting chondrocyte hypertrophy – a common issue with current CTE strategies. 
Therefore the first results chapter of this thesis - chapter 3, describes data which 
compares the effects of 5% with 2%O2 during hBM-MSC chondrogenesis.  
The primary mediator of signalling in response to physiological hypoxia is the HIF 
transcriptional complex. During BM-MSC chondrogenesis, the functions of HIF and 
its alpha subunit – HIF-1α are required for expression of articular chondrocyte 
markers and an ECM which mimics native articular cartilage. Therefore, the use of 
chemical agents which upregulate HIF-1α may provide a valid alternative to the use 
of hypoxia during hBM-MSC chondrogenesis.  
The use of HIF-1α-stimulating compounds would avoid the potential pitfalls 
associated with the incubation of BM-MSCs at low-oxygen conditions. These include 
the upregulation of the unfolded protein response which may reduce the protein 
translation required for stem cell differentiation. The use of HIF-1α-upregulating 
compounds would also enable spatial control of hypoxic signaling in BM-MSCs on a 
biomaterial scaffold. Therefore chapter 4 describes a study which compares the role 
of three widely-used HIF-1α-stimulating compounds during BM-MSC 
chondrogenesis. The aim of this study was to compare which of Cobalt Chloride, 
Desferroxamine and Dimethyloxaloylglycine are able to stimulate articular 
chondrogenesis, formation of articular cartilage ECM and inhibition of chondrocyte 
hypertrophy. 
The final results section – chapter 5, aims to investigate the crosstalk between 




mechanical stiffness of the cell microenvironment. As described in section____, 
mechanotransducive pathways have been shown to be integral during BM-MSC 
chondrogenesis, with ROCK-mediated cytoskeletal tension and a round cell 
morphology required for chondrocyte differentiation. In addition to the role of 
hypoxia during chondrogenesis, regulation of components of the 
mechanotransducive pathway by low-oxygen conditions has been demonstrated. 
Together, these suggest the potential of hypoxia in upregulating 
mechanotransducive pathways that are conducive for chondrogenesis. The results in 
chapter 5 investigates this effect of hypoxia with observations potentially informing 
CTE strategies in which hypoxic culture of BM-MSCs is combined with biomaterial 
scaffolds of a defined stiffness.  
The overarching hypothesis for the thesis is as follows: hypoxia is able to improve 
chondrogenesis of BM-MSCs and inhibit hypertrophy. This improvement of 
chondrogenesis is able to be replicated by the use of a HIF-1α-stabilising compound. 
Finally, hypoxia induces BM-MSC chondrogenesis through regulation of 
mechanotransducive pathways via generation of cytoskeletal tension and cell shape 
that are conducive for articular chondrocyte differentiation. Together, chapters 3-5 
detail results which inform the improvement of BM-MSC chondrogenesis to achieve 
an articular chondrocyte phenotype which more closely mimics those present in 
native articular cartilage. Such improvements utilising hypoxia would enable the 
development of CTE strategies for repair of chondral defects by ensuring production 
of an articular cartilage ECM and inhibition of chondrocyte hypertrophy. This would 




of articular cartilage whilst inhibiting inappropriate ossification of the graft when 
implanted in vivo. 
 
 
2. Materials & Methods 
 
 
2.1. Isolation of hBM-MSC 
hBM-MSCs were provided by Dr. Holgar Auner of Department of Medicine, Imperial 
College London. Due to this material being provided by a collaborator and not 
isolated by within the lab of Dr. Eileen Gentleman, it was not possible to obtain BM-
MSCs from more than a from a single donor . This introduces a caveat to the present 
study due to the heterogeneity exhibited by BM-MSCs harvested from different 
donors with regards to their chondrogenic potential. However, there exists a 
concordance between observations made of BM-MSCs here with that in the 
literature, such as the HIF-response to hypoxic incubation and chondrogenic-
induction by TGF-β3. This suggests that the novel observations made here are not 
indicative of an anomalous BM-MSC donor source but instead, may represent BM-
MSCs of similar characteristics as utilized in the literature. Thereby, these findings 
may inform the development of chondrogenic induction protocols for BM-MSCs. 
Human samples used in this research project were obtained from the Imperial 
College Healthcare Tissue Bank (ICHTB, HTA license 12275). ICHTB are supported by 
the National Institute for Health Research (NIHR) Biomedical Research Centre based 




College London. ICHTB is approved by the United Kingdom (UK) National Research 
Ethics Service to release human material for research (12/WA/0196), and the 
samples for this project were issued from sub-collection R16052. Bone marrow 
aspirates were collected and plated in CellSTACK® (Corning) culture chambers at a 
density of 10-25x106/636cm2. Cells were then cultured in αMEM supplemented with 
5% human platelet lysate (Stemulate) and cultured under standard conditions. When 
cell confluence of 90-100% was achieved (10-14 days), cells were detached with 
recombinant trypsin (Roche) and reseeded at 5000 cells/cm2.  
Cultures were immunophenotyped and found to express CD90, CD105, CD73 and not 
express hematopoietic markers CD34 and CD45 (data now shown). Antibodies used 
identify expression of these markers were: CD90-Fluorescein Isothiocyanate (FITC) 
[166-095-403], CD105-Allophycocyanin [385-094-926], CD73- Phycoerythrin (PE) 
[385-095-182], CD34-PE [385-081-002], and CD45-FITC (#130-098-043; all from BD 
Biosciences) using a FACSCalibur™ Analyser (BD Biosciences). 
 
2.2. Expansion  and cryopreservation of hBM-MSC, bovine chondrocytes and C28/I2 
cell line 
Following their isolation, hBM-MSCs were plated onto T-175 tissue culture flasks for 
their expansion in the following conditions: 20%O2, 5% Carbon Dioxide (CO2) at 37○C.  
Growth media (GM; 10% (v/v) Fetal Bovine Serum (FBS; Life Technologies) in α-
Minimal Essential Media (αMEM; Life Technologies)) was added to each flask and 




were passaged by an initial wash in Phosphate Buffered Saline (PBS; Life 
Technologies) and enzymatic dettachment from the flask surface with treatment 
with 0.05% (v/v) Trypsin-Ethylenediaminetetraacetic acid (EDTA) (Life Technologies) 
for 3 minutes at 37○C. Following collection of resulting cell suspension and washing 
of residual cells from the flask with GM, cells were centrifuged at 1200 Relative 
Centrifugal Field (RCF) for 5 minutes. The resulting pellet from one flask was then re-
suspended in GM and divided equally between three recipient flasks which was also 
each added to with GM. Flasks were incubated for 24 hours before their inspection 
on a Zeiss brightfield microscope and subsequently incubated for a further 48 hours 
before the GM was changed and expansion was carried out.  
For cryopreservation of hBM-MSCs, trypsin-EDTA was used for cell detachment and 
suspensions were pelleted as with the passaging protocol but pellets from each flask 
were instead re-suspended in a 1:1 mixture of GM and Cryopreservation media (20% 
(v/v) Dimethyl sulfoxide (DMSO; Sigma Aldrich) in FBS). The suspension from one 
flask was then transferred to a single cryopreservation vial which was frozen at -80○C 
in an iso-propanol container before transfer to storage in liquid nitrogen.  
For thawing of frozen cells, each vial was removed from liquid nitrogen storage and 
thawed rapidly at 37○C. This was subsequently followed by dilution of the cell 
suspension in GM in a 1:10 ratio. Suspensions were then centrifuged at 1200 RCF for 
5 minutes, before re-suspension of the pellet and division between three T-175 flasks 
each containing GM. Flasks were incubated for 24 hours before their inspection on a 
Zeiss brightfield microscope, changing of the GM and expansion as described above. 




with identical protocols to that used for hBM-MSC culture with the exception of the 
composition of GM. GM consisted of Dulbeccos MEM (DMEM; Sigma Aldrich) + 10% 
(v/v) FBS + 1% (v/v) Antibiotic Antimycotic (ABAM; Sigma Aldrich) for the bovine 
chondrocytes and DMEM + 10% (v/v) FBS for the C28/I2 cell line. 
 
2.3. Chondrogenic Induction of hBM-MSC and bovine chondrocytes as monolayers, 
pellets and on PA gels. 
Frozen vials of hBM-MSCs and bovine chondrocytes were thawed and expanded up 
until passage 5, before their trypsinisation and plating into multi-well tissue culture 
plates for monolayer chondrogenic induction. Following the cell counting of the BM-
MSC suspension, separate dilutions of this suspension were made in GM for seeding 
into tissue culture plates of each size of well. The cell suspensions were diluted such 
that when set volumes were pipetted into each well, a universal cell density of 
30,000/cm2 or 5000/cm2 was achieved for TCP or PA subtrates respectively . See 
appendix figure 1 for cell concentrations and pipetting volumes for wells of each size. 
See appendix figure 2 the overall workflow detailing the chondrogenesis of hBM-
MSCs. 
In addition to the universal cell densities used, other control measures were put into 
place to minimize the effect of sample-to-sample cell number variation due to 
proliferation/cell death. hBM-MSC cell number in control conditions did not vary 
significantly (p=<0.05) throughout chondrogenesis appendix figure 3. In conditions 
in which cell number at time of sample harvest did vary from the control condition, 




each assay entry in this chapter for how quantitiative/semi-quantitative data was 
normalized to cell number . 
 In addition to chondrogenic induction of hBM-MSCs, bovine chondrocytes were 
utililsed as a positive control for cartilage ECM formation. By detection of GAG’s 
produced by bovine chondrocytes, it was possible to optimize Alcian Blue staining for 
GAGs in addition to allowing selection between TGF-β1 or TGF-β3 for future 
chondrogenic-induction experiments. 
 For pellet chondrogenesis, hBM-MSC and bovine chondrocytes were divided into 
aliquots of 2x105 cells in 15ml flacon tubes before their centrifugation at 1200 RCF 
for 5 minutes. Monolayer cultures and pellets were incubated for 24 hours in GM, 
prior to induction using standard chondrogenic differentiation media (CDM). CDM 
consisted of High Glucose Dulbecco's Modified Eagle Medium (Sigma Aldrich) + 2mM 
L-Glutamine (Thermo Fisher Scientific) + 100nM Dexamethasome (Sigma Aldrich) + 
1% (v/v) Insulin, Transferrin, Selenium Solution (Thermo Fisher Scientific) + 1% (v/v) 
ABAM solution (Sigma Aldrich) + 50μg/ml Ascorbic acid-2-phosphate (Sigma Aldrich) 
+ 40μg/ml L-proline (Sigma Aldrich). This was then supplemented with either 
10ng/ml TGF-β1 or TGF-β3 (Peprotech).  
For upregulation of HIF-1α, CDM was supplemented with the following compounds 
(Sigma Aldrich): 100μM Cobalt Chloride (CoCl2), 50μM Desferrioxamine (DFX) and 
200μM DMOG. For hypoxic incubations, hBM-MSCs in un-supplemented CDM were 
incubated in a cell culture incubator which was set to 5%O2 + 5%CO2 or in an 
incubator set at 2%O2 + 5%CO2. To achieve HIF-1α inhibition, media was further 




were conducted to identify which of TGF-β1 or TGF-β3 were more optimal for 
chondrogenesis with bovine chondrocyte cultures used as a positive control for 
cartilage ECM production.  
hBM-MSCs and bovine chondrocytes were also differentiated as pellet cultures to 
ensure CDM promoted the production of cartilage ECM in 3D culture (Appendix Fig. 
4). This was due to the premise that results in the present study may enable 
improvement of strategies for cartilage tissue engineering within 3D biomaterial 
scaffolds.  Pellet cultures at time points specificed were washed in PBS and fixed in 
4% (w/v) Paraformaldehyde (PFA) before histological processing (Appendix Fig. 5). 
Following paraffin wax embedding, sectioning of pellets into 10μm slices and 
mounting onto glass cover slides, samples were then histochemically stained as 
described in Appendix Fig. 6. 
 
2.4. Polyacrylamide gel synthesis and hBM-MSC culture 
Synthesis of PA gels was conducted by Daniel Foyt who also aided in carrying out 
experiments in which BM-MSCs were chondrogenically-induced on these gels. 0.5ml 
of 100mM Sodium Hydroxide (NaOH) was dispensed evenly onto a 25mm glass 
coverslip and the water was allowed to evaporate at 80°C leaving a thin crystalline 
layer of NaOH. 0.2 mL of (3-Aminopropyl)triethoxysilane was dispensed evenly onto 
the NaOH coated coverslip and allowed to react for 5 min after which the coverslip 
was thoroughly washed with DI water and placed in 2ml of 0.5%(v/v) glutaraldehyde 
in PBS for 30min. Coverslips were then removed from the glutaraldehyde solution 




methylenebis(acrylamide), and PBS were mixed in the proportions shown in 
appendix figure 10A. Gel precursors were degassed under strong vacuum for 15min. 
Glass microscope slides were coated with 0.1 ml of Dichlorodimethylsilane (DCDMS) 
and allowed to react for 2min. Microscope slides were washed with DI water and 
dried. Tetramethylethylenediamine (TEMED) and ammonium persulfate (APS) were 
added to the gel precursors according to the ratios above and vortexed for 30 sec. 
0.05ml of gel solution was dispensed onto the DCDMS coated microscope slides. 
Coated coverslips were then placed coated side down onto the gel solution and the 
gel was allowed to cure for 30 min. Substrates were washed over night in 10 ml of 
PBS with gentle agitation.  
Substrates were washed again 3 times in 5ml of PBS for 5 min. 0.5ml of 0.5mg/ml 
sulfosuccinimidyl 6-(4'-azido-2'-nitrophenylamino)hexanoate (Sulfo-SANPAH) 
dissolved in 50mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 8.5) 
(HEPES) was dispensed onto the substrates and substrates were exposed to UV light 
for 20min. Substrates were wash 3 times in 5ml of HEPES. Substrates were placed in 
2ml of 0.015mg/ml fibronectin solution in HEPES and agitated gently over night at 
4°C. Fibronectin coated substrates were washed 3 times in PBS and stored at 4°C for 
up to 2 weeks.  
After washing in PBS overnight, one PA gel was placed in each well of a 6-well plate 
prior to seeding with hBM-MSCs and chondrogenic induction for which the following 
procedure was followed. hBM-MSCs were detached from the plastic surface with 
0.05% (v/v) Trypsin-EDTA, re-suspended in GM and cells were carefully distributed in 




an initial 4-hour attachment period at 20%O2, 5%CO2 and 37○C, each well containing 
a single PA gel was supplemented with 2ml GM. A further 24-hour incubation period 
was carried out and GM was then replaced by CDM containing TGF-β3 with each gel 
incubated further at either 20%O2 or 2%O2 conditions as indicated. The length of the 
final incubation step is indicated in each figure legend and represents the 
‘chondrogenic-induction phase’ of the experiment. Where also indicated, CDM was 
further supplemented with 10μM Y-27632 to achieve ROCK inhibition.  
 
2.5. PicoGreen assay for quantification of dsDNA and cell number  
At indicated time points, samples were washed in PBS and snap-frozen at -80 ⁰C 
followed by their digestion in 400μg/ml Papain in a 0.2M Trisodium Phosphate buffer 
which also included 10mM EDTA and 10mM L-Cysteine. This digestion step was 
carried out at 65⁰C for 18 hours with constant agitation after which the cell lysates 
were frozen at -20⁰C until quantification of double stranded DNA using a PicoGreen 
kit (Thermo Fisher Scientific). PicoGreen dye was diluted in a 1:200 ratio with TE 
buffer which consists of 10mM Tris-Hydrochloric Acid (HCL) and 1mM EDTA at pH 
7.5. PicoGreen dye was then further diluted in a 1:1 ratio with one of each of the 
Papain-digested lysates in a single well of an opaque 96-well plate. Samples of each 
lysate were prepared in triplicate in this manner. Following a subsequent 10-minute 
incubation step in the dark at room temperature, fluorescence intensity was 
quantified with a Flexstation fluorescent plate reader. Using double-stranded DNA 
(dsDNA) standards provided in the PicoGreen kit, a linear relationship was observed 




number were also used to determine a linear relationship between hBM-MSC 
number and PicoGreen fluorescence intensity. 
 
2.6. Neutral Red Assay for quantification of cell viability 
At the time points specified, cultures were washed with PBS and replaced with 
identical media + 10% Neutral red dye (Sigma-Aldrich). Samples were then incubated 
with hBM-MSCs for 2 hours in identical culture conditions as that prior to Neutral 
Red treatment.  This was followed by sample fixation in 0.1% (w/v) Cadmium Chloride 
(CdCl2) + 0.5% (w/v) PFA. Dye retained by hBM-MSC was solubilised in 1% (v/v) Acetic 
Acid + 50% (v/v) Ethanol for 10 mins with gentle agitation. Quantification of 
solubilised Neutral Red was then performed on an absorbance spectrophotometer 
at 540nm. Samples of known hBM-MSC number were also used to determine a linear 
relationship between hBM-MSC number and PicoGreen fluorescence intensity. 
 
 
2.7. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis for separation of 
proteins in cell lysate based on molecular weight 
Following 24-hours of culture, cells were washed once in PBS and lysed in a buffer 
consisting of 2M urea, 4.8% (v/v) Sodium Dodecyl Sulfate (SDS), 8% (w/v) sucrose (all 
Sigma Aldrich) in Deionised Water (dH2O) for 10 minutes on ice. Lysates were then 
removed from the cell culture vessel with a cell scraper and transferred to 1.5ml 
Eppendorf tubes where they were passed through a 23-guage needle with a 1ml 
syringe. Samples were then stored at -20○C until quantification of total protein with 




to enable equal loading of each conditions for the SDS-PAGE, thereby normalizing for 
changes in cell number at time of sample harvest . 
For the Bicinchoninic Acid (BCA) assay, 25μl of each sample was mixed with 200μl 
BCA solution (1:50 ratio of 4% (w/v) cupric sulfate:sodium carbonate+sodium 
bicarbonate+BCA+sodium tartrate in 0.1M sodium hydroxide) in a single well of a 96-
well plate followed by incubation for 30 mins at 37○C with gentle agitation 
throughout. The protein levels were then quantified using an absorbance 
spectrophotometer at 562nm wavelength. If sample were suspected to be highly 
concentrated or if lysate volume was low, samples were diluted by 2x or 5x in killer 
lysis buffer before mixing with BCA solution. 1, 0.8, 0.6, 0.4 and 0.2mg/ml solutions 
of Bovine Serum Albumin (BSA) were ran alongside samples of unknown protein 
concentration to generate a standard curve from which unknown concentrations 
could be determined.  
For running on the SDS-Polyacrylamide Gel Electrophoresis (PAGE), all samples 
quantified using the BCA assay were diluted to the same concentration. Each sample 
was then further diluted in a 1:4 ratio with Laemmli loading buffer (Biorad) containing 
10% (v/v) 2-mercaptoethnol (Sigma Aldrich) and boiled at 95○C for 5 minutes before 
resting on ice for 10 minutes. 40μl Prepared lysates in loading buffer were loaded 
into 10% (w/v) pre-cast PA gels (Biorad) and SDS-PAGE was performed at 120v for 45 
minutes in which the KaleidoscopeTM ladder (Biorad) was also ran to enable 
determination of protein molecular weight in samples. The buffer used in the SDS-
PAGE consisted of 0.3% (w/v) Trizma Base (Sigma Aldrich) + 1.4% (w/v) Glycine (Sigma 




transferred using the Trans-Blot Turbo Transfer System (Biorad) onto Polyvinylidene 
difluoride (PVDF) membranes which were pre-soaked in absolute Ethanol and 
transfer buffer (40% (v/v) absolute ethanol + 20% (v/v) BioRad Transfer Buffer in 
dH2O).  
 
2.8. Western Blot for detection of proteins separated by SDS-PAGE 
Following protein transfer, PVDF membranes were soaked in blocking solution (5% 
Non-fat milk (NFM) solution in TBST buffer (0.1% (v/v) Tween-20 (Sigma Aldrich) + 
Tris-HCL (Sigma Aldrich) in dH2O)) for 1 hour at room temperature with gentle 
agitation. Membranes were then cut and the half in which proteins were of 100Kda 
or above were incubated in a solution of anti-HIF-1α antibody (h-206; Santa Cruz) 
diluted 1:200 in 5%NFM solution, overnight at 4○C  with gentle agitation. The portion 
of the membrane in which proteins were below that of 100KDa in Molecular Weight 
(MW) were incubated with anti-β-Actin antibody (ab8227; Abcam) for 1 hour at room 
temperature with gentle agitation. β-Actin is a commonly-detected housekeeping 
protein whose expression does not change in response to hypoxic incubation. This 
therefore enabled normalization of the band due to HIF-1α to total protein/cell 
number of each sample . 
Following multiple washes in TBST, membranes were treated with a horseradish 
peroxidase-conjugated secondary antibody (sc-2004; Santa Cruz) for 1 hour at room 
temperature with gentle agitation.  Membranes were washed again in TBST and 
signal was generated from bound secondary antibody with the Chemiluminescent 




(Biorad). HIF-1α and protein levels were generated by densitometric analysis with 
ImageJ and normalised to that of β-Actin.  
 
2.9. Quantitative Polymerase Chain Reaction for quantification of mRNA 
At time points specified, samples were washed in PBS, lysed in buffer consisting of 
1% (v/v) 2-mercaptoethanol in RLT buffer (Qiagen) and stored at -80○C until RNA 
extraction procedure. RNA was extracted from lysates using the RNeasy Mini Kit 
(Qiagen) in which samples were lysed further by passing through Qiashredder spin 
columns before subsequent washes in RW1 and RPE buffers in RNeasy spin columns. 
RNA was eluted from the spin columns in RNase-free H2O and quantified on a 
NanoDrop spectrophotometer.  
100ng of RNA per sample was then reverse transcribed by first incubating with 
Random Primers (Promega) at 70○C for 5 minutes. cDNA complimentary to the input 
RNA was synthesized by incubation of the RNA-Random Primer solution for 1 hour at 
42○C with a solution consisting of 4% (v/v) Moloney Murine Leukemia Virus Reverse 
Transcriptase (MLV-RT; Promega) + 20% (v/v) MLV-RT buffer (Promega) + 5.4% (v/v) 
Polymerase Chain Reaction (PCR) Nucleotide Mix (Promega) all in molecular biology 
H2O (Sigma Aldrich). Resulting cDNA of 25μl final volume was stored at -20○C until 
amplification and quantification of specific transcripts with quantitative polymerase 
chain reactions (qPCR). The loading of 100ng of RNA in the RT of each sample ensures 
that the expression value obtained from the qPCR assay is normalized to cell 
number/total RNA content . 
qPCR was carried out in a CFX384 (Biorad). Each qPCR reaction mixture consisted of 




(Agilent) was used in conjunction with 250/500nM primers (IDT Technologies) 
specific to genes of interest. See qPCR reaction conditions and primer sequences in 
Appendix Fig. 7A and Appendix Fig. 7B respectively.  
Raw cycle of Ct values were converted to transcript copy number by the relative 
standard curve method of analysis, and expression levels were normalised to 
transcript levels of RPL13A . Following normalisation to the housekeeping gene, 
expression levels were then normalised to that of the untreated control to determine 
fold change in expression induced by each treatment.  
Optimal primers were identified through the use of cDNA from cell types theorised 
to express high levels of each transcript to which the primer is specific for. Each 
primer set tested following prediction of binding target with Nation Centre for 
Biotechnology Information (NCBI) Primer Blast was used to amplify serially diluted 
cDNA from these positive controls in order to generate standard curves. These 
standard curves were used to identify the existence of a linear expression between 
input cDNA concentration and Ct value in addition to enabling quantification of the 
reaction efficiency. Selection criteria for each gene of interest: single predicted 
product in NCBI Primer Blast results, a single peak in melt curve compared to no-
template control in which dH2O replaces the cDNA template and an R2 value of >0.9, 
theoretical reaction efficiency of 90-110%. 
 
2.10. Immunodetection of proteins in cultures on tissue culture plastic  
Cultures were washed in PBS, fixed in 4% (w/v) PFA for 15 minutes before further 
PBS washes and storage at 4○C until immunofluorescent staining protocol. Following 




goat serum (Sigma Aldrich) + in 0.1% (v/v) Triton X-100 (Sigma Aldrich) in H2O (PBT), 
fixed monolayers were treated with primary antibody (see Appendix Fig. 8 for 
specific antibodies and concentrations) made up in blocking solution overnight at 
4○C. After binding of the primary antibody to the specific antigen, monolayers were 
washed in 0.1% (v/v) PBT. Rabbit-derived primary antibodies were visualised by 
incubating monolayers with ab150077 (Abcam) for one hour at room temperature 
(dilutions in blocking solution are specified in Appendix Fig. 8 for detection of each 
primary antibody). Mouse-derived primary antibodies were detected by treatment 
with biotin (ab6788, Abcam) for one hour at room temperature and Streptavidin 
(S11223, Thermo Fisher Scientific) for one hour at room temperature with both 
diluted by 1:350 in blocking solution. Cultures were counterstained with 0.1μg/ml 
4',6-diamidino-2-phenylindole (DAPI; Sigma Aldrich) for 1 hour min to visualise cell 
nuclei and fluorescent signal was imaged on an Axiovert200M microscope (Zeiss).  
 
2.11. Immunofluorescence staining of proteins in cultures on PA gels  
Cultures were washed in PBS, fixed in 4% (w/v) PFA for 15 minutes before multiple 
15-minute PBS washes with gentle agitation. Samples were stored at 4○C until 
immunofluorescent staining protocol. Following a blocking and permeabilisation 
period of 1 hour at room temperature in 5% (w/v) BSA + in 0.1M Triton X-100 in H2O 
(PBT), fixed PA gels were treated with primary antibody (see Appendix Fig. 8 for 
specific antibodies and concentrations) made up in 5% (w/v) BSA + PBT overnight at 
4○C. After binding of the primary antibody to the specific antigen, monolayers were 
washed in 3% (w/v) BSA (Sigma Aldrich) + PBT with gentle agitation. Rabbit-derived 




with ab150077 (Abcam) for one hour at room temperature (dilutions in 5% (w/v) BSA 
+ PBT are specified in Appendix Fig. 8 for detection of each primary antibody). The 
secondary antibody solution also included 0.1μg/ml DAPI to visualise cell nuclei and 
fluorescent signal was imaged on an Axiovert200M microscope (Zeiss). Following 
imaging of signal generated due to detection of specific antigen, PA gels were re-
stained with Phalloidin (Sigma Aldrich) at 1:200 dilution in PBS for visualisation of the 
actin cytoskeleton.  
 
2.12. Alcian Blue Staining for detection of glycosaminoglycans 
At time point specified, cultures were washed in PBS, fixed in 4% (w/v) PFA, washed 
subsequently in PBS and stored at 4○C until Alcian Blue staining protocol. Staining 
procedure was as follows. Samples were first washed in 0.1N HCL and stained 
overnight at room temperature with 1% (w/v) Alcian Blue solution, pH 1.0 (Sigma 
Aldrich) prepared in 0.1N HCL. Following another 0.1N HCL wash, stained cultures 
were then rinsed repeatedly in PBS until the waste PBS no longer contained any 
residual Alcian Blue dye. Samples were then counterstained with Haematoxylin 
(Vector Laboratories) to visualise cell nuclei and washed in PBS until the waste PBS 
no longer contained any residual Haematoxylin dye. Staining was imaged with an 
Axiovert200M microscope (Zeiss).  
 
2.13. Glycosaminoglycan quantification 
At day 21 of chondrogenesis, cultures were washed in PBS and frozen at -80 °C before 
their digestion in Papain buffer as described in protocol for cell lysis for the PicoGreen 




GAG assay kit by Blyscan™ in which GAGs were dyed with 1,9‐dimethyl‐
methylene blue and subsequently dissociated with Propan-1-ol solution before 
quantification on an absorbance spectrophotometre at 640nm. Values per culture 
were normalised to levels of dsDNA, which were quantified using the PicoGreen 
assay .  
 
2.14. Immunofluorescence quantification 
Immunofluorescence images were captured using identical gain, exposure and offset 
for all conditions in each experiment. These were determined with positive controls 
that expressed the antigen of interest, and negative controls in which the primary 
antibody was omitted. The same threshold fluorescence intensity for images of all 
conditions within an experiment was set and signal below this threshold was negated 
as non-specific immunofluorescence.  The signal produced above the threshold was 
regarded as bona fide protein detection and was used to create a binary 
representation of the protein localisation pattern of each image. The percentage of 
immunofluorescence staining present within a specified area was then determined 
for each image within each condition. This percentage was then normalized to the 
number of DAPI-positive cells to account for changes in cell number due to 
proliferation/cell death . 
 
2.15. Quantification of cell colonies, area, circularity and HIF-1α/YAP nuclear 
localisation 
For quantification of cell colonies, area, circularity and HIF-1α/YAP nuclear 




Phalloidin staining of actin cytoskeleton was used. The same threshold of 
fluorescence intensity was set for images of all conditions within a single experiment 
and below this threshold, the signal produced was negated as non-specific 
immunofluorescence. The signal produced above the threshold was regarded 
as bona fide protein detection and was converted to a binary representation of the 
protein localisation pattern of each image. Using the corresponding DAPI channel as 
a reference, colonies were counted based on classification of direct cell-cell contact 
occurring with those not engaged in cell-cell contact classified as single cells 
(Appendix Fig. 10B).  
Number of single cells and colonies were quantified in this manner and total cells 
quantified in DAPI channel. Area of counted single cells and colonies in addition to 
single cell circularity were also quantified using the ‘measure’ function in ImageJ 
following thresholding and creation of binary images as described above.  
For quantification of HIF-1α/YAP nuclear localisation, DAPI channel and Alexa488 
channel indicating HIF-1α/YAP signal were used. As before, thresholding and binary 
representations were created from each image. Each DAPI-stained nuclei was 
selected in each image and these selections were superimposed onto the 
corresponding Alexa488 channel. ImageJ’s ‘measure’ function was utilised to 
quantify the percentage of signal present within each DAPI-demarcated area in the 
Alexa488 channel. 
 
2.16. Statistical Analysis 
All statistical analyses were performed in Prism7 (GraphPad) with the Mann-Whitney 




multiple condition comparisons. Non-parametric tests were used as we were unable 
to demonstrate normality in all datasets. Data comprise biological replicates (n 
stated in figure legends), where each replicate represents a single cell culture 













3. The role of low oxygen concentration during chondrogenic induction of human 
bone marrow-derived mesenchymal stem cells. 
 
3.1. Introduction 
CTE is required due to the insufficiency of palliative, reparative and restorative 
strategies for treatment of acute chondral and osteochondral defects. hBM-MSCs 
may represent the most suitable source for CTE due to their ease of isolation, ability 
to be expanded without loss of multipotency and the patient specificity of autologous 
cells. However, a potential limitation to the use of this cell type in articular CTE is the 
propensity for their differentiation into cells with hypertrophic characteristics. This is 
suggested due to observation of COL10A1 and COL1A1 mRNA expression in BM-MSCs 
prior to chondrogenesis [386, 387]. This indicates a priming of these cells for 
secretion of collagens required for hypertrophic and fibrotic cartilage respectively. 
BM-MSC pellet culture and chondrogenesis has also been shown to progressively 
upregulate the expression of both COL10A1 and IL1B mRNA compared to that prior 
to induction [388]. IL1B encodes Interleukin-1β which is a pro-inflammatory cytokine 
shown to induce articular cartilage hypertrophy [389] and development of an 
osteoarthritic phenotype [390]. As pertained to, TGF-β-mediated CTE may also result 
in chondrocyte hypertrophy [198] which may result in mineralisation of the 
regenerated tissue within the chondral defect site [196].  
From formation of the limb bud, through to cartilage growth plate formation and 
during homeostasis of adult articular cartilage, there exists a hypoxic state in which 




play essential roles in the proliferation, differentiation and maintenance of the 
articular chondrocyte phenotype. Unlike that of specific growth factors which are 
expressed in specific temporal patterns, hypoxia is constitutively present and plays 
active role throughout articular cartilage development [259, 262]. This suggests a 
potential role for hypoxia and HIF in CTE. Hypoxia has been shown to block 
chondrocyte hypertrophy and ossification. This demonstrates its potential for 
reducing the drawbacks associated with TGF-β treatment, whilst still allowing 
chondro-induction and cartilage formation.  
The potential for hypoxic signalling in CTE is demonstrated, for example, in a study in 
which BM-MSCs and chondrocyte co-cultures were differentiated within PE micro-
fibre scaffolds. Hypoxic incubation of differentiating cultures within these constructs 
induced expression of chondrogenic mRNA and GAG production, in addition to 
reducing activity of ALP [391]. Duval et al also demonstrated a role for hypoxia in 
improving the chondrogenic differentiation of hBM-MSCs cultured in alginate beads. 
These authors observed the induction of chondrogenic mRNA and reduction of 
transcripts which encode factors conducive for chondrocyte hypertrophy. An 
increased formation of a Collagen Type II and GAG-rich ECM was also observed of 
hypoxia-induced, alginate-encapsulated MSCs following subcutaneous implantation 
into mice [272]. The ability of hypoxia to alleviate chondrocyte hypertrophy in PLGA 
scaffolds was also demonstrated. Tan et al observed a decrease in expression of 
RUNX2 and COL10A1 and an increase in the ratio of COL2A1/COL1A1 mRNA due to 
2%O2, compared to incubation at 20%O2 [392]. Hypoxia in this study also increased 





The role of hypoxia in chondrogenic differentiation and maintaining the phenotype 
of articular chondrocytes relative to CTE approaches conducted at normoxia, 
highlights the potential role for hypoxia in the repair of acute chondral defects. A key 
question however, is that which asks of the severity of hypoxia required to promote 
articular chondrogenesis. The studies by Meretoja and Duval described above utilised 
5% oxygen as their hypoxic condition, with others performing chondrogenic 
induction of BM-MSCs at 3% oxygen for example [393]. Without a direct comparison 
during chondrogenic induction, it is impossible to determine the optimal oxygen 
concentration required to improve this process. For example, the oxygen 
concentrations in the studies by Meretoja and Duval cannot be directly compared 
with that by Bornes et al, due to the use of differing biomaterial scaffolds, which may 
influence the chondrogenic differentiation program of seeded cells. 
Foldager et al demonstrated a trend towards increased mRNA expression of SOX9, 
ACAN and COL2A1 with the oxygen concentration decreased from 21, to 5, to 1% 
during both scaffold and monolayer culture of primary articular chondrocytes [394]. 
Increased GAG release was also observed from human osteoarthritic chondrocytes 
due to 2% oxygen compared to those cultured at 5%O2 [395]. These and other studies 
identifying lower oxygen concentrations as more potent HIF stabilisers [396] points 
to the importance of identifying the optimal hypoxic oxygen concentration for MSC-
based CTE efforts. However, to date there exists no such direct comparison of 5% 
and lower values during hBM-MSC chondrogenesis. Therefore, the aims, hypothesis 





 Aim: Identify which of 5% or 2% oxygen induces greater chondrogenic 
induction of hBM-MSCs in a 2D system on tissue culture plastic (TCP). 
 
 Hypothesis: 2% oxygen stimulates greater stabilisation of HIF transcriptional 
complex than 5%O2, resulting in a greater level of chondrogenic induction. 
 
 Objectives:  
o To identify which of 2% or 5%O2 more potently stimulates HIF stabilisation 
and downstream transcriptional activity during in vitro hBM-MSC 
chondrogenic induction on TCP. 
o To identify which of 2% or 5%O2 more potently stimulates articular 
chondrogenesis and cartilage ECM formation during in vitro hBM-MSC 
chondrogenic induction on TCP. 
o To identify which of 2% or 5%O2 more potently inhibits hypertrophy 










3.2.1. Comparison of TGF-β1 and TGF-β3 during chondrogenic induction of hBM-
MSCs as monolayer and pellet cultures 
A difference between 2% and 5% oxygen regarding the degree of hBM-MSC 
chondrogenesis induced may inform CTE strategies in which hypoxia is to be utilised. 
We initially optimised chondrogenic induction of primary hBM-MSCs in a 2D 
monolayer culture system . This is due to the heterogeneity exhibited by BM-MSCs 
from different donors in terms of regulation of the molecular pathways required for 
their expansion and chondrocyte differentiation. BM-MSCs from female donors for 
example, exhibit higher clone-forming ability than their male counterparts, resulting 
in a higher proliferation rate [397]. BM-MSCs from differing donors also underwent 
varying degrees of chondrogenic induction, with changes in SOX9, Aggrecan and 
Collagen Type II protein demonstrated [398].  
 TGF-β ligands via SMAD3 are the most established drivers of in vitro chondrogenesis 
from hBM-MSCs [77]. The indispensable role of TGF-β ligands in chondrogenic 
differentiation of  limb bud progenitors and cartilage ECM production during limb 
development rationalizes their use within an in vitro model of stem cell 
chondrogenesis [189]. Current methods for in vitro chondrogenesis utilise either TGF-
β1 or TGF-β3 with no overwhelming preference for either demonstrated in the 
literature. Therefore a comparison of these two growth factors during 
chondrogenesis at was employed, with Alcian Blue staining for GAG’s utilised at day 




chondrogenesis with GAGs representing a large constituent of cartilage ECM [399], 
with a timepoint such as day 21 chosen to maximize the presence of GAGs . 
The concentration of 10ng/ml used for TGF-β1 and TGF-β3 represents that used by 
the vast majority of studies in which BM-MSCs are chondrogenically induced . In 
addition, to ensure that differentiating BM-MSCs were exposed to a bioactive 
concentration of either TGF-β ligand throughout the differentiating period, cultures 
were replaced with fresh chondrogenic media at 3-4 day intervals . Treatment of TGF-
β1/TGF-β3 was also combined with culture of hBM-MSCs at a high cell density. This is 
due to the importance of mesenchymal condensation of the limb bud at the onset of 
embryonic chondro-induction [400]. TGF-β1/TGF-β3 were also used in conjunction 
with Dexamethasome, L-Proline and Ascorbic Acid-2-Phosphate due to the role of 
these supplements in promoting cartilage ECM production in vitro [140, 184, 401] .  
Following 21 days of BM-MSC chondrogenic induction, no difference was observed 
in Alcian Blue staining of GAGs between cultures exposed to TGF-β1 or TGF-β3-
containing chondrogenic induction media (Figs. 3.1A-3.1C). This time point was 
chosen due to previous demonstration that abundant GAG production represents 
later stages of chondrogenic induction [402].  Adult bovine chondrocytes have also 
previously been used as an in vitro cartilage model due to the ability of these cells to 
abundantly produce cartilage ECM proteins in response to stimulatory conditions 
[403]. Therefore the effect of TGF-β1 and TGF-β3 again at 10ng/ml was compared 
with regards to GAG production from Bovine chondrocytes following 7 and 14 days 
of culture. At both time points, GAG production by bovine chondrocytes was greater 










Figure 3.1. Comparison of TGF-β1 and TGF-β3 for inducing presence of GAGs in ECM. 
Alcian Blue staining of GAG’s in the ECM surrounding hBM-MSCs and Bovine 
Chondrocytes in presence of TGF-β1/TGF-β3-containing chondrogenic media. A: hBM-
MSCs at day 21 of culture in expansion conditions. B+C: hBM-MSCs at day 21 of 
chondrogenic induction in presence of TGF-β1 (B) and TGF-β3 (C). D+E: Bovine 
chondrocyte cultures at day 7 of culture in chondrogenic media consisting of TGF-β1 
(D) and TGF-β3 (E). F+G: Bovine chondrocyte cultures at day 14 of culture in 








3.2.2. Effect on Collagen Type II mRNA and protein synthesis by human Bone 
Marrow-derived Mesenchymal Stem Cells following TGF-β3-mediated 
chondrogenic differentiation 
Following observation that TGF-β3 enhanced GAG production from chondrogenically-
induced hBM-MSCs compared to that due to TGF-β1, an effect on Collagen Type II 
mRNA and protein was assessed due to TGF-β3. This is due to the importance of 
Collagen Type II both during chondrogenesis and in cartilage ECM function [29]. 
mRNA encoding the alpha helix of Collagen Type II was examined due to the 
importance of COL2A1 transcription during cartilage development [404] . 
Immunostaining of Collagen Type II in chondrogenically-differentiated cultures was 
also conducted due to the large number of post-transcriptional regulatory elements 
of Collagen Type II. Visualisation of Collagen Type II protein therefore indicates 
formation of mature articular cartilage ECM [394]  and as with GAG production , was 
examined at day 21 due to this stage representing that at which adult cartilage is 
formed in vitro ((Solchaga, 2011 #1364)) . Expression of Collagen Type mRNA has 
previously been shown to be upregulated prior to Collagen Type II production and 
incorporation into the ECM at day 21. This therefore prompted investigation of 
COL2A1 expression at 14 of in vitro cartilage induction [269] . 
Figure 2 displays the optimisation of protocols conducted for COL2A1 mRNA 
quantification and Collagen Type II immunostaining. The suitability of primers which 
enabled specific amplification of the COL2A1 gene was assessed by generation of a 
standard curve in which the concentration of serially-diluted cDNA from the 




also repeated for identification of an optimal housekeeping gene to which all 
expression values in this study were normalised. Primers specific to the 
housekeeping gene; RPL13A were used (Fig. 3.2B). The COL2A1 and RPL13A standard 
curves demonstrate a linear relationship between cDNA concentration and cycle 
number in addition to amplifying target cDNA with a theoretical efficiency between 
90-110%. Fig. 3.2D demonstrates the binding of Collagen Type II by the primary 
antibody used in the immunostaining protocol here, following 21 days of 
chondrogenic induction. This is in contrast to that at day 0 of chondrogenesis (Fig. 
3.2C) . The lack of signal in figure 3.2E demonstrates that the signal observed in Fig. 
3.2D is due to the primary antibody and is not background signal or that due to the 
secondary antibody to which the fluorophore is conjugated. 
mRNA was extracted from differentiating cultures at day 14 and TGF-β3 was observed 
to increase levels of the COL2A1 transcript by 3-fold compared to that induced 
without TGF-β3. This was confirmed statistically by comparison of the averaged 
expression values due to each condition using a Mann-Whitney test (Fig. 3.3A). Even 
in the absence of TGF-β3, differentiating cultures at day 21 produced condensed 
clusters of Collagen Type II (Fig. 3.3B) and GAGs (Fig. 3.3D) as assessed by Collagen 
Type II immunostaining and the Alcian Blue histochemical stain respectively . This 
suggests an ability of high-density cultures + non-growth factor supplements in 
enabling a degree of cartilage ECM formation. This may perhaps have been predicted 
due to the ability of Dexamethasome, L-Proline and Ascorbate-2-Phosphate to 
induce ECM production. Despite this however inclusion of TGF-β3 appeared to 
increase the levels of Collagen Type II and GAGs (Figs. 3.3C+3.3E), demonstrating the 




TCP) in our model of chondrogenesis. These precise culture conditions were 








Figure 3.2. Identification of COL2A1-specific primers and optimization of Collagen 
Type II immunostaining. (A+B) Standard curve which demonstrates a linear 
relationship between input cDNA concentration and cycle (Ct) number when 
amplified using COL2A1 (A) and RPL13A (B)-specific primers. (C-E) Immunostaining of 
Collagen Type II in BM-MSC cultures incubated at 20%O2 at days 0 (C) and 21 (D+E) 
of chondrogenesis. Images C+D demonstrate immunofluorescent signal following an 
immunostaining protocol in which the primary antibody was included. Image E was 
taken following an immunostaining protocol in which the primary antibody was 
omitted. Scale bar = 200μm. 
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Figure 3.3. TGF-β3-containing chondrogenic differentiation medium enhances 
chondrogenesis of hBM-MSCs. (A) mRNA expression of COL2A1 at day 14 of 
differentiation under normoxic conditions after normalization to expression of the 
housekeeping gene; RPL13A. Values plotted are fold change relative to -TGF-β3 
condition from 4 independent experiments, with the solid line representing the 
mean.  *denotes p<0.05 compared to -TGF-β3 when compared with a Mann Whitney 
test. (B+C) Collagen Type II immunostaining with DAPI counterstain at day 21 of 
differentiation. Scale bar = 400μm. Representative images of 3 independent 
experiments are shown. (D+E) Alcian Blue staining for glycosaminoglycans with 
haematoxylin counterstain at day 21 of differentiation under normoxic conditions. 




3.2.3. Hypoxia Inducible Factor stabilisation by 5% and 2%O2  
Following identification of TGF-β3-containing induction media as a driver of in vitro 
BM-MSC chondrogenesis, the next aim was to examine the ability of either hypoxic 
state; 2/5%O2 in stimulating the HIF pathway – the archetypal response of cells to 
physiological hypoxia. Each hypoxic state was induced by the culture of BM-MSCs 
within incubators into which specific levels of Nitrogen gas are introduced to displace 
the oxygen and alter its bioavailability to cultured cells . BM-MSCs were induced with 
TGF-β3-containing chondrogenic media as before in a 2D, TCP system  but incubated 
at either hypoxic state for the full differentiating period. The phenotype of the 
chondrogenically-induced cultures which were incubated at hypoxia were compared 
with cultures differentiated at the normoxic (20%O2) condition.  
Cultures were exposed to hypoxia throughout the entire differentiating protocol due 
to the constitutive presence of this factor during in vivo cartilage development [259, 
262] . Compared to normoxic conditions, constitutive hypoxia in vitro did not 
negatively affect cell number throughout the differentiating process, thus suggesting 
their suitability for further experiments . This is illustrated by immuno-labelling and 
counting the number of nuclei in day 21 BM-MSC cultures which were 
chondrogenically induced at 20%, 5% and 2%O2 (Fig. 3.4A). 
One of the key biological markers of physiological hypoxia is increased total HIF-1α – 
the oxygen-responsive subunit of HIF as well as its enhanced nuclear localization. HIF-
1α protein levels are controlled by the hydroxylase; PHD2 whose inhibition reduces 
HIF-1α degradation and correspondingly, increases its stabilization [405] .  Therefore, 




demonstrate the ability of these hypoxic states to block availability of oxygen to the 
active sites of PHD2 and in doing so, stimulate the HIF pathway. This may therefore 
indicate the ability of 2 and 5% O2 to induce BM-MSC chondrogenesis compared to 
normoxic conditions, due to HIF activity being shown to enhance cartilage formation 
in vitro [272]. When assessed by whole-cell Western Blot, which is a common method 
utilised to determine total HIF-1α levels and therefore its stability [406]  , both 5% 
and 2%O2 increased HIF-1α stabilisation at day 1 of chondrogenesis compared to 
normoxic controls (Fig. 3.4B). This was validated by densitometric analysis of each 
biological repeat in which the levels to due to either hypoxic state were shown to be 
significantly higher than that at normoxia, as assessed by the Mann Whitney test (Fig. 
3.4C). The day 1 time point was selected due to the relatively rapid and acute 
upregulation of HIF-1α protein by hypoxia under chondrogenic conditions [407] . 
As with total HIF-1α protein levels, HIF-1α nuclear localization is an indicator of PHD2 
inhibition and suppression of HIF-1α degradation . This is due to evidence which 
demonstrates the passive translocation of HIF-1α into the nucleus and inhibition of 
this phenomenon occurring only due to PHD2-mediated HIF-1α degradation [44] . 
Conversely, increased levels of this protein results in enhanced nuclear translocation 
of HIF-1α and binding to target DNA sequences with the HIF complex [408] . The 
ability of 5% and 2%O2 to induce HIF-1α nuclear localisation was assessed by 
immunostaining for this protein. This was followed by semi-quantification of HIF-1α 
within the subcellular compartments of BM-MSCs in the resulting 
immunofluorescent images. As with analysis of total HIF-1α protein, this was 
conducted at day 1 of chondrogenesis. Under each condition, the total area of 




was above a standardized threshold, was measured in the nucleus of each cell. This 
value was then converted into a percentage of the total nucleus area of each cell 
which was demarcated by DAPI immunostaining .  
Both reduced oxygen concentrations appeared to induce more nuclear HIF-1α (Figs. 
3.4E+3.4F) compared to the normoxic control (Fig. 3.4D). Quantification of HIF-1α 
translocation in these images validated this observation in which nuclear localization 
due to either hypoxic state were shown to be significantly higher than that at 
normoxia, as assessed by the Mann Whitney test (Fig. 3.4G). At each hypoxic level 
compared to that at normoxia, there was an increased number of BM-MSCs in which 
over 50% of the nucleus was occupied by HIF-1α.  
Interestingly, HIF-1α protein was detected in normoxic cultures by Western Blot (Fig 
3.4B) but localisation appeared to be solely restricted to the perinuclear region of 
differentiating BM-MSCs (Fig. 3.4D). This perinuclear localisation of HIF-1α was also 
observed in each hypoxic condition which accompanied the increased nuclear 
presence of this protein (Fig. 3.4E+3.4F). Figure 3.4H illustrates that the signal 
generated in BM-MSC cultures at 2%O2 compared to 20%O2 is due to the HIF-1α 
antibody used and background fluorescence or due to the secondary antibody. It is 
important to note that nuclear fractionation of chondrogenically-induced BM-MSCs 
was attempted for the purpose HIF-1α semi-quantification by Western Blot in the 
nuclear compartment only. However, low levels of total protein per sample 





















Figure 3.4. Both 5% and 2% oxygen levels increase total HIF-1α levels and nuclear 
localisation. (A) Detection of HIF-1α, and housekeeping protein β-Actin at day 1 of 
chondrogenesis by Western Blot. Representative image of 4 experimental repeats 
shown. (B) Protein blots of HIF-1α were quantified by densitometric analysis and 
normalised to levels of β-Actin. Values plotted represent magnitude difference to 
20%O2 condition represented by the horizontal dotted line, with the solid coloured 
lines representing the mean for each condition and *denoting p<0.05 compared to 
20%O2 when assessed by the Mann Whitney test. (C-E) HIF-1α immunofluorescence 
staining at day 1 of chondrogenesis. Scale Bar = 50μm. Representative images of 3 
independent repeats shown. Images were cropped and magnified to clearly visualise 
localisation of HIF-1α. Brightness and contrast was adjusted for all channels to an 
equal degree between all conditions. (F) Quantification of nuclear HIF-1α 
immunofluorescence at day 1 of chondrogenesis. Each value plotted represents the 
percentage of a single DAPI-stained nucleus that is occupied by HIF-1α. Values from 
3 independent repeats shown with the red/black horizontal lines representing the 
mean and *denoting p<0.05 compared to 20%O2 when assessed by the Mann 
Whitney test.  (B-D) Immunostaining of HIF-1α in BM-MSC cultures incubated at 
20%O2 at days 1 of chondrogenesis at 20% (H) and 2%O2 (I+J). Images H+I 
demonstrate immunofluorescent signal following an immunostaining protocol in 
which the primary antibody was included. Image J was taken following an 






3.2.4. Induction of Hypoxia Inducible Factor target gene expression by 5% and 2%O2  
Following HIF-1α stabilisation and increased nuclear localization, an indicator of HIF-
1α upregulation is expression of genes whose promoters contain a HRE to which the 
HIF complex binds and induces transcription. In addition to being regulated by PHD2-
mediated HIF-1α degradation, the hydroxylase; FIH when active, hydroxylates HIF-1α 
and inhibits binding by its co-factors that are required for transcription of target 
genes. Therefore, expression of HIF target genes in BM-MSCs during TGF-β3-
mediated chondrogenesis at 2/5%O2, may indicate inhibition of both PHD2 and FIH 
and induction of HIF activity by these hypoxic states . 
To assess HIF-mediated transcription of target genes, qPCR was utilised to quantify 
exact number of mRNA transcripts. BM-MSC cultures differentiated in the TGF-β3-
mediated chondrogenic conditions optimized here, at 20%/5%/2%O2, were lysed and 
RNA was collected at specific time points. A day 1 time-point was selected to 
complement the studies into HIF-1α protein level and localization shown above and 
to assess early, acute effects of each oxygen concentration . PGK1, EGLN and VEGFA 
mRNA was also quantified at day 14 at which point, mature chondrogenic 
differentiation of progenitor cells is undergoing [269]. This would indicate HIF 
stabilisation and expression of HIF targets during chondrogenesis . Analysis of HIF 
target expression at day 14 would enable correlations to be made between the 
expression of established HIF targets, with those indicating chondrogensis .  
 The mRNA levels of three established HIF targets were assessed. VEGFA encodes a 
growth factor which is upregulated in response to ischemic conditions, as a primary 




(PGK1) is part of the array of glycolytic enzymes upregulated in response to hypoxia 
which enables the switch from aerobic to anaerobic respiration [410]. EGLN encodes 
the hydroxylase, PHD2 which is upregulated by HIF to provide a negative feedback 
loop  and preventing hyper-activation of HIF-mediated transcription [411] . RPL13A 
has been shown to be the most appropriate housekeeping gene for gene expression 
analysis of cultures exposed to physiological hypoxia. Its expression does not change 
significantly in response to hypoxic stimulation unlike that of GAPDH or ACTB [412] . 
RPL13A was therefore used throughout this and the next two chapters for 
normalization of gene expression data. 
The suitability of primers specific to VEGFA, PGK1 and EGLN were assessed by 
generation of a standard curve in which the concentration of serially-diluted cDNA 
from the chondrocyte cell line; C28/I2 were plotted against cycle number (Figs. 3.5A-
3.5C). Each standard curve demonstrated a linear relationship between cDNA 
concentration and cycle number in addition to amplifying target cDNA with a 
theoretical efficiency between 90-110%.  
Following identification of optimal primers, VEGFA, PGK1 and EGLN transcripts were 
amplified and quantified in differentiating cultures. Both 5% and 2%O2 significantly 
(p=<0.05) increased expression of VEGFA (Fig. 3.5D), PGK1 (Fig. 3.5E) and EGLN (Fig. 
3.5F), at day 1 of chondro-induction compared to that at 20%O2. However at day 14 
of culture, only 2%O2 maintained this increase of all three genes compared to 
normoxic conditions (Figs. 3.5G-5I). Furthermore, 2%O2 induced expression of VEGFA 
(Fig. 3.5G) and EGLN (Fig. 3.5I) to significantly higher levels than induced by 5%O2. 




Overall both 2 and 5%O2 appear to induce HIF-1α stabilisation and expression of HIF 







Figure 3.5. 2%O2 induces constitutive expression of HIF target mRNA and 5%O2 
induced expression of these genes at day 1 only.  (A-C) Standard curves which 
demonstrate a linear relationship between input cDNA concentration and cycle (Ct) 
number when amplified using VEGFA- (A), PGK1- (B) and EGLN-specific (C) primers (y 
axis = Ct, x axis = [cDNA] (%). (D-I) mRNA expression of VEGFA (D+E), PGK1 (F+G) and 
EGLN (H+I) throughout chondrogenesis. Values plotted are from 4 independent 
experiments and are fold change compared to the 20%O2 condition which is 
represented by the horizontal dotted line.  The solid coloured lines represent the 
mean for each condition with *denoting p<0.05 compared to 20%O2 and #denoting 
p<0.05 between 2% and 5%O2. Significant changes were determined by Mann 
Whitney statistical tests.  
  










0.1 1 10 100










0.1 1 10 100










0.1 1 10 100










3.2.5.  Effect of 5% and 2%O2 on chondrogenesis of hBM-MSCs 
As both 2% and 5%O2 increased levels of HIF-1α protein, HIF-1α nuclear translocation 
and expression of HIF target genes, the ability of these oxygen concentrations to 
increase chondrogenesis, utilising the same chondrogenic protocol was then 
assessed. Again, day 1 and 14 time-points were chosen to represent both early and 
more latent chronic effects of hypoxia during chondrocyte differentiation of BM-
MSCs . These time-points were also chosen to enable correlation between expression 
of established HIF target genes (VEGFA, PGK1, EGLN) with those involved in 
chondrogenesis.  
SOX9 is the master chondrogenic transcription factor that is essential during limb bud 
chondro-specification, in vitro chondrogenesis, production of an articular cartilage-
like ECM and inhibition of chondrocyte hypertrophy [94]. As described in section 
3.2.2, the product of COL2A1; Collagen Type II, plays key roles in the biology of 
chondrocytes in addition to maintaining the mechanical properties of articular 
cartilage. It is also a well-established transcriptional target of SOX9 and together with 
this transcription factor is part of a gene expression signature used to denote 
chondrogenesis [53] . Also part of this signature of cartilage differentiation is the 
gene ACAN, encoding Aggrecan which constitutes the largest proportion of the 
proteoglycans in cartilage ECM [413] . As with Collagen Type II, these proteoglycans 
are required to maintain the resistance of cartilage to compressive forces on the joint 
and residing articular cartilage [29]. 
The suitability of primers specific to SOX9 and ACAN were assessed by generation of 




chondrocyte cell line; C28/I2 were plotted against cycle number (Figs. 3.6A+3.6B). 
Each standard curve demonstrated a linear relationship between cDNA 
concentration and cycle number in addition to amplifying target cDNA with a 
theoretical efficiency between 90-110%. At day 1 of chondrogenesis, only 5%O2 
significantly (p=<0.05) increase mRNA of SOX9 but not at day 14 (Fig. 3.6C+3.6D). 
Increased expression of COL2A1 was only observed at day 14 of chondrogenesis due 
to 5%O2 compared to normoxic controls (Fig. 3.6F) with no changes observed due at 
day 1 (Fig. 3.6E). Despite not enhancing either SOX9 or COL2A1 expression, 2%O2 
increased the mRNA of the gene encoding Aggrecan at both day 1 and day14 with no 
change observed in the levels of this transcript due to 5%O2 (Figs. 3.6G+3.6H).  
As 5%O2 enhanced SOX9 and COL2A1 mRNA, both of which were not affected by 
2%O2, we expected to see an increase in Collagen Type II protein incorporated into 
the ECM due to 5%O2 only. However, despite observing a subtle increase (p=<0.05) 
in Collagen Type II due to 5%O2 compared to the normoxic control (Figs. 3.7A+3.7B), 
a much more drastic increase due to 2%O2 was observed (Fig. 3.7C). This immuno-
detection of Collagen Type II was quantified and the increase due to 2%O2 was 
statistically significant compared to both the normoxic cultures and those incubated 
at 5%O2 (Fig. 3.7D). When this quantification was normalised to the number of DAPI-
stained cells in each condition, the difference between 2% and 5%O2 was no longer 
statistically significant, with both hypoxic states inducing an increase compared to 
the normoxic control (Fig. 3.7E). 2%O2 also increased the number of DAPI-positive 







Figure 3.6.  5% but not 2%O2 induces expression of SOX9 and COL2A1 with 2% but 
not 5%O2 increasing ACAN mRNA. (A+B) Standard curves which demonstrate a linear 
relationship between input cDNA concentration and cycle (Ct) number when 
amplified using SOX9- (A) and COL2A1-specific (B) primers (y axis = Ct, x axis = [cDNA] 
(%). mRNA expression of SOX9 (C+D), COL2A1 (E+F) and ACAN (G+H) at days 1 and 14 
of chondrogenesis due to  5% and 2%O2. Values plotted are from 4 independent 
experiments and are fold change compared to the 20%O2 condition which is 
represented by the horizontal dotted line. The solid coloured lines represent the 
mean for each condition with *denoting p<0.05 compared to 20%O2. 
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Figure 3.7. 2%O2 increases total Collagen Type II deposition in the extracellular 
matrix with both hypoxic states inducing increases in this ECM protein per cell. (A-
C) Collagen Type II immunofluorescence staining at day 21 of  chondrogenesis due to 
incubation at 20% (A), 5% (B) and 2%O2 (C). Scale Bar = 400μm. Representative 
images of 4 independent repeats shown. (D)   Quantification of Collagen Type II 
immunofluorescence at day 21 of chondrogenesis and (E) normalised to DAPI 
immunofluorescence which equates to cell number. (F) Number of DAPI-positive cells 
at day 21 of chondrogenesis. Values plotted are from 4 independent experiments 
and are fold change compared to the 20%O2 condition which is represented by the 
horizontal dotted line.  The solid coloured lines represent the mean for each 





3.2.6.  Effect of 5% and 2%O2 on hypertrophy of chondrogenically-induced hBM-
MSCs 
Having determined that 5% and 2% O2 induced changes in the level chondrogenic 
mRNA and proteins during BM-MSC differentiation, the effect of these hypoxic states 
on chondrocyte hypertrophy were assessed. This is due to the significant problem of 
hypertrophy observed in current CTE strategies which may promote unwanted 
mineralisation upon implantation of the cartilage graft into the defect site [414]. 
Previous evidence demonstrates the ability of hypoxia in inhibiting hypertrophic 
signaling during chondrogenesis and stabilising the articular chondrocyte phenotype 
[272]. A key transcription factor involved in hypertrophy is RUNX2 [415] . This is 
responsible for expression of COL10A1, encoding the archetypal hypertrophic 
marker- Collagen Type X, and MMP13 whose gene product is responsible for 
degrading Collagen Type II during endochondral ossification and OA pathogenesis 
[86].  
Again to correlate with the expression of chondrogenic markers and established HIF 
targets, days 1 and 14 were selected as time points for harvesting RNA from 
differentiating cultures . Figure 3.8A details the standard curve generated by the 
RUNX2-specific primers used to amplify this gene. In chondrogenically-induced BM-
MSCs, RUNX2 expression was inhibited (p=<0.05) by 2%O2 at day 1 of chondrogenesis 
(Fig. 3.9A) with no change observed at day 14 (Fig. 3.9B) and no regulation due to 
5%O2 observed at either time point.   
One of the drawbacks however, of quantifying the transcript level of a single gene is 




function of multiple gene products, whether it is the post-translational modification 
of Collagen or transcriptional induction of a specific gene locus. Therefore, due to the 
multipotency of hBM-MSCs and the relative ease of an epigenetic shift towards an 
osteoblastic/hypertrophic phenotype [151], the ratio of SOX9 expression to that of 
RUNX2 was analysed. The phenotype of limb bud progenitors have been described 
to be controlled by the opposing actions of SOX9 and RUNX2, with overexpression of 
either shown to negate the effect of the other [416]. In the study here when RNA was 
analysed for expression of these two master transcription factors, despite the 
decrease in RUNX2 due to 2%O2, no change was observed in the ratio of SOX9/RUNX2 
at either time point at either hypoxic state (Figs. 3.9C+3.9D).  
COL10A1 is an established target gene of RUNX2, and together expression of these 
genes denotes progression of chondrocyte hypertrophy [417] . In the present study, 
the standard curve for the COL10A1-specific primers utilized here, demonstrate 
reactions within the accepted efficiency window in addition to a linear relationship 
between cDNA concentration and cycle number (Fig. 3.8B). During BM-MSC 
chondrogenesis, both hypoxic conditions inhibited COL10A1 expression (p=<0.05) at 
day 1 (Fig. 3.9E). However at day 14, a decrease was observed due to only 5%O2 with 
an increase in COL10A1 mRNA induced by 2%O2 at this time point (Fig. 3.9F). Similar 
to the ratio of SOX9 mRNA to that of RUNX2, the ratio of COL2A1/COL10A1 may 
indicate a transcriptional program that is conducive for production of articular or 
hypertrophic cartilage ECM. Both 2% and 5%O2 enhanced the ratio of COL2A1 to 
COL10A1 at day 1 (Fig. 3.9G), with 5%O2 significantly increasing this ratio at day 14, 
compared to both the normoxic control and 2%O2 (Fig. 3.9H). Together, these results 




2%O2, it clearly inhibits expression of the established hypertrophic marker COL10A1 
at the mRNA level. 
In terms of investigating the mechanistic details behind chondrocyte hypertrophy 
such as COL10A1 expression and its inhibition by hypoxic signaling, a number of key 
pathways are implicated. Signaling in response to BMP ligands, via binding of BMP 
receptors and phosphorylation of intracellular proteins; SMAD1/5/8 has been shown 
to be involved in progression of chondrocyte hypertrophy [418]. Similarly, the 
canonical Wnt signaling pathway which is propagated by conical Wnt ligand-Frizzled 
receptor binding and β-catenin-mediated transcription also induces chondrocyte 
hypertrophy [100]. In addition, there exist regulatory mechanisms which limit the 
signaling output of the BMP and Wnt pathways and the subsequent hypertrophy 
which these pathways mediate. One such class of regulatory mechanism is via the 
inhibition of the receptors to which BMP and canonical Wnt ligands bind. For 
example, Gremlin1 (GREM1) and Dickkopf WNT Signalling Pathway Inhibitor 1 (DKK1)  
are expressed during limb development and control of chondrocyte hypertrophy 
[419, 420] via their inhibition of canonical BMP and Wnt signalling respectively [101].  
The control of hypertrophy by Gremlin1 and DKK1-mediated inhibition of the BMP 
and Wnt pathways presents one of the mechanisms by which hypoxic signaling 
regulates this unwanted transformation of articular chondrocytes . GREM1 and DKK1 
expression have previously been shown to be increased in response to hypoxia 
during BM-MSC chondrogenesis [287]. Figure 3.8C+3.8D illustrate the ability of 




efficiency of 90-110%, ensuring a linear relationship between cDNA input and cycle 
number. 
During BM-MSC chondrogenesis only 2%O2 appeared to inhibit expression (p=<0.05) 
of GREM1 at day 1 of chondrogenesis (Fig. 3.9I) with no changes observed at day 14 
(Fig. 3.9J) or with regards to DKK1 mRNA at any time point (Figs. 3.9K+3.9L). These 
results suggest that the reduction of COL10A1 expression by culture at 5%O2 is not 
due to increases in GREM1 and DKK1, perhaps negating a role for Wnt and BMP 
signaling inhibition in that observed due to this hypoxic state. 
Collagen Type X immunostaining was utilised to investigate the protein levels of this 
hypertrophic marker at day 21 of chondrogenesis – a time point at which 
hypertrophy is observed to occur, following chondrocyte differentiation [421]  . 5%O2 
appeared to inhibit the production of Collagen Type X compared to that observed in 
the normoxic control (Figs. 3.10A+3.10B), with no noticeable change observed due 
to 2%O2 (Fig. 3.10C). Together, 5%O2 appears to confer advantages in terms of BM-
MSC chondrogenesis compared to that conducted at 20% and 2%O2 due to its unique 
ability to inhibit expression of hypertrophy, both at the mRNA and protein level. This 
therefore warrants its use in chapter 5 of the present thesis in which the role of HIF 







Figure 3.8. Standard curves which demonstrate a linear relationship between input 
cDNA concentration and cycle (Ct) number when amplified using RUNX2- (A), 
COL10A1- (B), DKK1- (C)  and GREM1-specific (D) primers (y axis = Ct, x axis = [cDNA] 
(%). 
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Figure 3.9. 5%O2 but not 2%O2 inhibits hypertrophic mRNA expression throughout 
chondrogenesis. mRNA expression of RUNX2 (A+B), COL10A1 (E+F), GREM1 (I+J) and 
DKK1 (K+L) at days 1 and 14 of chondrogenesis due to  5% and 2%O2. Ratios of mRNA 
of SOX9:RUNX2 (C+D) and COL2A1:COL10A1 (G+H) at days 1 and 14 of 
chondrogenesis due to 5% and 2%O2. Values plotted are from 4 independent 
experiments, and are fold change compared to the 20%O2 condition, represented by 
the horizontal dotted line.The solid coloured lines represent the mean for each 
condition with *denoting p<0.05 compared to 20%O2 and #denoting p<0.05 between 





Figure 3.10. 5%O2 but not 2%O2 reduces Collagen Type X protein during 
chondrogenesis of hBM-MSCs. (A-C) Collagen Type X immunofluorescent staining at 
day 21 of chondrogenesis due to incubation at 20% (A), 5% (B) and 2%O2 (C). Scale 









Many developing and adult tissues exist within a hypoxic microenvironment [422] 
[423]. Correspondingly, many genes which contain a HRE [424] are expressed in these 
tissues in response to transcriptional-induction by the HIF complex [211, 425]. One 
population of cells which depend on HIF signaling in response to hypoxic stimulation, 
are BM-MSCs. These cells exist within a hypoxic niche within the bone marrow [426] 
and as a result, respond to in vitro hypoxic conditions with changes in a variety of 
cellular behaviors. Such changes induced by hypoxia include migration, proliferation 
and differentiation [427]. In terms of differentiation, the lineages of differentiation 
of BM-MSCs have been shown to be differentially altered in response to hypoxia, 
with adipogenesis and chondrogenesis being elevated by hypoxia and osteogenesis 
inhibited [272, 428].  
Despite the conserved PHD2 and FIH-mediated mechanisms which exist to 
respectively control HIF-1α stabilisation and co-factor binding, the level of oxygen 
required to induce maximal HIF-mediated transcription varies from one tissue to 
another. Stroka et al demonstrated this via exposing a mouse model to systemic 
hypoxia and analysing HIF-1α stabilisation in different organs. They found that cells 
within the liver and kidney achieved maximal HIF-1α levels following 1 hour of 
hypoxic exposure, whereas a maximum was reached in 5 hours within cells of the 
brain. This demonstrates a differential sensitivity to oxygen, of the mechanisms 
regulating HIF-1α between the brain, lung and kidney, [211].  
This variation in the sensitivity of the HIF-regulatory mechanisms to oxygen is 




These impact the regulatory elements controlling HIF-1α availability. Stroka et al for 
example, observed reduced basal levels of HIF-1β at normoxia in the brain whereas 
in the lung and brain it is present at constitutively higher levels [211]. Alternatively, 
variation in expression of the HIF-1α-regulatory elements such as PHD2 results in cell-
specific regulation of HIF-1α and its participation in the HIF complex [406].  
In developing cartilage or in vitro chondrogenesis of stem cells, factors other than 
the PHD2/VHL/FIH pathway may regulate the participation of HIF-1α in the HIF 
complex. These may alter the induction of HIF in response to reduced local oxygen 
concentration compared to that observed in other systems. The TGF-β family of 
proteins may be such factors. Porcine periosteal cells when transfected with a BMP2-
overexpressing adenovirus, raised HIF-1α protein in the deep layer of articular 
cartilage following implantation back into a pig chondral defect [429]. Induction of 
HIF-1α by BMP2 was mediated by the Mitogen Activated Protein Kinase (MAPK) 
Kinase (MEK)/Extracellular Signal-Regulated Kinase (ERK) pathway, with TGF-β1 also 
shown to induce HIF-1α protein via SMAD2/3-mediated mechanisms in hepatoma 
and fibrosarcoma cell lines [273]. The elevated expression of TGF-β and its 
downstream signalling during limb development, together with its established use 
during in vitro chondro-induction protocols, may therefore suggest its role in 
regulating HIF-1α induction by hypoxia.  
Another factor utilised during in vitro chondrogenesis is Ascorbate. In addition to 
promoting collagen post-translational modification through induction of the 
Collagen-specific prolyl hydroxylase, Ascorbate has been shown to regulate HIF-1α 




5%O2 and chemical stabilisation of HIF-1α to reduce levels of this HIF subunit. This 
implicates its potential role during hypoxia-mediated chondrogenesis. The chemical 
stabilisers used in this were PHD2 inhibitors, and therefore this suggests that 
Ascorbate plays a role in HIF-1α regulation independently of its ability to promote 
PHD2 activity through recycling of the Fe2+ ion. This was also suggested by Miles et al 
who observed an increase in HIF-1α protein and HIF-mediated transcription in 
response to Ascorbate treatment of human melanoma cells [431]. These authors 
negated a role of PHD2 in their observations upon siRNA knockdown of PHD2 which 
had no effect on Ascorbate-mediated increased in HIF-1α. 
Factors such as TGF-β ligands or Ascorbate that during chondrogenesis, may affect 
hypoxic-induction of HIF-α, necessitate an investigation into the effect of varying 
oxygen concentration on chondrocyte differentiation. This would enable 
determination of the levels of oxygen required to mimic the in vivo function of 
hypoxia in promoting articular chondrogenesis. The existence of an oxygen gradient 
across the mesenchymal limb bud [262] and growth pate cartilage [259] and the 
observation that HIF-1α stabilisation can vary significantly through such an oxygen 
gradient [396] supports the requirement for such a study. A study by Bracken et al 
suggested that the relationship between oxygen concentration and HIF-1α levels in 
certain cell types is not linear, and significant stabilisation of HIF-1α occurs only 
following a threshold hypoxic level [396].  
Overall, the present study demonstrates key differences between mild (5%O2) and 
more severe (2%O2) hypoxic conditions on hBM-MSC chondrogenesis. Despite 




points examined, 2%O2 appeared to induce a transcriptional program independent 
of that involved in chondrogenesis. Without stimulating expression of SOX9 or 
COL2A1 and inhibiting hypertrophy, this oxygen concentration raised only ACAN 
expression and increased Collagen Type II protein. At the same time points however, 
5%O2 induced formation of an anti-hypertrophic, chondrogenic expression profile. 
This is suggestive of an important role for mild hypoxic signalling in CTE due to the 
risk of hypertrophy and mineralisation in current strategies for repair of acute 
chondral defects . 
As suspected and shown previously [396], both 5% and 2%O2 increased total HIF-1α 
protein and nuclear localisation in hBM-MSCs following 24-hour incubation. These 
increased protein levels demonstrate the inhibition of PHD2 by hypoxic conditions, 
which have been shown to result in increased nuclear localisation of HIF-1α where it 
is able to function as part of the HIF transcriptional complex. An interesting result 
however, is the observation of HIF-1α protein present in the normoxic conditions, 
where PHD2 would theoretically be most active. One explanation may be based on 
observations of PHD2 inhibition by TGF-β1 treatment via SMAD2/3 [273]. Therefore 
the TGF-β3 in the induction media used in the present study may reduce HIF-1α 
hydroxylation. This would result in a net increase in HIF-1α in the presence of 20% 
oxygen. Additionally, BM-MSCs compared to MSCs from other sources and non-MSC 
cell types, appear to show reduced senstivity to PHD2 activity with regards to HIF-1α 
levels [432]. This is suggested by Palomaki et al to be due to the increased transcript 
levels encoding HIF-1 α in BM-MSCs which would result in increased HIF-1α levels in 




Whatever the mechanism is behind the observed HIF-1α at normoxia, it appears to 
almost exclusively localise to a peri-nuclear region of the cell under normoxic 
conditions unlike at 2%/5%O2 where it localizes to within the nucleus. Moreover, the 
discrete, clustered pattern of peri-nuclear HIF-1α suggests encapsulation within an 
intracellular organelle as opposed to being freely diffusible within the cell. Storage of 
HIF-1α within perinuclear golgi has been shown in vitro, within colon cancer cells 
[433] and bovine chondrocytes [434], where it has been hypothesised to act as a 
reservoir to allow cells to respond to a rapid metabolic changes. Coimbra et al 
observed a reduction in nuclear HIF-1α in human articular chondrocytes in 
monolayer compared to suspension culture at normoxia [282]. These authors also 
observed under normoxic conditions, reduced nuclear HIF-1α in osteoarthritic 
chondrocytes compared to those from healthy cartilage. This suggests a deregulation 
of HIF-1α upon removal form the in vivo niche. There may also exist, a role of the 
golgi as a scaffold for HIF-1α which may facilitate modification to its amino acid 
sequence such as that by PHD2. This is supported by the evidence that OS9, as a HIF-
1α-downregulatory factor, plays key roles in trafficking proteins from the 
endoplasmic reticulum to the golgi [435]. 
VEGFA, PGK1 and EGLN represent HIF target genes. With the exception of PGK1, the 
increases in the expression of these due to 5%O2 at day 1 of chondrogenesis, did not 
occur at day 14. This is unlike that due to 2%O2 which induced transcription of all 
three genes at both time points. A limitation of this study may be the relatively few 
genes chosen to represent HIF targets as a proportion of the total genomic sequences 




of genes between relative short and long-term culture [436]. Therefore by analysing 
a small subset of genes here, those regulated by 5%O2 other than VEGFA, PGK1 and 
EGLN, would be omitted. However, the continued upregulation of VEGFA, PGK1 and 
EGLN by 2%O2 at day 14 is suggestive of a tolerance of the hBM-MSCs to 5%O2 at this 
time point, following an initial period of hypoxic stimulation.  
As validated by its use as a HIF target gene, EGLN when upregulated by hypoxic 
conditions, propagates a feedback loop via its product- PHD2, which increases HIF-
1α degradation [243]. It is therefore plausible to suggest the inability of 5%O2 to 
initially raise nuclear HIF-1α to levels beyond which it be abolished by this PHD2-
mediated negative feedback loop. As previously demonstrated [396], this may be at 
odds with that due to 2%O2 which overcomes the PHD2-mediated tolerance to 
stimulate constitutive expression of HIF target genes. If indeed, PHD2-mediated 
negative feedback and suppression of VEGFA, PGK1 and EGLN transcription did 
occur, this may highlight another limitation of the present study. The lack of longer 
term time points than 14 days may omit observations of latent recovery of HIF target 
mRNA after this time point which is a pattern described generally of negative 
feedback loops [437].  
An alternative explanation to the reduced effect of 5%O2 at day 14 may be due to the 
specific nature of HIF regulation in BM-MSCs. These cells have been shown to express 
increased mRNA levels of HIF1A which increases subsequent protein levels of HIF-1α, 
even in normoxic conditions [432]. This may therefore suggest that the 
chondrogenically-induced BM-MSCs require severe hypoxic conditions (i.e. 2%O2 




conditions. A similar mechanism may be induced by TGF-β3 treatment in this study 
which has been shown to raise the basal levels of HIF-1α at normoxia [273]. Inclusion 
of TGF- β3 in the chondrogenic media may therefore result in the inability of a mild 
hypoxic state such as 5%O2 to raise basal levels of HIF-mediated transcription in a 
sustained manner, beyond a TGF-β3-augmented level. This theory is also supported 
by a study in which the HRE sequence was deleted within the SOX9 promoter in 
chondro-induced ST2 cells. Robins et al in this investigation, observed the inhibited 
expression of SOX9 at 20%O2 due to this deletion [269]. This therefore suggests that 
high levels of HIF-mediated transcription exist at basal/normoxic conditions. With 
regards to the current study, this again suggests that a more potent hypoxic state is 
required to elevate HIF activity to levels beyond the basal levels. 
Corresponding to the increase in HIF target mRNA at day 1 of chondrogenesis due to 
5%O2, this oxygen concentration also induced expression of the master regulator of 
chondrogenesis, SOX9 following 24 hours of induction. This matches previous studies 
such as that by Robins et al who observed an increase in SOX9 mRNA 24 hours 
following chondro-induction of ST2 cells [269]. These authors demonstrated the role 
of HIF in that observed by identification of four HREs within the promoter region of 
the SOX9 gene which when deleted, reduced hypoxia-mediated transcription. Duval 
et al also investigated the mechanisms behind hypoxia-mediated chondrogenesis 
and observed an abolishment of HIF binding at the SOX9 promoter in response to 
treatment with the inducer of proteasome activity, CdCl2 [272]. This study 
demonstrated that hypoxia-mediated increases in chondrogenic mRNA such as SOX9 
are due to inhibition of PHD2/VHL-mediated degradation of HIF-1α which suggests a 




in VEFGA and EGLN due to 5%O2 at day 14, SOX9 expression was also not raised as 
this time point. This may suggest that SOX9 and those genes classically upregulated 
by hypoxia are regulated by similar mechanisms.  
COL2A1 was raised by only 5%O2 at day 14 of chondrogenesis. Induction of this gene 
at a similar time point was also previously demonstrated [269]. The product of 
COL2A1; Collagen Type II, plays an essential role cartilage ECM by forming a water-
perfused network with HA-Aggrecan to generate a structure capable of withstanding 
compressive forces on the joint. The importance of Collagen Type II in cartilage ECM 
is demonstrated by phenotypic observations following a deletion in the COL2A1 
gene. A specific mutation within the alpha helix gene results in degradation of 
Collagen Type II molecules and replacement with Type I and III collagens [438]. This 
predisposed the articular cartilage in developing limbs to OA. This was denoted as 
osteoarthritic due to the increased protein expression of Collagen Type X which is 
shown to be a common consequence of other mutations within the COL2A1 gene 
[439] [440].  
The promoter region within the COL2A1 contains multiple SOX9 binding sites [441] 
and this is concomitant with studies demonstrating the dependence of COL2A1 
expression on SOX9 activity during cartilage development [442]. The recovery of an 
articular chondrocyte phenotype from a hypertrophic state is also propagated by 
SOX9-dependant COL2A1 transcription [443]. In studies examining the relationship 
between SOX9 and COL2A1 during chondro-induction of hBM-MSCS, overexpression 
of SOX9 increases COL2A1 mRNA [272]. The early SOX9 transcription observed in the 




described previously as an in vitro-specific phenomenon. SOX9 expression is 
increased at an early time point during in vitro chondrogenesis of chick limb bud 
micromass cultures [402] whereas COL2A1 expression in vitro is generally thought to 
occur at latent stages of differentiation [444].  This contrasts with that which occurs 
during in vivo development in which both SOX9 and COL2A1 expression are observed 
at early points in the pre-cartilage cranial mesenchyme and at later time points [445]. 
This pattern of early SOX9 expression and latent COL2A1 expression by hypoxia in 
vitro was also demonstrated by Robins et al. These authors observed an increase in 
COL2A1 mRNA at day 16 due to incubation of mesenchymal progenitors at 1%O2.  
BM-MSCs incubated at 5%O2 were unable to maintain the day 1 increase in SOX9 
expression relative to normoxic conditions through to day 14. This perhaps indicates 
the sufficiency of early increases in SOX9 for transcription of its target genes, as also 
described by Gadjanski et al [446]. In the present study however, SOX9 cannot be 
implicated in COL2A1 transcription induced by 5%O2 by solely correlative evidence of 
increasing SOX9 and COL2A1 mRNA levels. This represents a limitation of this study 
with SOX9 deletion being required to implicate this protein in hypoxia-induced 
COL2A1 mRNA expression. Additionally, analysis of the mRNA expression encoding 
SOX9 binding partners, SOX5 and SOX6 in addition to protein analysis of these three 
transcription factors would enable a more robust conclusion to be made with regards 
to the effect of 5%O2 on the chondrogenic differentiation program.  
Unexpectedly, despite constitutive upregulation of VEGFA, PGK1 and EGLN and 
unlike that observed due to 5%O2, 2%O2 did not increase SOX9 expression at either 




that any increases in SOX9 mRNA due to 2%O2 would not be observed in this study if 
occurred between days 1 and 14 due to only these two timepoints utilised. This 
therefore prevents the dismissal of 2%O2 in raising SOX9 expression during 
chondrogenesis.  
Due to SOX9 transcription occurring due to 5%O2 here, it may be suggested that 2%O2 
stimulated expression of genes which do not require SOX9 to accompany the 
increases in VEGFA, PGK1 and EGLN. For example, Mitogen Inducible Gene 6 (MIG6) 
and Inhibin Beta A Subunit (INHBA) mRNA were induced by incubation of human 
articular chondrocytes cultured at 1%O2. These increases which were inhibited by 
HIF-1α deletion but were unaffected by SOX9 deletion [447]. MIG6 is involved in 
preventing hypertrophy of articular cartilage and ossification [448]. INHBA dimerises 
to form Activin A which inhibits secretion of MMP3 [449] and induces expression of 
tissue inhibitor of metalloproteinase-1. This is an anti-catabolic factor of cartilage 
[450].  
Unlike MIG6 and INHBA, expression of COL2A1 relies on SOX9 activity. Due to the 
observation in the current study that expression of SOX9 and COL2A1 were not 
increased by 2%O2 but increases were observed of established HIF target mRNA, this 
oxygen concentration may induce a SOX9-independent subset of genes in contrast 
to 5%O2. The stimulation of expression of different and specific subsets of genes by 
different hypoxic states has been suggested in the literature and is dependent on the 
ability of each hypoxic state to inhibit FIH as well as PHD2. FIH inhibition induces 
expression of HIF target genes distinct from that observed due to inhibition of PHD2 




the ability of varying hypoxic states to inhibit PHD2 and FIH to different magnitudes 
[452]. This correlates with that shown by Tian et al, who observed a greater 
resistance of FIH (compared to PHD2) to hypoxia-mediated inhibition [453]. 
Therefore, in the present study, it could be hypothesized that 5% compared to 2%O2 
may stimulate HIF target gene expression primarily through PHD2 inhibition. In the 
presence of a more severe hypoxia at 2%O2, the BM-MSCs may exhibit expression of 
an alternate subset of genes through dual inhibition of PHD2 and FIH. However, with 
the observations made in this study, this theory is purely speculative. This therefore 
requires further analysis of the contribution of FIH and PHD2 before conclusions on 
the role of these enzymes can be made. 
ACAN is the most abundant non-collagenous protein in cartilage ECM, providing the 
essential structural integrity for joint function in the face of compressional load and 
fluid flow experienced during locomotion. Mutations in the ACAN gene can result in 
skeletal abnormalities and development of severe OA [413] which demonstrates the 
essential nature of this structural protein in cartilage ECM. Co-localisation of 
Aggrecan and SOX9 delineates skeletal progenitors which go onto the form the 
growth plate [454]. Expression of ACAN has been shown to be dependent on SOX9 
expression and activity.  For example, SOX9-specific siRNA reduces ACAN expression 
in articular chondrocytes [455]. Liu et al identified an enrichment of SOX9 and SOX6 
at the ACAN promoter in a growth plate chondrocyte cell line [456]. In addition, ACAN 
mRNA and Alcian Blue staining of GAGs were reduced upon deletion of SOX9 in 
developing cartilage [457] with overexpression of SOX9 in chondro-induced hBM-
MSCs inducing ACAN transcription [272]. Hypoxic conditions have been repeatedly 




This was shown to be mediated via HIF-1α during hBM-MSC and limb bud 
chondrogenesis [263, 272]. In the present study, 5%O2 did not affect expression of 
ACAN despite its induction of SOX9 and COL2A1 transcription. This may suggest a lack 
of complete chondrogenic differentiation induced by 5%O2. This conclusion may be 
made due to ACAN expression denoting late stages of chondrocyte formation from 
mesenchymal precursors [402]. This lack of ACAN expression induction by 5%O2 may 
correspond with the lack of sustained expression of HIF targets- VEGFA and EGLN, in 
addition to SOX9 at day 14. Alternatively, an increase in ACAN expression may have 
been observed if mRNA was collected from differentiating cultures at day 21, due to 
this stage of in vitro chondrogenesis denoting the end-point for differentiating 
cultures [458]. 
In BM-MSCs in which COL2A1 expression remains constant, an increase in cell 
number would result in a cumulative increase of Collagen Type II incorporated into 
the ECM [459]. The increased cell number observed here due to 2%O2 may therefore 
represent the mechanism behind the high levels of total Collagen Type II protein 
observed compared to that induced by normoxia and 5%O2. Such a conclusion may 
be made due to the observed reduction in Collagen Type II fluorescence to similar 
levels to that of 5%O2 when the quantity of signal was normalised to the number of 
DAPI-stained cells. Interestingly, the amount of Collagen Type II in the ECM at 5%O2 
was enhanced to a significant level compared to 20%O2 only when normalised to cell 
number and not without normalisation. This increase per cell correlates with the 
induction of COL2A1 transcription due to 5%O2. A notable caveat to these 
observations is that quantification of Collagen Type II immunofluorescence is only a 




of differential hypoxic cultures on Collagen Type II protein, Enzyme-Linked 
Immunosorbent Assays (ELISAs) must be conducted. This would enable 
quantification of Collagen Type II protein and dismiss the contributing effect of 
background fluorescence to the semi-quantitative observations here. 
Despite inducing transcription of SOX9, 5%O2 did not reduce RUNX2 mRNA as 
previously demonstrated [460] and 2%O2 induced a very marginal decrease in its 
expression. The relative activity levels of SOX9 and RUNX2 determines the respective 
chondrogenic or osteogenic lineage commitment in osteochondral progenitors 
which arise from the mesenchymal limb bud [52]. In cells destined to become resting 
chondrocytes, SOX9 overcomes the activity of RUNX2 to provide a bias towards 
articular rather than hypertrophic chondrogenesis. This has been theorised to occur 
due to the hypoxic nature of the developing limb bud, resulting in HIF-mediated 
upregulation of SOX9 [259]. Following this activation, SOX9 then inhibits the function 
of RUNX2 [461] which as a master transcription factor, stimulates chondrocyte 
hypertrophy and endochondral ossification if left unhindered [462].  
In the present study, the lack of significant increase in the ratio of SOX9 to RUNX2 
due to either hypoxic state suggests that the transcriptional programs induced by 
these conditions are not conducive for chondrogenesis at the expense of ostegenesis. 
However this observation may also be explained by the specific time points chosen 
for RNA isolation here and the possibility of significant changes in SOX9:RUNX2 
expression occurring at other points throughout BM-MSC chondrogenesis. An 
example of such as  time point may be the terminal stages of chondrogenesis where 




Irrelevant of the time points chosen to examine the relative expression of SOX9 and 
RUNX2, both oxygen concentrations induced changes in the expression of COL10A1, 
a marker of hypertrophy as well as changes in the expression ratio of 
COL2A1:COL10A1. The ratio of these compounds is suggestive of the type of ECM 
that is produced by differentiating BM-MSCs or chondrocytes, with increases in this 
ratio indicating articular cartilage ECM and a decrease suggesting hypertrophic 
cartilage [464]. Expression of COL10A1 and other hypertrophic factors such as 
MMP13 [415] as well as induction of Wnt-mediated hypertrophy [100] are 
downstream effects of RUNX2-mediated transcription.  
In the present study, both hypoxic states inhibited COL10A1 expression at day 1 and 
the ratio of expression of COL2A1:COL10A1 at this time point. This early suppression 
suggests the bias of the condensed mesenchymal population to articular 
chondrogenesis and not hypertrophy. This function of hypoxia is suggestive of its role 
in patterning articular cartilage and growth plate cartilage destined to become 
ossified bone [100]. However as with any cellular process, progression of 
hypertrophy is not denoted by expression of a single gene. Therefore, analysis of 
other hypertrophic markers such as MMP13 and ADAMTS5 at the mRNA and protein 
level would be required in order to strengthen the conclusion of hypertrophy 
inhibition by hypoxia.  
Despite that observed at day 1 due to either hypoxic states, inhibition of COL10A1 
mRNA and increase in the ratio of COL2A1:COL10A1 mRNA was induced by only 5%O2 
at day 14. Conversely 2%O2 increased COL10A1 expression at this time point. A 




5%O2 with a lack of change induced by 2%O2. This suggests a requirement of 
constitutive inhibition of COL10A1 transcription may be required for corresponding 
changes in protein levels to be exhibited. It is imperative to reduce protein levels of 
this hypertrophic marker to inhibit the downstream hypertrophic signalling which it 
induces which results in apoptosis of this cells and spontaneous ossification [465]. 
These observations therefore suggest that 5%O2 compared to 2%O2 is suitable for 
CTE due to its ability to induce a transcriptional profile and corresponding ECM that 
is suggestive of articular and not hypertrophic cartilage.  
In terms of the mechanism behind this decrease in COL10A1 expression due to 5%O2 
at day 14, it could be suggested that HIF activity was not required as indicated by a 
lack of observed increase in HIF targets- VEGFA, PGK1 and EGLN at this time point. 
The increase in COL2A1 due to 5%O2 at this time point also suggests that HIF activity 
is not required for latent expression of this gene due to hypoxia. Representing a 
limitation of the present study, this lack of correlation between COL10A1/COL2A1 
and HIF targets may be due to the relatively low number of time points or HIF targets 
chosen. By not utilising time points between days 1 and 14, and with VEGFA, PGK1 
and EGLN not representing the full complement of HIF target genes, observation of 
HIF-mediated transcription required for COL10A1/COL2A1 regulation may have been 
omitted. However in terms of hypertrophy, HIF-independent inhibition of this 
process in hypoxic conditions was demonstrated by Lee et al [466]. These authors 
observed the role of PI3K/Akt-dependent mechanisms in hypoxia-mediated 




The increase in SOX9 expression due to 5%O2 may be involved in the latent 
suppression of COL10A1 mRNA, due to the role that SOX9 plays in inhibition of 
RUNX2-mediated hypertrophy. However, as described earlier, ablation of SOX9 
would be required in order to implicate this transcription factor in the suppression 
of hypertrophy observed due to 5%O2. This rationale would also apply in order to 
dismiss the role of HIF in regulation of COL10A1/COL2A1 expression due to 5%O2.  
The increase in COL10A1 mRNA at day 1 due to 2%O2 may be due to an absence of 
hypertrophic-suppressive mechanisms. For example in this study, mRNA encoding 
the inhibitor of BMP signalling- Gremlin1, is reduced at day 1 by 2%O2. Gremlin1 acts 
to inhibit hypertrophic signalling induced by specific BMP ligands upon binding to 
their receptors in articular chondrocytes [101]. The decrease in GREM1 due to 2%O2 
observed here suggests a role for BMP signalling in raising COL10A1 mRNA in BM-
MSCs cultured at this hypoxic state. However, as with the role of HIF and SOX9 in the 
observations due to hypoxia here, data regarding this role of Gremlin1 is correlative 
only. This therefore requires manipulation of the BMP antagonist at the genetic or 





4. Comparison of HIF-stimulating compounds in the chondrogenenic 
differentiation of BM-MSCs. 
 
4.1. Introduction 
The previous chapter demonstrated the ability of both 5% and 2% oxygen to induce 
transcriptional and proteomic changes during hBM-MSC chondrogenesis, thereby 
suggesting a role for either in CTE for repair of acute chondral defects. Despite this 
however, the use of physiological hypoxia may be associated with inherent risks and 
logistical problems with regards to generating a translational product for use in the 
clinic. In addition to functioning through HIF, hypoxia has been shown to stimulate 
HIF-independent mechanisms to induce a global decrease in protein translation. This 
phenomenon occurs via inhibition of mTOR signalling [467]. mTOR controls global 
translation machinery by inducing ribosomal protein S6 kinase, eukaryotic initiation 
factor 4E binding protein 1 and eukaryotic elongation factor 2 kinase [468].  Hypoxia 
has been shown to inhibit mTOR signalling via a number of mechanisms as described 
by Wouters & Koritzinsky [469] with the overall effect being a reduction in cap-
dependent initiation of protein translation.  
Also independently of HIF, hypoxia has also been shown to induce activity of the 
Unfolded Protein Response (UPR), a cell response to endoplasmic reticulum stress 
and inefficient protein folding which results in targeting of unfolded proteins for 
proteasomal degradation [470]. HIF independent regulation of protein translation 
and UPR may have severe consequences in terms of CTE. Placing brakes on 




MSCs. This is due to the requirement of protein synthesis for propagating 
transcriptional programs and processing of cartilage ECM [471]. This also correlates 
with findings that protein synthesis is the key regulatory mechanism of cellular 
processes during differentiation [472] as opposed to protein degradation [473].  
Another potential drawback of hypoxia is the susceptibility of its downstream 
pathways to negative feedback loops, suppressing the pro-chondrogenic activity 
required throughout chondrogenic induction [289]. This was indeed observed in the 
previous chapter due to 5%O2, in which the increase in HIF target gene expression 
observed at day 1 of chondrogenesis was abolished at day 14. Such a situation may 
arise due to hypoxia-induced UPR, shown to enable tolerance of tumour cells to 
hypoxic conditions for progression of the malignancy [474].  
Logistically, hypoxia may present complications during translation to the clinic for 
CTE. As described by Liu et al, a current paradigm for repairing chondral defects is 
the requirement of injectable scaffolds loaded with a specific cell source and 
bioactive factors for regeneration [475]. Biomaterial scaffolds have evolved to retain 
these factors and release them over a sustained period of time ensuring a reservoir 
of pro-regenerative signals to the donor cells for in vivo defect repair [476]. The use 
of hypoxia would prove difficult for this strategy due to the requirement to reduce 
the bioavailability of oxygen in situ as opposed to its release.  
The use of hypoxia may also be limited for tissue engineering applications where both 
the articular cartilage and underlying subchondral bone are damaged, as observed in 
full osteochondral breaks [111]. As described in section 1.3.5, a continuous scaffold 




1α perhaos enabling spatial control of cartilage and bone regeneration. In addition 
to the potential role for OCTE, the use of HIF-1α-stimulating compounds would also 
ameliorate the other pitfalls of utilising hypoxia. Injectable scaffolds with a sustained 
release of a HIF-stablising compound may aid in vivo CTE efforts, promoting articular 
chondrogenesis and inhibiting hypertrophy. In addition, stimulating HIF during hBM-
MSC chondrogenesis, as opposed to the full complement of hypoxic effects, such as 
HIF-independent mTOR inhibition or UPR stimulation would avoid the decrease in 
overall translation and tolerance of hypoxic pathways required for chondrocyte 
differentiation.  
CoCl2, DFX and DMOG are the most widely used of the HIF-stabilising compounds and 
each target PHD2 and/or FIH via different mechanisms of action. As observed in 
regions of diminished oxygen concentration, PHD2 inhibition has the net effect of 
inhibiting HIF-1α prolyl hydroxylation and its degradation with FIH inhibition reducing 
asparagine hydroxylation of HIF-1α which would result in blocking of its 
transcriptional co-factors [268]. DMOG strongly binds to the 2-OG binding pocket of 
both FIH and PHD2, acting as a competitive inhibitor [44]. DFX sequesters and 
reduces intracellular Fe2+ thereby reducing activity of both FIH and PHD2 due to their 
dependence on this ion [477]. This is unlike the effect induced by CoCl2 which binds 
directly to the PHD2 active site and demonstrates specificity for this hydroxylase 
[453].  
Evidence exists of the use of CoCl2, DFX or DMOG for cartilage regeneration. Duval et 
al demonstrated the role for CoCl2 in such a context. They observed an increase in 




encapsulated within alginate beads, in addition to a corresponding increase in 
chondrogenic mRNA expression due to CoCl2 [272]. In an investigation by Huang et 
al, DFX in conjunction with TGF-β1 increased expression of SOX9, COL2A1 and ACAN 
in chondrogenically-induced ATDC5 cells compared to TGF-β1 supplementation alone 
[478]. This was also shown to increase the detection of GAGs in the ECM, again 
compared to the use the growth factor alone. Finally DMOG’s potential role in CTE 
was also implicated by Thoms et al who observed an increase in SOX9 protein in 
human articular chondrocytes treated with DMOG [278]. This corresponds to a study 
by Gelse et al, in which SOX9 mRNA was induced in murine chondrocyte cultures due 
to DMOG treatment, together with an inhibition of COL1A1 expression, required for 
matrix ossification [479]. 
In addition to aiding the CTE field, use of compounds such as CoCl2, DFX or DMOG 
enable insights to be made into the regulation of HIF by the HIF hydroxylases during 
chondrogenesis. Generally speaking, hypoxia induces complete PHD2 inhibition 
whilst FIH activity has been shown to remain in cells cultured at low oxygen levels 
[453]. This was demonstrated by Tian et al in the renal cell carcinoma line, RCC4. 
These authors observed an inhibition of HIF-1α hydroxylation due to incubation at 
1%O2 compared to those at normoxia. At this oxygen concentration, Asparagine 
hydroxylation remained and was reduced only by the much more severe hypoxia of 
0.01%O2. This study demonstrated the reliance of hypoxic conditions in inhibiting 
PHD2-mediated HIF-1α degradation which, in the presence of residual FIH activity, is 




Inhibition of FIH and asparagine hydroxylation however, is not redundant and has 
been shown to act synergistically with PHD2 suppression, stimulating maximal 
activation of HIF and expression of its target genes. An example of such a study was 
that by Huang et al who observed in mouse myoblast cells, a synergistic effect of 
PHD2 and FIH knockdown. Due to this combinatorial knockdown, these authors 
observed an increase in fluorescence of a HIF-response element-tagged reporter 
compared to knockdown of either hydroxylase alone, in addition an increase in 
mRNA encoding angiogenic factors in response to PHD2 and FIH ablation [481]. In 
addition, evidence exists for the role of FIH inhibition in propagating a specific 
transcriptional program that is separate from that induced by PHD2 ablation. FIH 
inhibition is able to induce expression of a subset of hypoxia-inducible genes, not 
observed during PHD2 ablation [451]. 
There is a lack of clear evidence of the precise mechanisms between HIF regulation 
during chondrogenesis and the contribution of PHD2 and FIH during this process. By 
comparing the effect of distinctly-functioning hydroxylase inhibitors on HIF-1α 
stabilisation, HIF-mediated transcription and chondrogenic induction, it may be 
possible to determine key mechanistic details behind HIF signalling during cartilage 
development. Therefore due to this lack of clarity of HIF regulation during hypoxic 
cartilage development, and an absence of studies which compare the roles of CoCl2, 
DFX and DMOG for cartilage regeneration, the following aim, hypothesis and 





 Aim: To determine which of CoCl2, DFX or DMOG most strongly induces HIF-
mediated transcription, hBM-MSC chondrogenesis and inhibition of 
hypertrophy. 
 Hypothesis: DMOG due to its high specificity compared to CoCl2 or DFX which 
may target other iron-utilising enzymes will induce the largest effect during 
hBM-MSC chondrogenesis in terms of induction of chondrogenic mRNA 
expression and cartilage ECM production. 
 Objectives:  
o To identify non-toxic doses of CoCl2, DFX or DMOG for use in a 21-day 
protocol 
o During hBM-MSC chondro-induction, to identify which of CoCl2, DFX or 
DMOG more potently stimulates HIF stabilisation and downstream 
transcriptional activity 
o To identify which of CoCl2, DFX or DMOG more potently stimulates 
articular chondrogenesis and cartilage ECM formation. 
o To identify which of CoCl2, DFX or DMOG more potently inhibits 
hypertrophy during chondrogenesis. 
o To confirm that CoCl2, DFX or DMOG function though HIF-1α during their 







4.2.1.  Identification of non-toxic doses of CoCl2, DFX and DMOG for 21-day hBM-
MSC chondrogenesis 
Observation of the hypoxia’s effect on chondrogenesis in chapter 3 suggests the role 
of compounds which stimulate HIF- the primary transducer of physiogical hypoxia, 
during chondrocyte lineage commitment and cartilage ECM formation. CoCl2, DFX 
and DMOG, which al stimulate HIF-1α were therefore included in separate TGF-β3-
containing chondrogenic induction media to determine their ability to induce HIF 
activity and subsequent chondrogenesis of hBM-MSCs. Demonstration of the ability 
of these compounds to stimulate formation of articular cartilage, whilst inhibiting 
hypertrophy may indicate new strategies for CTE. In addition, the differential 
mechanisms of action of CoCl2, DFX and DMOG may illuminate the regulatory 
mechanisms by which HIF activity is controlled during chondrogenesis. 
As previously pertained to, hypoxia and HIF activity are present throughout the entire 
phase of articular cartilage development from the limb bud mesenchyme up to the 
resting chondrocyte population. This indicates the requirement of constitutive HIF 
activity during hBM-MSC chondrogenesis for CTE. Therefore to avoid any deleterious 
effects of each of the HIF-stabilising compounds on the hBM-MSCs during chondro-
induction, CoCl2, DFX and DMOG were included in TGF-β3-containing chondrogenic 
induction media at varying concentrations. BM-MSCs in each of these media 
compositions were then cultured in the identical culture system utilised in chapter 3. 




most widely used in the literature (DMOG: 1mM (Nguyen, 2013 #343), CoCl2: 200μM 
[272], DFX: 200 μM [234]) . These values however, were utilised in cultures of 
relatively short incubation times in the studies references – approximately 24 hours-
7days, compared to the culture period utilised in the current study of 14-21 days. 
Therefore, the toxicity of a range of reduced values than those shown as shown 
previously [453], were tested to ensure high cell viability throughout chondrogenic 
induction of BM-MSCs .  
The majority of assays used to assess cell viability rely on quantification of cell 
metabolism such as the Alamar Blue or MTT assays, or quantify metabolic enzyme 
activity such as the Lactate Dehydrogenase assay. These cell parametres are affected 
by hypoxia independently of cell viability, therefore invalidating their use in the 
resent study. The neutral red assay which quantifies the neutral red dye taken up by 
viable cells within their lysosomes, was therefore used to assess cell viability. This 
was compared with the PicoGreen assay which enable cell number to be determined 
by quantification of double-stranded DNA. Figures 4.1B and 4.1C demonstrate a 
linear relationship between cell number and Neutral Red/PicoGreen quantification 
respectively. To ensure the functionality of the Neutral Red assay as a measurement 
of viability, vehicle-only and high, toxic doses of CoCl2, DFX and DMOG were utilised 
as respective negative and positive controls. 
Throughout this study, the effect of each of the three HIF-stabilising compounds, in 
addition to being assessed against an untreated control at normoxia, were also 




to the ability of only 5% in reducing hypertrophic marker expression which is a key 
problem faced in CTE strategies . 
 1mM of CoCl2 resulted in zero viability at days 7, 14 and 21 compared to the no-
treatment control (p<0.05) as determined by the Kruskal-Wallace multiple-
comparison test (Fig. 4.1D) . Throughout the 21-day period, 50, 100 and 200μM CoCl2 
did not alter viability until day 21 at which point the 200μM appeared to reduce 
vaibility compared to the untreated control (p>0.05) . The toxic, 1mM dose of DFX 
resulted in complete ablation of viability after 14 days (p<0.05) (Fig 4.1E) . The 100 
and 200μM doses of DFX appeared to reduce viability of the differentiating BM-MSCs 
compared to the no-treatment control at days 14 and 21 (p>0.05) . Conversely the 
20 and 50μM doses of DFX did not reduce viability compared to the untreated control 
as observed due to 100 and 200μM (p>0.05) .  5mM of DMOG also completely 
reduced viability at days 7, 14 and 21 (p<0.05) (Fig. 4.1F) . At days 7 and 14, no 
obvious change in viability was induced by any of the other DMOG doses compared 
to the untreated control. At day 21 however 500 and 1000μM concentrations of 
DMOG appeared to reduce viability (p>0.05) , with no apparent effect observed due 
to 100 or 200μM.  
Overall, 100μM of CoCl2 (Fig 4.1D), 50μM of DFX (Fig 4.1E) and 200μM of DMOG (Fig 
4.1F) were the highest concentrations of each compound to not induce ≥25% 
decrease in viability compared to the untreated control. To ensure the viability assay 
translated into actual cell number, the PicoGreen assay was used to quantify dsDNA 
throughout differentiation. None of the doses chosen of each compound altered the 




analysed using the Kruskal-Wallace multiple-comparison statistical test (Fig 4.1G) 
(p>0.05) . Together these results indicate that 100, 50 and 200μM are the highest 
concentrations of CoCl2, DFX and DMOG respectively to be taken forward for 
experiments in which thier effect on BM-MSC chondrogenesis is to be assessed. 
These results also coccur with studies such as that by Tian et al, in which these doses 






A  CoCl2 DFX DMOG 
Negative Control (μM) 0 0 0 
Concentration #1 (μM) 20 20 100 
Concentration #2 (μM) 50 50 200 
Concentration #3 (μM) 100 100 500 
Concentration most widely used in literature (μM) 200 200 1000 
Toxic Dose (μM) 1000 1000 5000 
 
Figure 4.1. CoCl2 at 100μM, DFX at 50μM and DMOG at 200μM do not reduce cell viability 
to below 75% during 21-day chondrogenic differentiation and do not reduce cell number 
during this incubation period. (A) Table detailing concentrations of CoCl2, DFX and DMOG 
tested. (B+C) Standard curves detailing linear relationship between Neutral Red 
(B)/PicoGreen (C) readings and cell number. (D-F) Cell viability throughout 21-day 
chondrogenic differentiation with varying concentrations of CoCl2 (D), DFX (E) and DMOG (F) 
included in the induction media as measured by the neutral red toxicity assay. Values plotted 
are a percentage of the untreated control  which is represented by the grey line. *represents 
significant difference (p<0.05) between the positive (1000/5000μM for CoCl2+DFX/DMOG 
respectively) and no treatment (0μM) control. when analysed with a Kruskal-Wallace test 
with Dunn’s correction. (G) Cell number during the chondrogenic differentiation of hBM-MSC 
in the presence of CoCl2, DFX, DMOG or 5%O2. Values plotted represent the mean from 3 
independent experiments and are a percentage of the cell number at day 0. Error bars show 
the standard error of the mean.   
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4.2.2. Induction of HIF-1α stabilisation by CoCl2, DFX and DMOG  
CoCl2, DFX and DMOG are all described as hypoxia-mimicking agents due to their 
ability to increase HIF-1α protein levels, induce its nuclear translocation and 
stimulate expression of HIF-target genes. Therefore as with experiments in which the 
stimulation of hypoxic pathways were investigated in choater 3, HIF-1α stabilisation 
by Western Blot, immunolocalisation and mRNA quantification of HIF-target 
transcripts were undertaken in BM-MSCs in response to treatment with either CoCl2, 
DFX and DMOG. As in response to hypoxia, a change in these parametres would 
demonstrate inhibition of PHD and/or FIH – two hydroxylases in the HIF pathway 
[453]. As qualitatively assessed by Western Blot and densitometric analysis, no 
compounds increased total HIF-1α levels significantly compared to the untreated 
control, however all treatments did induce a trend towards its increase (Fig. 
4.2A+4.2B).  
As with assessment of HIF-1α stabilisation by hypoxia, increase in nuclear HIF-1α 
localisation occurs as a result of PHD2 inhibition [482]. All three compounds induced 
HIF-1α nuclear localisation compared to the untreated control upon immunostaining 
of HIF-1α in the presence of each compound for 24 hours. A higher proportion of the 
nucleus of each cell was occupied by HIF-1α in the presence of CoCl2, DFX or DMOG 
compared to that due to the untreated control (Fig 4.2C). This quantification 
represents the images in Figures 4.2D-4.2K with HIF-1α-occupation of the nuclei 
increased due to each compound compared to the untreated control. Interestingly 




nuclear staining was observed in discrete patterns suggesting localisation within a 
subcellular organelle.  
Overall, all three HIF-1α-stimulating compounds used here induced HIF-1α nuclear 
localization. This suggests their potential for increasing formation of an active HIF 
transcription complex and subsequent transcription of HIF target genes. A selection 
of such HIF-target genes are those whose products mediate articular chondrogenesis 
and are inhibitory to chondrocyte hypertrophy. This has been demonstrated by 
inhibition of HIF-1α during hypoxia-mediated chondrogenesis inhibiting 
chondrogenic transcript and ECM formation in BM-MSCs, whilst stimulating 
hypertrophy [272]. This demonstrates the suitability of CoCl2, DFX and DMOG for 
experiments in which their effect on BM-MSC chondrogenesis is to be investigated. 
Such a study would enable suitability of such compounds for CTE strategies for repair 





Figure 4.2. CoCl2, DFX and DMOG induce HIF-1α nuclear localisation. (A) Detection 
of HIF-1α, and housekeeping protein β-Actin at day 1 of chondrogenesis by Western 
Blot. (B) Protein blots of HIF-1α were quantified by densitometric analysis and 
normalised to levels of β-Actin. Values plotted represent magnitude difference to the 
untreated control which is represented by the horizontal dotted line. The solid 
coloured lines represent the mean for each condition with *denoting p<0.05 
compared to the untreated control. (C) Quantification of nuclear HIF-1α 
immunofluorescence at day 1 of chondrogenesis. Each value plotted represents the 
percentage of a single DAPI-marked nucleus that is occupied by HIF-1α. Values from 
3 independent repeats shown with the coloured horizontal lines representing the 
mean and *denoting p<0.05 compared to the untreated control. (D-K) HIF-1α 
immunofluorescence staining at day 1 of chondrogenesis. Scale Bar = 50μm. 
Representative images of 3 independent repeats shown. Images were cropped and 




4.2.3. DMOG induced constuitive expression of HIF target genes compared to that 
induced by CoCl2 or DFX  
To determine if the increased HIF-1α nuclear localisation induced by CoCl2, DFX and 
DMOG translated into enhanced functional activity of the HIF transcriptional 
complex, we used qPCR to quantify mRNA of established HIF targets throughout the 
entire chondrogenic induction period. The genes analysed are identical to those used 
in chapter 3 in which the effect of hypoxia was investigated. DMOG treatment at days 
1, 7 and 21 increased expression of VEGFA by approximately 5, 10 and 15x that of 
the untreated control respectively (Fig. 4.3A). At all 4 time points, DMOG also 
upregulated expression of PGK1 (4x, 7x, 6x, 6x respectively for days 1, 7, 14 and 21; 
Fig 4.3B) and EGLN (7x, 10x, 27x, 9x respectively for days 1, 7, 14 and 21 Fig 4.3C). 
DFX induced expression of PGK1 at day 14 (Fig 4.3B) and EGLN at day 21 (Fig 4.3C) 
compared to the untreated control with CoCl2 not inducing expression of any the 
three HIF-targets chosen.  
Taken together, despite all three compounds inducing HIF-1α nuclear localization 
only DMOG appeared to constituitively induce expression of genes documented to 
contain HREs are which are responsive to HIF induction. This therefore suggests that 
2-OG analogues compared to those which sequester Fe2+ (CoCl2/DFX) may induce 
stonger transcriptional activity at the promoter regions of HIF-target genes. This 
indicates that 2-OG inhibitors may represent the more appropriate class of inhibitor 
















Figure 4.3. DMOG stimulates transcription of HIF targets constuitively throughout 
the 21-day chondrogenic induction period. mRNA expression of VEGFA (A), PGK1 (B) 
and EGLN (C) throughout chondrogenesis. Values plotted are from 4 independent 
experiments and are fold change compared to the untreated control which is 
represented by the horizontal dotted line.  The solid coloured lines represent the 






4.2.4. Effect of CoCl2, DFX and DMOG on transcription conducive for hBM-MSC 
chondrogenesis 
Expression of SOX9 and its downstream targets- COL2A1 and ACAN are essential for 
chondrogenesis and cartilage ECM formation. Together, these are required for the 
repair of chondral defects in CTE strategies, and replacement with tissue which 
mimicks native articular cartilage, both biochemically and mechanically. Stimulation 
of HIF-1α during chondrogenesis is important for hypoxia-mediated chondrocyte 
differentiation and expression of SOX9, COL2A1 and ACAN [262, 269]. Therefore, to 
investigate the ability of CoCl2, DFX and DMOG to stimulate expression of these genes 
during chondrogenesis qPCR was utilised to quantify their corresponding mRNA 
levels. The major role of SOX9 during chondrogenesis, from early chondrogenic 
lineage commitment to inhibition of hypertrophy promoted investigation at days 1, 
7, 14 and 21 of chondrogenesis. As in chapter 3, latent, day 14 expression of ACAN 
and COL2A1 which precedes cartilage ECM formation, denotes a typical 
chondrogenic differentiation program. 
Compared to the untreated control, DMOG induced significant expression of SOX9 at 
days 7 and 21 by approximately 4x at each of these time points (Fig. 4.4A). DFX 
appeared to show a trend towards increasing SOX9 transcripts at days 14 and 21, but 
these were not statistically significant. Unlike that shown in chapter 3, figure 3.3 
where we observed increases in SOX9 due to 5%O2 at day 1, those differences were 
no longer statistically significant when analysed using the multi-variant Kruskal-
Wallace test in which the effects of DMOG were included. Despite these increases 




expression of its target, COL2A1 (approximately 3.5x, 4x, 3x, 1.5x by CoCl2, DFX, 
DMOG and 5%O2 respectively; Fig. 4.4B). However, no conditions significantly raised 
expression of ACAN despite each treatment showing trend towards increases in this 
transcript (approximately 7.5x, 11x, 5x by CoCl2, DFX and DMOG respectively; Fig. 
4.4C).  
In addition to investigating the expression of ‘classic’ chondrogenic markers, it is also 
important to quantify expression of gene whose products play other key role during 
cartilage ECM formation. P4HA1 which encodes the CP4HA1 and LOX which encodes 
LOX and plays key roles in the formation of the collagen helical structure important 
in native cartilage ECM function and polymerisation of multiple collagen helices.  A 
key facet therefore of any CTE strategy is maintaining these post-translational 
modifications of the collagen helices, which are important for function of the 
collagen network in cartilage ECM [483]. The product of P4HA1 catalyses the 
hydroxylation of specific proline residues [484]. LOX coverts lysine and hydroxylysine 
residues to their aldehyde form which facilitates covalent crosslinks between 
individual collagen fibrils [483]. Both of these enzymes have been shown to be 
upregulated by HIF and hypoxia [280, 485] and indeed both DFX and DMOG induced 
LOX expression significantly by approximately 2x and 3x respectively compared to 
untreated controls (Fig. 4.4D). P4HA1 was significantly upregulated by approximately 
6x in response to DMOG treatment (Fig. 4.4E). Figures 4.4F+4.4G demonstrate the 
suitability of LOX and P4HA1-specific primers with regards to the efficiency of the 
qPCR reaction which they mediate and a linear relationship between cycle number 




Overall, DMOG displayed the greatest advantages with regards to induction of 
chondrogenic mRNA during BM-MSC chondrocyte differentiation. It enhanced 
expression of the master chondrogenicn transcription factor; SOX9 throughout 
chondrogenesis with no change seen due to CoCl2 or DFX. DMOG also induced 
expression of LOX and P4HA1 – genes whose products are integral in Collagen 
deposition in cartilage ECM. Together, these suggests that DMOG may have the 
















Figure 4.4. DMOG induces a transcriptional profile in differentiating BM-MSCs 
which is conducive for chondrogenesis and cartilage formation. mRNA expression 
of SOX9 (A), COL2A1 (B), ACAN (C), LOX (D) and P4HA1 (E) throughout 
chondrogenesis. Values plotted are from 4 independent experiments, and are fold 
change compared to the untreated control which is represented by the horizontal 
dotted line.  The solid coloured lines represent the mean for each condition with 
*denoting p<0.05 compared to 20%O2. (F+G) Standard curve which demonstrates a 
linear relationship between input cDNA concentration and cycle (Ct) number when 
amplified using LOX (F) and P4HA1 (G)-specific primers. 
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4.2.5.  DMOG inhibits the presence of Collagen Type II and GAGs in the ECM during 
chondrogenesis of hBM-MSCs  
To assess if the changes in chondrogenic gene expression due to CoCl2, DFX and 
DMOG translates into an increased presence of deposited cartilage ECM 
components, we examined the presence of Collagen Type II and GAGs in the 
produced by differentiated hBM-MSCs. This was accomplished by immunostaining 
and Alcian Blue histochemical staining for Collagen Type II and GAGs respectively at 
day 21 of chondrogenesis. Such an investigation would indicate the suitability of 
CoCl2, DFX and DMOG for inclusion in a CTE strategy due to the requirement of a 
Collagen Type II and GAG-rich ECM for articular cartilage function [33, 438]. 
Neither CoCl2 (Fig. 4.5B) nor DFX (Fig. 4.5C) induced changes in Collagen Type II 
compared to the untreated control (Fig. 4.5A). This was also mirrored by a lack of 
change in staining for GAGs due to CoCl2 (Fig. 4.5F) or DFX (Fig. 4.5G) compared to 
the untreated control (Fig. 4.5E). DMOG however appeared to inhibit both 
incorporation of Collagen Type II (Fig. 4.5D) and GAG’s (Fig. 4.5H) into the ECM. 
Quantification of Collagen Type II immunofluorescence confirmed this inhibition due 
to DMOG when the signal due to the presence of Collagen Type II was normalised to 
the number of DAPI-stained nuclei in each image (Fig. 4.5I). This significance was 
determined by a Kruskal Wallace multiple comparison test (p<0.05). The decrease in 
GAGs due to DMOG were not significant (p<0.05) when total GAGs were quantified 
and normalised to cell number as determined by the PicoGreen assay (Fig. 4.5J). 
Overall, despite DMOG demonstrating advantages at the mRNA levels with regards 




II by these cultures. This represents a major issue with regards to use of DMOG in 
CTE. This is due to the requirement of cartilage ECM for maintaining viability of the 
resident chondrocytes, enabling resistance to compressive forces applied on the 







        
  
Figure 4.5. DMOG inhibits Collagen Type II deposition in the extracellular matrix by 
reducing its production per cell. (A-D) Collagen Type II immunofluorescence staining 
at day 21 of chondrogenesis. Scale Bar = 400μm. Representative images of 4 
independent repeats shown. Alcian Blue staining for glycosaminoglycans with 
nuclear haematoxylin counterstain at day 21 of differentiation. Scale bar = 400μm. 
Representative images of 3 independent experiments are shown. (I-J) Quantification 
of Collagen Type II immunofluorescence (I) and Glycosaminoglycans (J) at day 21 of 
chondrogenesis both without and with values normalised to DAPI 
immunofluorescence/total double stranded DNA. Values plotted are from 4 
independent experiments, and are fold change compared to the untreated control, 
represented by the horizontal dotted line.  The solid coloured lines represent the 
mean for each condition and *denotes p<0.05 compared to the untreated control. 





























4.2.6. DMOG induced an anti-hypertrophic transcriptional profile and inhibits 
Collagen Type X protein levels 
To identify any changes in hypertrophy of the chondrogenically-induced hBM-MSCs 
as observed due to 5%O2 in chapter 3, we investigated changes in transcription of 
RUNX2 and COL10A1 but also quantified MMP13 mRNA in response to CoCl2, DFX 
and DMOG treatment. Increased expression of MMP13 is observed during 
chondrocyte hypertrophy [486], plays a significant role in OA pathogenesis via 
digestion of Collagen Type II [487], and is downregulated by hypoxia and HIF [288]. 
Together, an effect on hypertrophic mRNA expression would demonstrate the 
suitability of either compound for CTE strategies. Chondrocyte hypertrophy during 
BM-MSC differentiation is a significant pitfall of current attempts articular cartilage 
regenerative medicine due to the subsequent mineralisation which subsequently 
occurs [414]. 
 No conditions induced increases in RUNX2 mRNA at any time point during 
chondrogenesis (Fig. 4.6A). DMOG treatment caused a significant increase in the 
ratio of SOX9:RUNX2 mRNA at days 7, 14 and 21 (approximately 4x, 3x, 3x 
respectively) compared to the untreated control (Fig. 4.6D). DMOG also significantly 
inhibited expression of COL10A1 mRNA (Fig. 4.6B) and this significantly increased the 
ratio of COL2A1:COL10A1 by approximately 6x due to DMOG compared to the 
untreated control (Fig. 4.6E). No changes were apparent in MMP13 expression due 
to any condition (Fig. 4.6C). In terms of Collagen Type X protein, both DFX (Fig. 4.7C) 




compared to the untreated control (Fig. 4.7A), with CoCl2 inducing a more subtle 
decrease (Fig. 4.7B).  
Overall, DMOG at the transcript level, demonstrated clear advantages with regards 
to promotion of an articular chondrocyte phenotype and inhibition of hypertrophy. 
Compared to that induced by CoCl2 or DFX, an increase of SOX9 compared to levels 
of RUNX2 and inhibition of Collagen Type X (at the mRNA and protein level) by 
DMOG, suggests its use in programming BM-MSCs down an articular chondrocyte 













Figure 4.6. DMOG induces a transcriptional profile in differentiating BM-MSCs 
which is inhibitory to chondrocyte hypertrophy. mRNA expression throughout 
chondrogenesis of RUNX2 (A), COL10A1 (B), MMP13 (C) and  SOX9 & COL2A1 
normalised to RUNX2 & COL10A1 respectively (D+E). Values plotted are from 4 
independent experiments and are fold change compared to the untreated control 
which is represented by the horizontal dotted line.  The solid coloured lines represent 









Figure 4.7.  DFX and DMOG reduce Collagen Type X protein in chondrogenically-
differentiating hBM-MSCs. (A-D) Collagen Type X immunofluorescent staining at day 
21 of chondrogenesis. Scale Bar = 400μm. Representative images of 3 independent 






4.2.7.  Effect of CoCl2, DFX and DMOG on expression of Bone Morphogenetic 
Protein, Indian Hedgehog and Wnt pathway components during hBM-MSC 
chondrogenesis 
The differential effects CoCl2, DFX and DMOG on the chondrogenic gene expression 
profile during induction of hBM-MSCs prompted investigation into the expression of 
components of other pathways important during cartilage development. Canonical 
Wnt signalling plays a key role during limb development. β-Catenin activity is 
required for early limb bud initiation via FGF signalling [488] and plays key roles in 
determining cell fate of the early mesenchymal limb bud population between the 
osteoblastic or chondrogenic cell fates [66] It is also involved in propagating 
chondrocyte hypertrophy and endochondral ossification [100]. Secondly, BMP 
signaling has also been shown to mediate hypertrophic signaling during cartilage 
development and in vitro [489, 490]. 
The importance of Wnt and BMP signaling in cartilage hypertrophy prompted 
investigation of the effect of the HIF-1α-stabilising compounds on genes whose 
products regulate the activity of Wnt and BMP signalling. Such data may provide 
insights into how these compounds are able to inhibit hypertrophy during BM-MSC 
chondrogenesis which is an essential facet of any CTE strategy. As described in 
chapter 3, hypoxia has been shown to upregulate Wnt and BMP antagonists- DKK1 
and Gremlin1 during chondrogenesis of BM-MSCs. As HIF-1α is known to play key 
roles during hypoxia-mediated chondrogenesis, we therefore examined expression 
of DKK1 and GREM1 here in response to treatment of CoCl2, DFX and DMOG. In 




Expression of these targets- AXIN2 and LEF1 may give a diect indication of the activity 
of the Wnt pathway during chondrogenesis of BM-MSCs. This may therefore enable 
correlations to be made with hypertrophic marker expression and how these 
together are regulated by HIF-1α-stabilising compounds.  
Compared to the untreated control, expression of DKK1 appeared to follow a trend 
towards downregulation at day 1 and upregulation at day 21 due to DMOG (Fig. 
4.8A). DFX induced a trend of upregulation in DKK1 at days 7, 14 and 21 of 
differentiation (Fig. 4.8A). No effect on DKK1 expression appeared to be induced by 
CoCl2. Compared to the untreated control, all compounds appeared to also show 
trends towards increases of Wnt targets AXIN2 (Figs. 4.8C) and LEF1 (Figs. 4.8D) at 
day 14, with an increase in LEF1 also observed at day 1 due to DMOG. Interestingly, 
this effect at day 14 was also preceded by a suppression of AXIN2 at day 7 due to all 
compounds compared to the no-treatment control (Figs. 4.8C). In terms of 
expression of the BMP antagonist- GREM1, CoCl2 and DMOG appeared to more 
strongly induce GREM1 expression at days 7 14 and 21 compared to that observed 
due to DFX and the untreated control (Figs. 4.8B).  
Overall, all 3 compounds appeared to induce DKK1 or GREM1 expression, however 
this did not appear to correlate with expression of Wn targets, AXIN2 and LEF1. In 
addition, the inhibition of hypertrophy specifically by DMOG shown previously did 
not appear to correlate with an inhibition of Wnt or BMP signaling. This perhaps 
indicates that DMOG’s anti-hypertrophic effect is not mediated through inhibition of 




Indian Hedgehog signalling is another pathway whose output is important in 
regulating the phenotype of different populations of chondrocytes during 
endochondral ossification. It maintains articular chondrocytes distally located from 
the primary ossification centre, whilst inducing hypertrophy in those more proximal 
to the centre of the developing bone. The gene product of IHH, which upon binding 
to Patch1 receptors on articular chondrocytes, sitmulates expression of PTHRP 
whose product inhibits hypertrophic progression. Therefore, expression of IHH and 
PTHRP  in response to treatment of chondrogenically-induced BM-MSCs with HIF-1α-
stabilising compounds, would also illustrate regulation of hypertrophic signaling by 
these compounds.  
Despite there being no significant changes in expression of the genes encoding the 
two ligands- IHH (Figs. 4.8E) and PTHRP (Figs. 4.8F), there was a trend towards 
increase in the mRNA of those at day 14 in the presence of all compounds. There was 
also a similar trend at in expression of IHH at day 1 due to DMOG (Figs. 4.8E). Overall 
and as with expression of Wnt/BMP antagonists, there appeared to be no correlation 
between the DMOG’s unique inhibition of hypertrophy and expression of anti-
hypertrophic Indian Hedghog signaling genes. Instead all three compounds appeared 
to upregulate IHH and PTHRP, indicating the ability of CoCl2, DFX and DMOG to 
provide an anti-hypertophic signaling milleu during BM-MSC chondrogenesis. Figure 
4.8G-4.8J demonstrate the ability of AXIN2, LEF1, IHH and PTHRP-specific primers to 
amplify input cDNA with reaction efficiencies between theoretical values of 90-110%. 










Figure 4.8. During BM-MSC chondrogenesis, CoCl2, DFX and DMOG induce changes 
in the mRNA of genes whose products are involved in the Bone Morphogenetic 
Protein, Wnt and Indian Hedgehog signalling pathways. (A-F) mRNA expression of 
DKK1 (A), GREM1 (B), AXIN2 (C), LEF1 (D), IHH (E) and PTHRP (F) throughout 
chondrogenesis. Values plotted represent the mean value of 4 independent 
experiments and are fold change compared to the untreated control (20%O2). Data 
illustrated as scatter plots in appendix figure 6. [491] Standard curves which 
demonstrate a linear relationship between input cDNA concentration and cycle (Ct) 
number when amplified using AXIN2- (G), LEF1- (H), IHH- (I)  and PTHRP- (J) specific 
primers (y axis = Ct, x axis = [cDNA] (%).  
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4.2.8.  Identification of a HIF-1α inhibitor for use during hBM-MSC chondrogenesis 
The regulation of HIF-1α during chondrogenesis of BM-MSCs is poorly understood. 
The use of CoCl2, DFX and DMOG during this process may enable elucidation of HIF-
1α control due to the differential mechanism of action of these compounds and 
varying extent to which they inhibit PHD2 and FIH. However, before any 
interpretation can be made from experiments in which CoCl2/DFX/DMOG stimulate 
chondrogenesis, it is required to confirm that these effects are indeed mediated via 
HIF-1α. Therefore, to determine if the potent transcriptional effect of DMOG is 
mediated via stabilisation of HIF-1α, we sought to identify an inhibitor of its HIF-1α 
that is downstream of the proposed effect of DMOG which inhibits PHD2 and FIH-
mediated hydroxylation of HIF-1α.  
One such compound is Acriflavine which acts to block the dimerization of HIF-1α with 
an essential transcriptional co-factor in the HIF complex- HIF-1β [492]. ACF has 
therefore been demonstrated to reduce the availability of HIF-1α in the HIF 
transcriptional complex, without affecting its protein levels [493]. To determine if 
ACF retained this biological effect when used in conjunction with TGF-β3-containing 
chondrogenic media and DMOG, we quantified the effect of 5μM ACF on the levels 
of mRNA encoding established HIF targets after a 24 hour treatment period.  DMOG 
induced expression of VEGFA, EGLN, PGK1 and GLUT2 by approximately 9x, 2.5x, 3x 
and 4x respectively compared to the untreated control, and these increases were 
abolished in the presence of ACF (Fig. 4.9A). To ensure ACF treatment did not 
significantly alter cell number throughout chondrogenic differentiation we measured 




number was observed due to ACF in the presence of DMOG compared to DMOG 
treatment alone (Fig 4.9B).  
Together, these results demonstrate that ACF can be used to inhibit DMOG-mediated 
expression of HIF targets without negatively affecting cell number for 14 days, at 











Figure 4.9. Acriflavine abolished DMOG-mediated upregulation of HIF target 
transcription and does not alter cell number after 21 days in DMOG-supplemented 
conditions. (A) mRNA expression of VEGFA, EGLN, PGK1 and GLUT2 following a 24-
hour incubation period (n=1). Values plotted are fold change compared to the 
untreated control without DMOG. (B) Quantification of DAPI-stained nuclei following 
14-day incubation in chondrogenic conditions in the presence of DMOG+/-
Acriflavine. Values plotted are from 4 independent repeats and are fold change 
compared to DMOG treatment without Acriflavine which represented by the 





4.2.9.  DMOG-mediated changes in transcription during hBM-MSC chondrogenesis 
are mediated by HIF-1α 
Acriflvaine was shown to be a suitable HIF-1α inhibitor to investigate the mechanism 
of DMOG-mediated gene expression changes and thereby give insight into HIF-1α 
regulation during chondrogenesis. The effect of ACF at day 14 of BM-MSC 
differentiation was subsequently examined due to many of the DMOG-induced 
expression changes occurring at this time point, relative to the untreated control. 
Such changes include genes involved in correct folding and polymersiation of 
Collagen Type 2 triple helices as well as those involved in chondrocyte hypertrophy. 
The significant increases in SOX9 mRNA due to DMOG compared to the untreated 
control (approx 6x), were abolished in the presence of ACF (Fig. 4.10A) and this 
pattern was observed when the expression of HIF targets- VEGFA and EGLN were 
quantified. DMOG as before induced significant increases in both VEGFA (Fig. 4.10B) 
and EGLN (Fig. 4.10C) at day 14 of chondrogenesis compared to the untreated control 
(increases of 20x and 6x respectively) and these significant differences were not 
present following ACF treatment. The significant increase in COL2A1 mRNA by DMOG 
compared to the untreated control (approximately 2x) was also abolished by ACF 
(Fig. 4.10D) and the significant downregulation of COL10A1 mRNA due to DMOG 
compared to the untreated control (approx. 0.5x) was also abolished in the presence 
of ACF (Fig. 4.10E). A corresponding significant reduction in the ratio of 
COL2A1:COL10A1 due to DMOG was observed in the presence of ACF. This is in 
comparison to the ACF-free conditions in which the COL2A1:COL10A1 ratio was 




ACF also had an effect with regards to the gene expression induced by 5%O2. In the 
ACF-free conditions, 5%O2 induced no changes in expression of SOX9 and COL2A1 
mRNA. In the presence of ACF, hypoxic incubation significantly reduced SOX9 (Fig. 
4.10A) and COL2A1 (Fig. 4.10D) mRNA, as well as the ratio of COL2A1:COL10A1 (Fig. 
4.10F).  
The global effect of DMOG on HIF target and chondrogenic transcripts are shown in 
Figures 4.10G-4.10N. DMOG induced a trend towards the upregulation of SOX9 (Fig. 
4.10G), COL2A1 (Fig. 4.10H), VEGFA (Fig. 4.10I), EGLN (Fig. 4.10J), DKK1 (Fig. 4.10K) 
and LOX (Fig. 4.10L) mRNA and inhibits COL10A1 (Fig. 4.10N) transcription compared 
to all other conditions. The effect of ACF in reducing the observed expression changes 
due to each of the three HIF-stimulating compounds is most apparent in the presence 
of DMOG. The reduction in DMOG-mediated gene expression changes by ACF appear 
to be larger than the differences observed in the presence of either CoCl2 or DFX.  In 
addition, for COL10A1 expression, the decreases induced by CoCl2 and DFX were not 
reversed as emphatically by ACF as observed in the presence of DMOG (Fig. 4.10N). 
Overall, DMOG’s effects on stimulating the expression of pro-chondrogenic mRNA at 
day 14 of chondrogenesis were inhibited by ACF treatment. This demonstrates the 
importance of HIF-1α in the HIF transcriptional complex in response to DMOG 
treatment and its integral role in expression of HRE-containing genetic loci. In 
addition ACF had a greater impact on DMOG-mediated gene expression compared 
to the effect of ACF when used in conjunction with CoCl2/DFX. This indicates that HIF-
1α mediates DMOG’s effect to greater extents than CoCl2/DFX’s effects and suggests 




more on 2-OG than Fe2+. This also has importance implications for CTE strategies and 
indicates the role that 2-OG inhibitors may play in enhancing BM-MSC articular 
chondrogenesis via HIF-1α. The use of such inhibitors may be essential due to 
demonstration that HIF-1 deletion in adult articular cartilage results in chondrocyte 
death and development of an OA-like phenotype [288]. 2-OG inhibitors may 
therefore enable formation of a cell population that faithfully mimics those found in 







Figure 4.10. Acriflavine, an inhibitor of HIF-1α+HIF-1β binding, reduces DMOG-
mediated transcriptional changes during chondrogenesis. mRNA expression 
throughout chondrogenesis of SOX9 (A), VEGFA (B), EGLN (C), COL2A1 (D), COL10A1 
(E) and the ratio of COL2A1/COL10A1 (F). Values plotted are from 4 independent 
experiments and are fold change compared to the untreated control without DMOG 
which is represented by the horizontal dotted line. The solid coloured lines represent 
the mean for each condition. *denotes p<0.05 when compared to 20%O2+/-ACF and 
#denotes p<0.05 between +/-ACF conditions within DMOG and 5%O2 groups. The 
heat maps shown in G-N illustrate the effect of Acriflavine in the presence of each 






4.2.10. HIF-1α inhibition alleviates the decrease in Collagen Type II observed due to 
DMOG 
With observation that the gene expression changes induced by DMOG are mediated 
by HIF-1α, we sought to identify if the ability of DMOG to inhibit incorporation of 
Collagen Type II into the ECM was also mediated by HIF-1α. As previously, DMOG 
reduced Collagen Type II in the ECM (Fig. 4.11B) compared to the untreated control 
(Fig. 4.11A), and this decrease was alleviated slightly in the presence of ACF (Fig. 
4.11C). This is represented in the quantification of this immunofluorescent staining 
in which the significant decrease due to DMOG, is rendered no longer significant by 
the addition of ACF (Fig. 4.11D). This result indicates that the DMOG’s determental 














Figure 4.11. Inhibition of HIF-1α partially rescues the DMOG-mediated decreases in 
the presence of Collagen Type II in the ECM. (A-C) Collagen Type II 
immunofluorescent staining at day 14 of chondrogenesis due to DMOG in the 
absence and presence of Acriflavine. Scale bar = 400μm. Representative images of 3 
independent repeats shown. (D) Quantification of Collagen Type II 
immunofluorescence at day 14 of chondrogenesis due to DMOG in the absence and 
presence of Acriflavine. Values plotted are from 4 independent experiments, and are 
fold change compared to the untreated control without DMOG which is represented 
by the horizontal dotted line. The solid orange lines represent the mean for each 











4.2.11. Late treatment of DMOG induces pro-chondrogenic transcriptional changes 
whilst maintaining cartilage ECM 
To attempt to alleviate the effect of DMOG in inhibiting production of Collagen Type 
II which is an important structural component of articular cartilage, the period of 
DMOG treatment during hBM-MSC chondrogenesis was adjusted. Treatment of 
DMOG for the final 7 days of chondrogenic induction could potentially reduce the 
cumulative inhibitory effect on Collagen Type II incorporation into the ECM. 
Chondrogenic transcript quantification by qPCR and collagen type 2 immunostaining 
were performed at day 21 of chondrogenesis following either continuous DMOG 
treatment or supplementation for the final 7 days of culture.  
Treatment of DMOG for days 14-21 of the chondrogenic protocol only did not reduce 
Collagen Type II in the ECM (Fig. 4.12C) compared to the untreated control (Fig. 
4.12A) as was observed due to continuous treatment for the full 21 days of 
chondrogenesis (Fig. 4.12B). This was confirmed by quantification of the 
immunostaining which were normalised to the number DAPI-stained cells (Fig. 
4.12D). Despite achieving similar Collagen Type II protein compared to the untreated 
control, DMOG treatment for days 14-21 enhanced mRNA expression of SOX9 (Fig. 
4.12E), P4HA1 (Fig. 4.12G) and HIF targets- VEGFA (Fig. 4.12H) and EGLN (Fig. 4.12I), 
as observed due to continuous treatment for 21 days. Unlike these transcripts, the 
SOX9 target- COL2A1 was not induced by late treatment as with continuous dosage 
(Fig. 4.12F). 
Overall, late DMOG treatment appeared to alleviate the determinal effect of 




maintaining the strong induction of transcription of chondrocgenic mRNA. This 
therefore indicates tha late DMOG treatment may be a valid CTE strategy for 
improving chondrogenic differentiation of BM-MSCs whilst maintaining the cartilage 











Figure 4.12. Late treatment of DMOG does not reduce Collagen Type II in the 
ECM as with continuous exposure, but still induces chondrogenic gene 
expression in differentiating BM-MSCs.  (A-C) Collagen Type II 
immunofluorescence staining at day 21 of chondrogenesis. Scale Bar = 400μm. 
Representative images of 4 independent repeats shown. (D) Quantification of 
Collagen Type II immunofluorescence at day 21 of chondrogenesis which was 
normalised to DAPI immunofluorescence. Values plotted are from 4 independent 
experiments and are fold change compared to the untreated control without 
DMOG which is represented by the horizontal dotted line. The solid coloured lines 
represent the mean for each condition and *denotes p<0.05 compared to the 
untreated control without DMOG. (E-I) mRNA expression throughout 
chondrogenesis of SOX9 (E), COL2A1 (F), P4HA1 (G) VEGFA (H) and EGLN (I). 
Values plotted are from 4 independent experiments and are fold change 
compared to the untreated control without DMOG which is represented by the 
horizontal dotted line. The solid orange lines represent the mean for each 







The pro-chondrogenic effects of hypoxia are thought to be mediated primarily 
through HIF-1α which is part of an active transcription factor complex at target genes. 
It has been shown to mediate not only initial chondrogenic differentiation of 
mesenchymal precursors [262] but also have a role in stabilising the articular 
chondrocyte phenotype [288] and ensuring cartilage ECM production [277]. 
Therefore it is not overly presumptive to predict that compounds which stimulate 
HIF-1α, may improve de-novo articular cartilage formation. Previous studies have 
examined the effect of CoCl2 [272], DFX [494] and DMOG [278]; compounds with HIF-
α-stabilising ability, for enhancing cartilage ECM formation from articular 
chondrocytes, reducing hypertrophy or even rescuing from an osteoarthritic 
phenotype. However, no evidence exists for the comparison of the effect of DMOG, 
a 2-OG analogue with that of Fe2+ analogue and chelator, CoCl2 and DFX [467] during 
chondrogenesis of hBM-MSCs.  
The results detailed in this chapter clearly indicate an advantage of DMOG in 
stimulating expression of chondrogenic mRNA including those whose products are 
quired for chondrocyte differentiation and complete folding and polymerization of 
Collagen Type II triple helices. In addition, compared to that observed due to CoCl2 
or DFX, DMOG inhibited expression of hypertrophic markers at the mRNA and 
protein leevsl. Together, these suggest the suitability of DMOG for incorporation into 
a CTE strategy in which BM-MSCs or a similarly multipotent cell population are 
directed down an articular chondrocyte lineage within a 3D biomaterial scaffold. The 




produce cartilage that resembles that which arises during native articular cartilage 
development – essential for repair of acute chondral defects. However, a potential 
pitfall is demomstrated by the decrease in Collagen Type II protein induced by DMOG 
treatment. This was alleviated by treatment of DMOG for the final 7/21 days of 
chondrogenesis only whilst maintaining the transcriptional changes induced by this 
2-OG inhibitor.  
Prior to assessing the role of these HIF-stabilising compounds for chondrogenic 
induction, it was imperative to identify concentrations which were not toxic to the 
hBM-MSCs and did not significantly reduce cell number during the 21-day 
differentiating period. The highest concentrations of each compound which were 
used as a positive control for cell death, did not cause a complete abolishment in cell 
viability at 0.5 days for CoCl2 and DMOG and not at day 0.5 or 7 for DFX. This suggests 
either a lack of drug absorption by the cells prior to 0.5 days which would have 
otherwise resulted in a cumulative toxic dose.Alternatively, and particularly in the 
case of DFX, hBM-MSCs may retain have been able to excrete/metabolise the 
compounds at early time points before their toxicity took effect. The constitutive 
treatment and build-up of each compound following 0.5-7 days may then have 
overcome any ability of the cell for excretion or metabolism.  
Another possibility for the lack of toxicity at these early time points is that observed 
may be due to the initial ability of hBM-MSC treated with these compounds to inhibit 
apoptotic processes via HIF-mediated mechanisms. Although HIF-1α stabilisation 
was not examined at 0.5 days, each compound increased nuclear HIF-1α at 24 hours, 




previously in breast cancer cells, where resistance to a chemotherapeutic agent 
being abolished upon HIF-1α deletion [495], and also in a hepatocyte cell line in which 
fatty acid-induced apoptosis was inhibited by HIF-1α overexpression [496]. Following 
the initial tolerance, DFX appeared to cause a larger drop in viability due to the 100 
and 200μM doses. This was unlike that observed due to CoCl2 at these doses. This 
may suggest the propensity of DFX, which is a specific iron-chelating agent, to 
sequester Fe2+ ions from enzymes responsible for maintaining cell viability, such as 
cytochrome complexes of the mitochondria [497].  
Following identification of appropriate doses to use of each compounds, the ability 
of CoCl2, DFX and DMOG to induce HIF-1α nuclear localisation was confirmed. In 
addition, as with hypoxic incubations, treatment with each of the compounds did not 
alter the peri-nuclear localisation of HIF-1α observed in the control conditions. 
Subcellular localisation of the HIF hydroxylases is important in their regulation of HIF-
1α. It has been reported that PHD2 protein primarily resides and hydroxylates  of HIF-
1α within the nucleus in certain cell types [498] which perhaps rationalises the 
presence of HIF-1α external to the nucleus. This is also supported by the observation 
of increased hydroxylase activity of nuclear PHD2 compared to the cytoplasmic 
fraction [498]. In normoxic untreated conditions, this may result in a net increase in 
hydroxylation, ubiquitination and degradation of nuclear HIF-1α and comparatively, 
a preservation of HIF-1α in the cytoplasm.  
Despite each compound inducing nuclear HIF-1α localisation compared to the 
untreated control, only DMOG appeared to constitutively induce mRNA expression 




CoCl2 causing no transcriptional effect. Increases in VEGFA and EGLN mRNA by DMOG 
were shown through the use of Acriflavine, to be mediated by HIF-1α interacting with 
HIF-1β in the HIF transcriptional complex. As with observations in the previous 
chapter, a limitation in this study may be the relatively low number of HIF-target 
genes selected to denote activation of HIF-mediated transcription. PHD2 and FIH 
inhibition stimulates differential HIF-mediated gene expression programs, with these 
hydroxylases inhibited by CoCl2, DFX and DMOG to different extents [453]. This 
therefore suggests that expression of alternative HIF target genes than those shown 
here may be induced by CoCl2 and DFX which may have validate their potency as 
inducers of HIF activity. 
The differences in HIF-mediated transcription induced by Acriflavine in the presence 
of DMOG were larger than the effect of Acriflavine in the presence of DFX. This 
suggests the transcriptional changes induced by DMOG compared to that stimulated 
by DFX were dependent to a greater extent on the participation on HIF-1α. 
Interestingly DMOG’s potent transcriptional effects relative to both the untreated 
control and DFX were not a result of increased HIF-1α protein induced by the 2-OG 
analogue. This is demonstrated by the lack of observed differences in the total levels 
and nuclear localisation of HIF-1α between that induced by DFX and DMOG. One 
limitation of this study is the lack of analysis of HIF-1α protein throughout 
chondrogenesis induced by these compounds after day 1. This would have enabled 
correlation or a lack thereof between HIF-1α protein, transcription of HIF targets and 
chondrocyte differentiation. Furthermore, as opposed to HIF-1α semi-quantification, 




nuclear compartments using ELISAs or DNA-binding ELISAs. This may enable the 
discerning of any subtle changes in HIF-1α stabilization between CoCl2, DFX and 
DMOG treated cultures. 
These differences in expression of HIF targets due to these HIF-stimulating 
compounds may therefore highlight distinct mechanisms by which the different 
hydroxylase inhibitors function, and by which HIF-1α is regulated in hBM-MSCs. Tian 
et al examined the ability of each of the presently used compounds to inhibit the 
activity of PHD2 and the HIF asparagine hydroxylase, FIH. In a renal carcinoma cell 
line, Tian et al utilised identical concentrations of CoCl2, DFX and DMOG identical to 
that used in the present study. They observed a complete reduction in FIH activity 
due to DMOG as evidence by abolishment of HIF-1α asparagine hydroxylation. This 
was accompanied by a decrease in proline hydroxylation which is indicative of PHD2 
inhibition. Due to DFX, the decrease in asparagine hydroxylation did not occur as 
robustly as with DMOG and a lack of change in this was observed in response to 
treatment with 100μM CoCl2 compared to the untreated control. However both DFX 
and CoCl2 induced similar decreases in proline hydroxylation as observed due to 
DMOG in this study. Overall the observations made by Tian et al suggest the role of 
FIH and PHD2 inhibition in mediating DMOG’s effect on HIF target gene expression 
compared to that stimulated by DFX and CoCl2 which may primarily function solely 
via PHD2 inhibition. This corresponds to the lack of effect of CoCl2 in the present 
study. CoCl2 here may be unable to sufficiently inhibit FIH, which would result in high 
HIF-1α asparagine hydroxylation and a lack of HIF enrichment at the promoters of 




a lack of FIH inhibition by CoCl2 may induce a different subset of HIF targets [451] 
which were not investigated here and which may validate CoCl2 as a potent HIF-
stimulator during chondrogenesis.  
Further supporting a role for FIH in the observations made here in response to DMOG 
treatment, FIH compared to PHD2 has an increased Km value for 2-OG [499]. This 
translates into a requirement of FIH for greater levels of 2-OG than required by PHD2 
for these two enzymes reach the same activity level. DMOG treatment also increased 
HIF-mediated transcription compared to that observed in the presence of a PHD2-
selective inhibitor [44]. Together these studies suggest that FIH is more sensitive than 
PHD2 to DMOG and this enhances HIF-mediated transcription relative to PHD2-only 
inhibition. Furthermore, Palomaki et al suggested the greater dependence on 
inhibition of FIH rather than PHD2 for HIF-mediated transcription specifically in BM-
MSCs. This is due to the observation in this study of increased HIF-1α mRNA levels 
observed in this cell type [432]. This increased transcription and corresponding 
protein levels of HIF-1α was hypothesised to compensate for any decrease in HIF-1α 
stability due to PHD2-mediated hydroxylation.  
The studies described above, may rationalise the potent effect of DMOG in the 
present study and suggests this compound as potent FIH inhibitor compared to DFX 
or CoCl2. In mouse myoblasts, FIH knockdown was shown to induce significant higher 
levels of HIF-mediated transcription compared to PHD2 knockdown which 
demonstrates the potential for a FIH-selective mechanism that is stimulated by 
DMOG here [481]. These rationalisations of the contrasting effects of CoCl2 and 




inhibition to these observations are of course, only speculative. Aside from the use 
of Acriflavine which inhibits HIF-1α-HIF-1β heterodimerisation and is therefore 
downstream of FIH and PHD2 activity, no manipulation of the PHD2/FIH/HIF 
signalling pathways was conducted during CoCl2/DFX/DMOG-treated 
chondrogenesis.  
If DMOG does indeed induce its transcriptional effects via inhibition of PHD2 and FIH, 
as opposed to PHD2 inhibition alone as induced by DFX and CoCl2 this would correlate 
with our observations of DMOG’s effect on inducing a chondrogenic gene expression 
profile. Chan et al compared the effects of PHD2-specific inhibitor, IOX2 and FIH-
specific inhibitor, N-Oxalyl-(d)-Phenylalanine (NOFD) with that of DMOG on 
transcription of HIF targets in MCF-7, Hep3B, and U2OS cell lines [500]. These authors 
observed an increase in SOX9 expression due to DMOG but not due to IOX2 or NOFD. 
This implies that SOX9 is a genetic locus that is regulated by HIF in a manner 
dependent on inhibition of both PHD2 and FIH by DMOG as opposed to inhibition of 
either hydroxylases alone.  
In the present study, DMOG-mediated upregulation of HIF-target gene expression 
appeared to correlate with the generation of a chondrocyte expression profile, 
including an induction of SOX9 expression. As with expression of HIF targets 
described above, the role of dual FIH and PHD inhibition in mediating the effect of 
DMOG on SOX9 expression here is only theoretical. Confirmation of such a 
mechanism would require genetic or inhibitor-based manipulation of PHD2 and FIH 
during DMOG-mediated chondrogenesis. Also observed was an upregulation of SOX9 




differentiation over that of an osteoblast/hypertrophic chondrocyte. This would 
confer advantages to any CTE strategy. For example, Ma et al created a doxycyline-
inducible SOX9 transgene within C3H10T1/2 cells which when seeded 
subcutaneously into a mouse model resulted upregulation of cartilage ECM 
formation upon Doxycycline treatment [501]. 
 Despite only DMOG inducing significant SOX9 expression, all three compounds 
appeared to induce expression of its target gene- COL2A1 at day 14. Provot et al 
deleted HIF1A in the limb bud mesenchyme. Despite observing an abolishment in 
COL2A1 mRNA at the onset of chondrogenesis, SOX9 mRNA was largely unaffected 
both at the same developmental time point, and at the earlier stage of mesenchymal 
condensation [262]. This implicates a SOX9-independent induction of COL2A1 during 
HIF-1α-mediated cartilage development or at least an uncoupling of SOX9 
transcription with that of COL2A1 in response to HIF-1α stimulation. A similar 
mechanism may be induced by CoCl2 and DFX due to observations of an absence of 
SOX9 expression accompanying the increase in COL2A1 by these compounds.  As 
shown previously [272] HIF-1α may upregulate SOX5/6 which would increase COL2A1 
expression by facilitating SOX9-mediated transcription of this genetic locus [502]. 
This would therefore require no increase in SOX9 expression to achieve increased 
COL2A1 expression. Again, the correlative observations of SOX9 and COL2A1 
transcription here enable only a suggestion of the mechanisms which dictate the 
levels of their mRNA in respect of each other. For any such mechanism to be 
validated, genetic manipulation of SOX9 in addition to SOX5 and SOX6 would be a 




1 and 7 or between days 7 and 14, it is not possible to rule out an increase in SOX9 
transcription prior to the increase in COL2A1 mRNA at day 14. 
Unlike COL2A1 transcription which is upregulated by all three compounds, COL10A1 
involved in chondrocyte hypertrophy appeared to be selectively downregulated by 
DMOG only. This also resulted in a corresponding upregulation of the ratio of 
COL2A1:COL10A1 mRNA. This pattern appears to manifest in the protein levels of 
Collagen Type X which were also reduced by DMOG treatment. This and increased 
SOX9 expression, therefore suggests DMOG compared to CoCl2 or DFX as the 
chemical agent which offers advantages regarding hBM-MSC-based CTE. However, a 
significant limitation of this study is represented by the difference of 2D culture on 
TCP with 3D culture of hBM-MSCs in a biomaterial scaffold. In a 3D 
microenvironment created by a scaffold, a multitude of regulatory cues exist 
compared to 2D culture. This is summarised by Sart et al who gathered evidence of 
studies in which cartilage induction of MSCs was regulated differentially by 2D and 
3D aggregate culture [503]. Therefore before the role of DMOG may be suggested 
for CTE applications, it is a requirement to assess its effect on BM-MSC 
chondrogenesis in a 3D, biomaterial scaffold environment. Chondrocyte hypertrophy 
is a significant problem in CTE so therefore a small molecule which is able to reduce 
hypertrophic signalling within scaffold-seeded mesenchymal progenitors would be 
highly advantageous.  
Regarding the design of continuous scaffolds for full osteochondral tissue repair, 
spatial control of hypertrophic expression (in addition to that of SOX9) would also 




described by Sun and Beier [504], strategies in which hypertrophy is able to be 
spatially controlled would be advantageous due to the opposing requirements of 
hypertrophy during cartilage and bone formation. Such a strategy would also enable 
formation of the hypertrophic ‘tidemark’ present between native articular cartilage 
and subchondral bone. This region plays an important structural role in 
osteochondral tissue by facilitating communication between the cartilage and bone 
layers. This is required for complete joint function and to enable communication 
between tissues with such contrasting structural, mechanical and biochemical 
properties. Da et al observed an enhanced tensile and shear strength of an interface-
containing scaffold compared to that containing none They also observed increased 
in vivo regeneration of osteochondral tissue following implantation into a rabbit 
defect model [505]. Clinical trials of a collagen type I-hydroxyapatite multiphasic 
scaffold inclusive of an interface region were implanted into osteochondral defects 
of the femoral condyle. Patients were reported as having experienced good clinical 
outcome following 2 years post-operative observations [506]. 
Interestingly, despite COL10A1 being downregulated by DMOG, MMP13 was not 
inhibited by this compound. DMOG also did not downregulate RUNX2 mRNA 
compared to the non-treated control throughout chondrogenesis. This perhaps 
suggests that DMOG-induced HIF activity did not reduce COL10A1 expression by 
reducing RUNX2-mediated transactivation of the COL10A1 promoter. 
Correspondingly, expression of MMP13 was also not altered by DMOG treatment at 
the same time as the observed COL10A1 downregulation. MMP13 is thought to be 
regulated are part of a RUNX2-mediated transcriptional program which 




COL10A1 mRNA here suggests that DMOG is not inhibiting the entire regulatory 
network conducive for hypertrophy but instead is targeting COL10A1 expression 
specifically. Of course, expression of both RUNX2 and MMP13 may be regulated by 
DMOG at time points other than those observed here. Regardless of time points 
chosen however, the role of RUNX2-mediated COL10A1 and MMP13 regulation in 
the present study is speculative without genetic manipulation of RUNX2 during 
DMOG-treated chondrogenesis. 
As opposed to regulating RUNX2, upregulation of SOX9 by DMOG may indicate the 
potential role of SOX9-mediated repression of COL10A1 transcription. This has been 
shown to occur via co-binding of SOX9 target sites by the Gli transcription factors 
which causes a decrease in COL10A1 transcription by SOX9 [53]. In the present study, 
we can also negate a role for HIF-2α in the mechanism of action of DMOG. HIF-2α 
has repeatedly been shown to induce a hypertrophic and osteoarthritic 
transcriptional profile within in vivo murine models [509]. The lack of upregulation of 
both MMP13 and COL10A1 suggests upregulation of HIF-1α due to DMOG as 
opposed to HIF-2α. This also corresponds to previous reports which indicate a bias 
for HIF-1α over HIF-2α stabilisation upon PHD2 and FIH inhibition [396]. Again, if the 
role of factors such as SOX9 or HIF-2α are to be investigated during DMOG-mediated 
chondrogenesis, their genetic manipulation would need to be undertaken. 
Despite a lack of effect on expression of SOX9 or hypertrophic markers due to CoCl2 
and DFX, these compounds both stimulated changes in mRNA encoding the articular 
chondrocyte markers, Gremlin1 and DKK1. Throughout chondrogenesis, DFX 




A trend was also observed towards increased expression of BMP antagonist- GREM1 
from day 7 onwards due to CoCl2 or DMOG treatment. This demonstrates again that 
during hBM-MSC chondrogenesis, the effect of HIF-1α activation on target gene 
expression is not an ‘all or nothing’ response and that different mechanisms of HIF-
1α upregulation may result in different subsets of HIF-targeted genes being 
transcribed. Iron chelation by DFX appears to generate an anti-Wnt signalling milieu 
within the cell whereas competitive inhibition of PHD2 by CoCl2 or DMOG appears to 
upregulate the BMP antagonist. However, these observations on the differential 
transcription of DKK1 and GREM1 do not robustly validate a conserved mechanism 
by which HIF controls expression of these genes. This instead would be demonstrated 
by the use of other iron-chelators and competitive PHD2 inhibitors. This would 
determine if the effects on DKK1 and GREM1 expression is a specific effect of the 
compounds used here or not. 
Studies suggest a requirement for β-catenin-mediated transcription during 
chondrocyte hypertrophy. There exists therefore a requirement to inhibit canonical 
Wnt signalling during the latter stages of BM-MSC chondrogenesis to suppress 
hypertrophy. This therefore may correspond to the expression patterns here of the 
Wnt antagonist- DKK1 which was induced by DFX throughout chondrogenesis and by 
DMOG at day 1. An observation which was not made here and one in which would 
determine the necessity of Wnt inhibition during chondrogenesis, is that of β-catenin 
activity. This would allow a greater or lesser significance to be drawn of DFX/DMOG-
mediated DKK1 transcription, dependent on the relative activity levels of the 




Despite changes in expression of the Wnt antagonist; DKK1, there was a lack of 
corresponding decrease in expression of AXIN2, a gene which is designated as a 
conserved canonical Wnt signalling target [510]. There was also a lack of decrease in 
expression of LEF1 which is another transcriptional target of β-Catenin whose 
product is part of the TCF-LEF complex active at Wnt target genes [511]. As described, 
this lack of correlation in AXIN2 and LEF1 mRNA may be due to the relatively few time 
points utilised as a proportion of the total differentiating period. Regulation of AXIN2 
and LEF1 may occur by DMOG after day 14 of chondrogenesis, following DKK1 
upregulation at this time point. Despite observing no changes in AXIN2 and LEF1 
mRNA due to DFX, we did observed a trend towards an increase in LEF1 mRNA at day 
1 due to DMOG. This may be suggestive of a DMOG-mediated mechanism for 
increasing Wnt signalling at this early time point in chondrogenesis at which point it 
is required for early chondrocyte specification. DMOG may stimulate the role of LEF1 
as the co-factor required for expression of Wnt target genes. To confirm this role of 
DMOG, it would be required to genetically downregulate components of the Wnt 
pathway such as β-Catenin. If DMOG does indeed increase Wnt signalling during its 
during early chondro-induction, robust knckdown of β-Catenin may reduce the 
potent effects of DMOG on the chondrogenic gene expression observed. 
In terms of Indian Hedgehog signalling, we also observed a trend for increase at day 
1 due to DMOG, which would also correspond to a role for this compound in 
inhibiting hypertrophy. This is due to the role of IHH ligand in suppressing progression 
of hypertrophy in pre-hypertrophic chondrocytes via increased PTHRP expression 
[93]. However, we observed no changes in expression of PTHRP at this same time 




required process during spatial regulation of hypertrophy and normal bone 
development. This is as opposed to an autocrine mechanism of action which may be 
observed here, in which the entire cell population increases expression of IHH. As 
with regulation of Wnt signalling by DMOG, it may be required to examine time 
points other than those utilised here to enable suggestion that Indian Hedgehog 
signalling is stimulated in response to DMOG treatment.  
Despite its strong transcriptional induction of chondrogenic genes, DMOG had a 
negative effect on cartilage-like ECM production. This was shown to be partly 
mediated via HIF-1α, but a large decrease in Collagen Type II due to DMOG was 
observed still in the presence of Acriflavine. DMOG has been shown to reduce the 
activity of CP4HA1 which is required for processing of collagen fibrils [278]. 
Correspondingly, both FIH and CP4HA1 have similar affinities for 2-OG which is 
represented by a similar Km value of these enzymes for this co-factor [512]. This 
would manifest in an equal sensitivity of FIH and CP4HA1 to DMOG. This suggests the 
strong induction of HIF target genes due to DMOG via FIH inhibition would be 
accompanied by a similarly potent inhibition of Collagen processing and 
incorporation into the ECM. It is also worth noting that the suggested inhibition of 
CP4HA1 by DMOG would also negate the positive effect of the increases observed in 
CP4HA1 and LOX mRNA due to DMOG. The lack complete folding and formation of 
collagen triple helices due to CP4HA1 inhibition, would make further mRNA 
expression of CP4HA1 and LOX, redundant in terms of an effect on Collagen Type II 
in the ECM. It is also important to note that current observations here are merely 




above in which suggestions were made to examine the role of PHD2 and FIH in the 
effects observed due to DMOG, the role of CP4HA1 may be investigated by its genetic 
overexpression. Via examination of Collagen Type II protein in response to this 
overexpression, the role of CP4HA1 in the detrimental ECM changes induced by 
DMOG would be validated.  
Timed exposure of the hBM-MSCs to DMOG may help alleviate the negative effect 
on Collagen Type II incorporation into the ECM. Treatment with DMOG for the final 
7 days of induction did at least in part restore the poor levels of type II collagen 
secretion that resulted from continuous treatment. This could have been mediated 
by a lack of continuous inhibition of the CP4HA1. In addition we observed enhanced 
expression of HIF targets VEGFA and EGLN and chondrogenic marker SOX9, to similar 
levels as observed with continuous DMOG treatment. This suggests a role of late 
DMOG treatment in CTE strategies as opposed to continuous treatment. However, 
late DMOG treatment was not able to stably induce expression of SOX9 target, 
COL2A1. This suggests that HIF activity is required throughout the early and late 
phases of differentiation in order to induce expression of SOX9 targets, including 
COL2A1. This may be predicted due to the constitutive role of SOX9 throughout 






5. The role of hypoxia in regulation of mechanosensing during chondrogenesis. 
 
5.1. Introduction 
As already pertained to, the low oxygen state which persists throughout cartilage 
development and adult cartilage, plays essential roles in generating and maintaining 
the articular chondrogenic phenotype. The relative permanence of hypoxia and its 
downstream transcription factor- HIF, suggest this stimulus is one of the fundamental 
factors residing in the limb bud and chondrocyte cell niche. This is demonstrated by 
the loss of the cartilage growth plate/articular cartilage upon HIF-1α conditional 
deletion at various stages throughout limb development [259, 262]. 
As described in this introduction, another set of omnipresent cell signals during 
cartilage development are those which activate intracellular pathways in response to 
mechanical changes in the cell microenvironment. Evidence exists for a role of these 
pathways from the mesenchymal limb bud stage through to the resting articular 
cartilage, as observed with hypoxia-stimulated pathways. Condensation of the limb 
bud mesenchyme is required to initiate chondrogenesis in formation of the growth 
plate [178]. The role of mechanical signals in pre-condensation mesenchymal 
progenitors was demonstrated by Carrion et al. These authors observed the effect of 
soft PEG hydrogels on the induction of condensation and chondrogenesis of 
encapsulated mesenchymal progenitor line, ATDC5 [513]. Hydrogels with a shear 
modulus of 7.5KPa exhibited more compact arrangement of cells compared to those 
in gel of 25KPa and induced greater levels of chondrogenesis as assessed by COL2A1 




was shown to exhibit differential tension as assessed by atomic force microscopy, 
between its centre and flanking regions [514]. The increase in tension due to FGF8 
treatment of the flanking regions was reduced by an inhibitor of Actin 
polymerisation. This suggests that the specific mechanical properties of the limb bud 
are maintained by a cytoskeletal-mediated mechanism.  
Takahashi et al demonstrated the mechanosensing ability of mouse embryonic limb 
bud cells for their chondrogenesis. Static compressive loading was observed to 
increase SOX9 mRNA and both Aggrecan and Collagen Type II protein secretion from 
limb bud cells cultures in Collagen Type I scaffolds [515]. A dose-dependent 
relationship between the magnitude of static compression and COL2A1 expression 
was also demonstrated. One of the mechanisms behind this response to mechanical 
compression is suggested to be the secretion of autocrine factors by the limb bud 
mesenchyme. This was demonstrated by Elder who observed an increase in GAG 
production and proliferation of chick limb bud cells during chondrogenesis carried 
out in media conditioned by mechanically-compressed limb bud cells [516].  
The sensitivity of growth plate chondrocytes to mechanical cues for their lineage 
commitment was first suggested by Wolpert et al. They observed the generation of 
tension upon proliferation of growth plate chondrocytes of the developing limb, 
which was imposed by the surrounding perichondrium. This tension prevented cell 
growth, hypertrophy and endochondral ossification along the transverse axis and 
instead induces a longitudinal growth of the developing bone [517]. Foolen et al 
utilised a model in which developing chick tibia were stripped of their perichondrium, 




perichondrium was left intact [518]. Explant cultures with their perchondrium intact 
exhibited no change in cartilage growth length in response to changes in ECM 
stiffness whereas the 3KPa surface induced cartilage growth relative to the 80KPa 
substrate in explants in which the perichondrium was removed. This growth 
advantage on the soft substrate was abolished by treatment of explants with an 
inhibitor of myosin contraction. This again was compared to cultures in which the 
perichondrium was left intact and in which the inhibition of myosin contraction had 
no effect on either substrate. Overall this study suggests a role of the perichondrium 
in regulating the mechanosensing ability of growth plate chondrocytes and that the 
proliferation of the growth plate and cartilage growth is in part, dependent on a 
cytoskeletal tension-mediated response to changes in ECM stiffness.  
The mechanical properties of adult articular cartilage are products of the collagen-
proteoglycan network and the osmotic pressure created by water-retention of the 
tissue. These together function to maintain the articular chondrocyte phenotype 
[519]. Darling et al identified the specific elastic modulus of both the pericellular 
matrix surrounding the articular chondrocytes as well as that of the ECM more 
distally–located from these cells [520]. These authors identified a softer ECM in the 
immediate area around the chondrocytes compared to that of the remaining ECM. 
Accordingly, adult articular cartilage is dependent on a specific, relatively low 
mechanical stiffness for maintenance of an articular chondrocyte phenotype. This 
was demonstrated by Kim et al who observed an increase in articular chondrocyte 
markers and decrease in hypertrophic markers on soft substrates compared to stiffer 
surfaces [352]. This was shown to be dependent on myosin-mediated cytoskeletal 




substrates were lost due to inhibitors of ROCK and myosin contraction. In addition 
these authors observed the requirement of ROCK-mediated cytoskeletal tension in 
protection from OA following surgical destabilisation of the medial meniscus.  
Together the studies described above demonstrate a requirement of 
mechanosignalling throughout chondrogenic development. This is demonstrated by 
the mechanosensing ability of mesenchymal progenitors, immature chondrocytes 
and articular chondrocytes in order to generate stable articular cartilage. Another 
key set of observations which indicates the role of constitutive mechanosignalling 
throughout cartilage development is that of the ligand which stimulates these 
pathways. Unlike growth factor ligand bio-availability which is temporally-controlled 
during cartilage development, mechanical stimulation of the cell is not transient. This 
is due to the constitutive remodelling and perturbation of the ECM during sequential 
formation of the limb bud, growth plate and adult osteochondral tissue.  
At the start of limb bud formation, the ECM is composed of Hyaluronic Acid. Maleski 
and Knudson demonstrated the function of HA in cell-cell adhesion at the limb bud 
stage by observation of a decrease in cell-cell binding upon treatment of chick limb 
bud cultures with the HA-digesting enzyme, hyaluronidase [178]. HA is then 
downregulated following onset of condensation and chondrogenesis, and this 
specific temporal regulation of HA was shown by Li et al to be a pre-requisite for 
cartilage development [177]. In the centre of the developing limb bud at the very 
start of mesenchyme condensation, both Collagen Type I and Fibronectin were 




Fibronectin has since been shown to also be required for mesenchymal condensation 
as demonstrated by Singh and Schwarzbauer who observed a decrease in MSC 
condensation in vitro in response to siRNA knockdown of fibronectin [522]. These 
authors also demonstrated the expression of Fibronectin-coding mRNA prior to 
condensation which increases following induction of cell compaction. Protein 
expression of collagen type I, fibronectin are then reduced following the initial 
induction of chondrogenesis and are eventually replaced by a matrix rich in Collagen 
Type II. [521].  
Many studies are suggestive of the role of this changing ECM milieu of developing 
cartilage in stimulating mechanosensing pathways of the cells involved in 
chondrogenesis. Somaiah et al observed a change in actin organisation and RhoA 
activation of MSCs which was dependent on their culture on Collagen or Fibronectin-
coated surfaces [523]. Varying the HA concentration within cell-laden hydrogels was 
also shown to induce changes in the mechanical properties of the construct and 
downstream changes in cell morphology and spreading [524]. Oberhauser et al 
demonstrated that the elasticity of fibronectin is significantly altered in response to 
mechanical loading of this protein due to conformation changes and unfolding of its 
tertiary structure. This therefore indicates the elasticity of Fibronectin-containing 
ECMs as being highly subject to change by mechanical forces which would have a 
knock-on effect on the stimulation of mechanosensing pathways in mesenchymal 
progenitors. Indeed, fibronectin-containing extracellular matrices have also been 
shown to upregulate specific integrin receptors and resulting in induction of 




in Collagen Type I-Fibronectin mixed ECM, that Collagen digestion reduces the 
mechanical strain of fibronectin [525].  
The roles HA, fibronectin and Collagen Type I in regulating the mechanical properties 
of the ECM in which they reside, are suggestive of their stimulation of mechano-
signalling pathways in limb bud cells and chondrocytes during cartilage development. 
The perturbations from the constantly remodelled ECM during articular cartilage 
development are sensed by integrin receptors [526]. The pathway which is 
downstream of integrin receptors is also key in maintaining the constitutive response 
of cells to the changing ECM as they transition from mesenchymal progenitor to 
resting articular chondrocyte. For example, the cytoskeleton is omnipresent within 
cells due the essential roles it plays during development and tissue homeostasis 
[527].The dependence of cells on this sub-cellular structure is also represented by 
the vast multitude of organelles to which it is connected [528]. The constitutive 
presence of the cytoskeleton is required for continued sensitivity to mechanical 
stimuli due to its role as a mediator of mechanical signal transduction from the cell 
surface to the nuclei where it induces transcriptional changes [529].  
The nucleoskeleton which plays key roles in facilitating the transmission of force from 
the cytoplasm [340] is also constitutively present. This is due to the essential roles it 
plays during the maintenance of nuclear integrity [347] and regulation of chromatin 
epigenetics [530]. Other components of the mechanotransducive pathway have also 
been shown to be either primed constitutively for activation or are readily de-
repressed following their initial stimulation. For example, the mature focal adhesions 




complexes composed of α-actinin [531]. These structures couple myosin contraction 
with integrins even prior to the stimulation of these receptors, and have been shown 
to be integral in maturation of focal adhesion complexes through Talin and Kindlin2 
[532]. In order to remain sensitive to mechanical signals, the mechanosensing 
pathway must ‘reset’ itself for repeated stimulation. Actin-myosin contraction which 
is stimulated by ROCK-mediated phosphorylation of myosin light chain 2, is subject 
to de-phosphorylation by myosin light chain phosphatase [533]. This results in a 
relaxation of the actin-myosin network, dissolution of stress fibres and a 
susceptibility of the cell to integrin-mediated tension once more.  
In terms of the specific effect on chondrogenic lineage commitment of mesenchymal 
progenitors, the literature suggests an advantage of mechanical environments which 
promotes a round, less spread cytoskeletal arrangement and cortical actin fibres - 
e.g. substrates of a relative low stiffness. [354, 355]. Promotion of a cortical actin 
organisation and around cell shape is also conducive for maintenance of the articular 
chondrocyte phenotype as opposed to conditions which promote stress fibre 
formation and cell spreading [350, 352]. This has been investigated extensively as a 
strategy to improve protocols for MSC chondrogenesis. Bian et al observed an 
increase in ACAN expression and a decrease in MMP13 and COL10A1 mRNA upon 
encapsulation and differentiation in HA hydrogels of lower elastic modulus compared 
to relatively stiffer hydrogels [534]. Sun et al also observed a similar trend with 
increases in SOX9, COL2A1 and ACAN expression observed in MSCs seeded on Poly 
Lactic Acid-PEG scaffolds of a lower compressive modulus compared to those of a 




Despite these improvements of CTE strategies, evidence in the literature is 
suggestive of unique mechano-regulatory mechanisms during chondrogenesis which 
could be exploited for de novo cartilage formation. Unlike other cell fates which are 
also promoted due to a lower relative substrate stiffness and reduced, round cell 
area, ROCK-mediated cytoskeletal tension appears to remain and play a role in 
chondrocyte specification. Adipogenesis is one of the classic examples used to 
describe the polar effects of cell stiffness and cytoskeletal tension on cell fate. 
McBeath et al observed that a round MSC morphology is conducive for an adipocyte 
cell fate, with treatment of a constitutively active RhoA inhibiting this effect and 
hyper-active ROCK treatment inducing osteogenesis instead [307]. Increased myosin 
contraction and cytoskeletal tension has also been shown to be inhibitory to other 
cell fates which constitute ‘soft’ tissues. This includes neuronal cells, the 
differentiation of which is the preferred cell fate on softer substrates where stress 
fibre formation and cell area is reduced [304] and in conditions in which myosin 
contraction is abolished [536].  
In contrast to neurogenesis or adipogenesis, chondrogenesis appears to be an 
anomaly amongst those cell fates preferred on softer substrates. Studies such as that 
Allen et al by have demonstrated the preservation during chondrocyte 
differentiation, of RhoA/ROCK-mediated cytoskeletal tension, despite induction of a 
cortical actin arrangement and a rounder cell shape. This ROCK activity was 
subsequently shown to be required for full chondrogenic induction of ATDC5 cells on 
soft substrates. This was demonstrated by ROCK inhibition reducing chondrogenic 
mRNA and protein expression [355]. This was in contrast to that observed in cells on 




COL2A1 and ACAN expression. These observations are supported by Park et al who 
observed an increase in COL2A1 expression in hMSCs in response to transfection of 
constitutively active RhoA on soft substrates compared to hMSCs expressing wild 
type RhoA [537]. 
Overall, the literature is suggestive of a role for ROCK activity and cytoskeletal tension 
during chondrogenesis on soft substrates. This is unlike other cell fate changes which 
are also favoured on softer substrates in which ROCK-mediated cytoskeletal tension 
is an inhibitory factor. This indicates that during cartilage development, factors which 
maintain ROCK-mediated actin-myosin tension in the round mesenchymal 
progenitors of the limb bud [353] may be essential for chondrogenesis. Hypoxia is a 
factor which mediates a plethora of pro-chondrogenic effects and akin to signalling 
in response to mechanical stimuli, is constitutively active during cartilage 
development. The evidence which describes hypoxia-mediated regulation of 
mechanotransducive pathways, indicates its potential in mediating the transduction 
of mechanical signals during chondrogenesis of the limb bud.  
Hypoxia and HIF have been shown to influence activity of both RhoA and ROCK [372, 
379] which induces corresponding changes on cytoskeletal arrangement via action-
myosin contraction [375]. Reduced oxygen concentration has also been shown to 
induce F-Actin polymerisation [375]. No such studies exist which examine the 
crosstalk between hypoxic/HIF and mechanosensory pathways during MSC 
chondrogenesis. Answering such a question may provide further insight into the 




to aiding CTE efforts which may benefit from combinatorial modulation of the HIF 
and mechanotransducive pathways. 
 
 Aim: To determine the existence of an effect of hypoxia on the 
mechanosensing ability of chondrogenically-induced progenitor cells. 
 
 Hypothesis: Hypoxia upregulates ROCK-mediated cytoskeletal tension in 
MSCs with round morphologies on mechanically-soft substrates and in doing 
so, enhances downstream chondrogenesis. 
 
 Objectives:  
o To identify an effect of hypoxia on the cytoskeletal arrangement of hBM-
MSCs on 2D mechanically soft and stiff substrates 
o To identify an effect of hypoxia on pathways involved in, and downstream 
of, cytoskeletal tension in hBM-MSCs on 2D mechanically stiff and soft 
substrates. 
o To identify if hypoxia has a differential effect on hBM-MSC 








5.2.1. Validation of 40/0.5KPa polyacrylamide substrates for manipulation of 
cytoskeleton arrangement 
Hypoxia has been shown to indue chondrogenesis of BM-MSCs both in the previous 
chapters here and previous studies. This is often described as occurring via direct 
mechanisms- HIF binding to chondrogenic target genes under low-oxygen conditions. 
However, hypoxia has also been shown to regulate a set of pathways which 
themselves have great impact on chondrocyte differentiation, maturation and 
cartilage ECM formation. These are the mechanosensory pathways which enable 
chondrogenically-induced cells to respond to substrates of varying stiffness, and 
which have been shown to dictate the chondrogenic differentiation program. The 
potential ‘crosstalk’ during chondrogenesis, between the hypoxia pathways and 
those which respond to mechanical stiffness, have largely been unexplored. Such a 
study may provide insights which are useful for the development of CTE strategies in 
which hypoxic culture of BM-MSCs is combined with biomaterial scaffolds of a 
defined stiffness. 
 PA gels have been established as a tool for assessing the effect of mechanical stimuli 
on cell behaviour. In the present study, these substrates were used to expose the 
cells to opposite extremes of stiffness with the purpose of inducing differential 
arrangement of the actin cytoskeleton via contraction of the associated myosin. 
0.5KPa and 40KPa were selected as the low and high stiffness values due to the use 




control of BM-MSC lineage commitment by substrate stiffness [304]. These stiffness 
values were utlised by Engler et al, and subsequently in the present study to induce 
completely polarising effects on the mechanotransducive pathways. Cell parameters 
such as substrate adhesion [538], actin-myosin contraction and cell morphology 
[304]  are affected differentially by stiffness values in the 0.5-1 and 25-40KPa range. 
Critically, differential regulation of these cell characteristics by the magnitude 
induced by the 0.5-40KPa stiffness range has been shown to be key in differentially 
regulating BM-MSC fate decisions [304].  
To confirm the function of fibronectin-coated PA gels, initial experiments were 
conducted to compare the cell response to stiff (40KPa) and soft (0.5KPa) gels. An 
established method for detecting cell response to mechanical stiffness is through 
visualisation of cytoskeleton rearrangement. This occurs due to the differential 
contraction of MLC2 on each substrates. Immunodetection of the actin cytoskeletal 
network was therefore performed, by binding to Phalloidin conjugated with a 
fluorophore . BM-MSCs on the 40Kpa surface exhibited a spread cytoskeleton with 
visible actin stress fibres (Fig. 5.1A) and cells on the 0.5KPa substrate forming a much 
round cell shape (Fig. 5.1B).  
To provide a quantifier of actin rearrangement in response to 0.5 and 40KPa 
substrate, binary equivalents were created of each image in which the actin 
cytoskeleton was immunofluorescently labelled with Phalloidin.  The cell area and 
circularity of each BM-MSC in each binary images was then quantified in ImageJ . The 
degree of spreading and circularity of the cells has been shown to be a key indicator 




The qualitative observation of actin rearrangement on the 40 and 0.5KPa substrates 
were confirmed by this quantification analysis. The area of single BM-MSCs 40KPa 
were significantly larger (p=<0.05) than those on 0.5KPa surface (Fig. 5.1C). 
Quantification of the circularity of single BM-MSCs enabled the observation that cells 
on the 0.5KPa substrate were significantly more circular in morphology than those 
on the 40KPa substrate (Fig. 5.1D).  
Regulation of cytoskeletal arrangement are normally thought to occur largely due to 
change in RhoA/ROCK activity rather than transcription or translation of their 
genes/mRNA. However studies such as that by Mih et al demonstrated the effect of 
ROCK1+2 siRNA in abolishing responses of lung fibroblasts to substrates of varying 
stiffness [305]. This indicates a role for ROCK1 and 2 at the mRNA level to play a role 
in mechanosensing. Figure 5.2 illustrates the suitability of RHOA, ROCK1, ROCK2, 
CTGF and ANKRD1-specific primers for amplification of these genes. Each standard 
curve demonstrates a linear relationship between input [cDNA] and cycle number in 
addition to theoretical reaction efficiencies between 90-100%. When BM-MSCs were 
cultures for 24 hours on each substrates, no significant changes were induced due to 
0.5KPa compared to 40KPa. However, ROCK2 and RHOA expression demonstrated a 
trend towards increase (Fig. 5.1E).  
YAP/TAZ localisation and their downstream function as binding partners for the TEAD 
family of transcription factors are markers of increased cytoskeletal tension on stiff 
substrates [330]. This therefore prompted investigation into their localisation on the 
substrates used here. Figures 5.2F-5.2H demonstrate the specificity of the anti-YAP 




primary antibody and not the fluorophore-conjugated secondary antibody. At 40KPa, 
YAP/TAZ were restricted to the nucleus of BM-MSCs (Figs. 5.1F+5.1G) and they 
showed a more dispersed pattern around the cell on the 0.5KPa substrate (Figs. 
1H+1I). This difference between YAP/TAZ nuclear localisation on 40 and 0.5KPa 
substrates was confirmed by quantification of the percentage of each nuclei occupied 
by this protein pair. Cells on 40KPa induced a significantly greater nuclear YAP/TAZ 
localisation than on the 0.5KPa substrate (Fig. 1J). Finally, mRNA expression of TEAD 
targets were examined to validate our observation on YAP/TAZ nuclear localisation 
and neither CTGF nor ANKRD1 expression were altered due to culture on the 0.5KPa 
substrate compared to that on 40KPa (Fig. 5.1K).  
Overall, the PA gels of 40KPa and 0.5KPa stiffness are transduced by the seeded BM-
MSCs to result in cell phenotypes which are typical of cells on stiff and soft substrates 
and which induce differential activation of the mechanosensory pathways. This 
therefore suggests the suitability of these substrates for investigation of the effect of 








Figure 5.1. 40 and 0.5KPa induce differential cytoskeletal arrangement, cell shape 
and YAP/TAZ nuclear localisation in hBM-MSCs cultured in chondrogenic 
differentiating media. (A+B) Actin immunodetection by Phalloidin with DAPI 
counterstain at after 24 hours of culture on 40KPa (A) and 05KPa (B) substrates. 
Representative images of 4 independent repeats shown. Brightness and contrast 
were adjusted for all channels to an equal degree between all conditions. (C+D) 
Quantification of cell area (C) and circularity based on phalloidin staining. Values 
plotted represent the area/circularity of a single cell, with values from 4 independent 
repeats plotted and the mean values represented by the red line. (E+K) mRNA 
expression of ROCK1, ROCK2, RHOA¸ SOX9, COL2A1 (E), CTGF and ANKRD1 (K) 
following 24 hours of culture. Values plotted represent expression on the 0.5KPa 
substrate from 4 independent experiments, and are fold change compared to 
expression on the 40KPa substrate represented by the horizontal dotted line.  The 
solid grey lines represent the mean expression value for each gene. (F-I) YAP/TAZ 
immunodetection with DAPI counterstain after 24 hours of culture on 40KPa (F+G) 
and 05KPa (H+I) substrates. Representative images of 3 independent repeats shown. 
Brightness and contrast were adjusted for all channels to an equal degree between 
all conditions. (J) Quantification of nuclear YAP/TAZ on each stiffness. Each value 
plotted represents the percentage of a single DAPI-marked nucleus that is occupied 
by YAP/TAZ. Values are from 3 independent repeats with the red horizontal lines 
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Figure 5.2. Standard curves which demonstrate a linear relationship between input 
cDNA concentration and cycle (Ct) number when amplified using RHOA- (A), ROCK1- 
(B), ROCK2- (C)  CTGF- (D) and ANKRD1-specific (E) primers (y axis = Ct, x axis = [cDNA] 
(%). (F-K) Immunostaining of YAP (F-H) and pMLC2 [230] in BM-MSC cultures 
incubated at 20%O2, with (F+I) and without (G, H, J, K) ROCK inhibitor- Y-27632 for 
24 hours. Images F, G, I and J demonstrate immunofluorescent signal following an 
immunostaining protocol in which the primary antibody was included. Images H and 
K were taken following an immunostaining protocol in which the primary antibody 





5.2.2.  ROCK governs cytoskeletal arrangement of hBM-MSCs on soft and stiff 
substrates 
RhoA/ROCK activity has been established as the key mediator of cytoskeletal 
organisation in response to varying substrate stiffness, ligand availability and integrin 
engagement [307]. Therefore in order to confirm the role of ROCK in governing cell 
morphology of BM-MSCs cultured on 40 and 0.5KPa substrates, cultures here were 
incubated with and without the ROCK inhibitor- Y-27632. This compound acts to bind 
the ATP-binding pocket at the catalytic site of both ROCK1 and ROCK2, inhibiting 
myosin light chain phosphorylation and reducing stress fibre formation [539].  
Following optimization of pMLC2 immunostaining as detailed in Figure 5.2F-5.2H, 
Immuno-detection of phosphorylated MLC2 was performed on BM-MSC cultures on 
substrates of both stiffness following a 24-hour treatment with Y-27632. BM-MSCs 
treated with the ROCK inhibitor (Figs 5.3C+5.3D) displayed abolished pMLC detection 
compared to the untreated control (Figs 5.3A+5.3B). In terms of actin organisation, 
Y-27632 appeared to reduce the formation of stress fibres in hBM-MSCs compared 
to that observed in the untreated control on the 40KPa substrate (Figs 5.3E+5.3G). 
Y-27632 also increased formation of protrusions from the cell body. On the 0.5KPa 
substrate compared to the control, Y-27632 treatment increases the cell area of 
hBM-MSCs and reduces the round morphology of these cells (Figs 5.3F+5.3H). These 
observed changed in cell area were confirmed by quantification of the phalloidin-
stained images with a significant increase on the soft surface due to Y-27632 and no 
change on 40KPa substrates (Figs 5.3I+5.3J). The ROCK inhibitor also significantly 




Overall, the characterisitic cell morphologies observed on the 0.5 and 40KPa 





Figure 5.3. The ROCK inhibitor, Y-27632 reduces myosin light chain 2 
phosphorylation and induces differential effects on the cytoskeletal arrangement 
and cell shape of hBM-MSCs cultured on 40 and 0.5KPa substrates. (A-D) pMLC2 
immunodetection with DAPI counterstain after 24 hours of culture without Y-27632 
on 40KPa (A) and 05KPa (B) substrates and with Y-27632 (C+D). Representative 
images of 3 independent repeats shown. Brightness and contrast were adjusted for 
all channels to an equal degree between all conditions. [375] Actin immunodetection 
by Phalloidin with DAPI counterstain after 24 hours of culture without Y-27632 on 
40KPa (E) and 05KPa (F) substrates and with Y-27632 (G+H). Brightness and contrast 
were adjusted for all channels to an equal degree between all conditions. (I+J) 
Quantification of single cell area based on phalloidin staining in E-H on 40KPa (I) and 
0.5KPa (J) with and without Y-27632. (K+L) Quantification of single cell circularity 
based on phalloidin staining in E-H on 40KPa (K) and 0.5KPa (L) with and without Y-





5.2.3. Hypoxia partially inhibits small, round hBM-MSC morphology on 0.5KPa 
substrates and increases cell condensation on both surfaces. 
As pertained to, hypoxia may regulate the mechanotransducive ability of BM-MSCs 
in response to culture on substrates of varying stiffness. As such pathways have 
themselves been shown to regulate chondrocyte differentiation, it is rational to 
hypothesize that hypoxia may regulate chondrogenesis through RhoA/ROCK-
mediated mechantransducive signaling in BM-MSCs. This is demonstrated by studies 
in which the abrogation of stiffness-mediated cell proliferation and differentiation 
were observed in response to inhibition of actin polymerisation [540]. This may have 
significant implications for CTE strategies which aim to direct BM-MSCs down a 
chondrogenic cell fate by a combination of hypoxic culture and 3D biomaterial 
scaffolds of a defined stiffness.  
Due to the relatively poor understanding of the crosstalk betweek the hypoxia and 
mechanotransducive pathways, the ability of hypoxia to induce changes in 
cytoskeletal organisation of hBM-MSCs on soft and stiff substrates was investigated 
here.   Of the two hypoxic oxgen concentrations used thus far in chapters 3 and 4, 
2%O2 was selected for two reasons. The first of these is that oxygen levels below 5% 
are utilised by the majority of studies which investigate hypoxia’s effect on 
mechanotransducive pathways [372, 541]. In addition, as seen in chapter 3, 2%O2 
raised expression of HIF targets- VEGFA, PGK1 and EGLN  by significant levels at both 
days 1 and 14 of chondrogenesis, whereas expression of these were raised 
significantly by 5%O2 at day 1 only. This sustained expression of VEGFA, PGK1 and 




of other HRE-containing genes whose products are involved in 
mechanotransduction, if indeed there exists crosstalk between these pathways 
during chondrogenesis. 2%O2 was disregarded  in chapter 4 due to the requirement 
of hypoxia in that chapter to inhibit hypertrophy in long-term differentiation 
experiments, which in chapter 3 was shown to occur due to 5%O only. This culture 
system also included TGF-β3-containing chondrogenic media to mimic standard 
differentiating conditions.  
On the 40KPa substrate, hypoxia did not induce changes on cytoskeletal organisation 
of hBM-MSCs compared to that at 20%O2 (Figs. 5.4D+5.4E). Accordingly, no changes 
in cell area or circularity were observed, as confirmed by quantification of these cell 
parameters (Figs 5.4A-5.4C). On the 0.5KPa substrate, hypoxia increased the area of 
single cells (Fig 5.4J) and colonies (Fig 5.4K) in addition to reducing their circularity 
(Fig 5.4L). Hypoxia also appeared to increase the number of thin projection or 
protrusions extending from the centre of hBM-MSCs on the soft substrate. The 
changes in cell area and circularity on the 0.5KPa substrate were confirmed as 
significant by quantification of these parameters (Figs 5.4G-5.4I).  
As a precursor to chondrogenic induction, the limb bud mesenchyme forms a 
condensation which initiates the transcriptional program required for 
chondrogenesis [178]. The mesenchyme at this stage of limb development is hypoxic 
as a result and this low-oxygen states plays keys role during chondrogenic induction 
at this stage of limb development [262]. This therefore prompted investigation of the 
effect of hypoxia on cell condensation and colony formation. On both the 40 and 




cells present in colonies as a percentage of the total cell count. This was coupled with 
a trend towards a decrease observed in the proportion of single, isolated cells as a 
percentage of the total cell count (Fig. 5.4M). Hypoxia increased the ratio of colonies 
to single cells on substrates of both stiffness (Fig. 5.4N), whilst inducing no changes 
in the total cell count (Fig. 5.4O) and number of cells present per colony (Fig. 5.4P).  
Overall hypoxia appears to affect cytoskeletal re-organisation on the soft substrate 
only. Addiotnally, whilst hypoxia increases condensation on both the 0.5kPa and 
40KPa substrates, the condensations on the soft surface are more compact and 






Figure 5.4. Hypoxic incubation induces changes in hBM-MSC morphology on 0.5KPa 
substrates and increases cell condensation on substrates of 40 and 0.5KPa. (A-C+J-L) 
Quantification of single cell (A+J) and colony (B+K) area and single cell circularity (C+L) 
based on phalloidin staining in images D-I on 40KPa (A-C) and 0.5KPa (J-L) at 20% and 
2%O2. Values plotted represent the area/circularity of single cells/colonies from 4 
independent repeats with the mean values represented by the black lines. (D-I) Actin 
immunodetection by Phalloidin with DAPI counterstain after 24 hours of culture on 
40KPa (D-F) and 0.5KPa (G-I) at 20%O2 (D+G) and 2%O2 (E, F, H, I). Representative images 
of 4 independent repeats shown. Brightness and contrast were adjusted for all channels 
to an equal degree between all conditions. (M) Number of single or colony-forming cells 
on 40KPa and 0.5KPa at 20% and 2%O2 as a percentage of the total cell count within each 
condition. Values plotted are the means from 4 independent repeats, with error bars 
representing the standard error of the mean. [419] Quantification of colonies normalised 
to single cell count (N), total cell number (O) and number of cells per colony (P) in 
response to 2%O2 on 40KPa and 0.5KPa. Values plotted are from 4 independent repeats 
and are fold change compared to that at 20%O2 on the respective substrate, represented 
by the horizontal dotted line, with grey/red lines representing the mean values. 




5.2.4. Hypoxic incubation increases phosphorylation of myosin light chain 2 on 
0.5KPa substrates 
The ability of hypoxia to induce ROCK activity during its regulation of 
mechanotransductive pathways has been documented in a variety of cell types such 
breast cancer cells [372] and pulmonary artery smooth muscle cells [542]. In addition, 
regulation of ROCK activity represents the most plausible mechanism by which 
hypoxia induces the cytoskeletal re-arrangement observed on the 0.5KPa substrate. 
The effect of hypoxia on MLC2 phosphorylation was therefore investigated due to 
pMLC2 levels being indicative of ROCK activity [543]. Hypoxia did not induce any 
change in pMLC2 in hBM-MSCs on the 40KPa substrate compared to 20%O2 (Figs. 
5.5A+5.5B). However reduced oxygen levels did increase pMLC2 in cells cultured on 
0.5KPa surfaces (Figs. 5.5C+5.5D). This significant increase due to hypoxia on only the 
soft substrate, was confirmed by quantification of pMLC2 immunostaining following 
normalisation to cell number and average area (Figs. 5.5E).  
RHOA, ROCK1 and ROCK2  have been shown to contain HREs in their promoter 
regions in addition to their expression being induced by hypoxia [544]. Therefore, 
investigation of this phenomenon was carried out in the present study, but no 
significant changes were induced by hypoxia in the expression of RHOA (Fig. 5.5F), 
ROCK1 (Fig. 5.5G) or ROCK2 (Fig. 5.5H) mRNA on either substrate. However, a trend 
towards increase was observed in the mRNA of all three genes due to hypoxia on the 
40KPa surface and that of ROCK1 on the 0.5KPa substrate. Taken together, these 
results indicate that 2%O2 induced changes in ROCK activity only in BM-MSCs on the 






Figure 5.5. Hypoxic incubation increases phosphorylation of myosin light chain 2 on 
0.5KPa substrates. (A-D) pMLC2 immunodetection with DAPI counterstain after 24 
hours of culture at 20%O2 (A+C) and 2%O2 (B+D) on 40KPa (A+B) and 05KPa (C+D) 
substrates. Representative images of 4 independent repeats shown. Brightness and 
contrast were adjusted for all channels to an equal degree between all conditions. 
(E) Quantification of pMLC2 immunofluorescence in response to 2%O2 on 40KPa and 
0.5KPa substrates, normalised to DAPI-stained cell number and mean area of cells in 
each condition, calculated from Phalloidin images in figure 2D-I. (F-H) mRNA 
expression of RHOA (F), ROCK1 (G) and ROCK2 (H) following 24 hours of culture at 
2%O2 on 40KPa and 0.5KPa substrates. Values plotted in E-H are from 4 independent 
experiments, and are fold change compared to pMLC2 immunofluorescence/mRNA 
expression at 20%O2 which is represented by the horizontal dotted line. Mean values 






5.2.5. Hypoxia reduces the presence of YAP/TAZ in the nuclei of hBM-MSCs on the 
40KPa substrate. 
Reducing the oxygen concentration appears to reduce YAP protein expression, 
nuclear localisation and its downstream activity as a transcriptional co-factor [383]. 
The central role that YAP appears to play in the transduction of mechanical stimuli 
into transcriptional changes [545], prompted the investigation into YAP function in 
the present study.  
Hypoxia appeared to reduce the overall presence of YAP/TAZ protein in hBM-MSCs 
cultured on the 40KPa substrate (Fig. 5.6A-5.6D) which  resulted in a decrease in the 
nuclear localisation of this protein (Fig. 5.6I). This effect on the stiff substrate was 
not accompanied by a change in cytoplasmic localisation of YAP/TAZ. As observed 
previously, YAP/TAZ localisation on the 0.5KPa substrate at normoxia appeared to be 
more dispersed around the cell compared to that on the stiff substrate on which 
localisation was restricted to the nucleus of hBM-MSCs (Fig. 5.6E-5.6H). 
Quantification of YAP/TAZ localisation demonstrated a much more varied spread of 
YAP nuclear localisation on the soft substrate (Fig. 5.6J) compared to that due to 
40KPa, which were polarised to the 50% level and above (Fig. 5.6I). However, no 
change in total or nuclear YAP/TAZ levels appeared to be induced by hypoxia on the 
0.5KPa substrate.  
Expression of TEAD targets were assessed to validate the observations of YAP/TAZ 
nuclear localisation. Hypoxia appeared to induce a trend towards increased 
expression of CTGF (Fig. 5.6K) and ANKRD1 (Fig. 5.6L) on the 40KPa substrate, with a 




Together, these results indicated that YAP localization and expression of its 
transcriptional targets are not subject to regulation by mechanotransducive 






Figure 5.6. Hypoxia reduces the presence of YAP/TAZ in the nuclei of hBM-MSCs on 
the 40KPa substrate but does not induce corresponding changes in YAP-TEAD 
target genes. (A-H) YAP/TAZ immunodetection with DAPI counterstain after 24 hours 
of culture on 40KPa (A+D) and 0.5KPa (E+H) substrates at 20%O2 (A, B, E, F) and 2%O2 
(C, D, G, H). Representative images of 3 independent repeats are shown. Brightness 
and contrast were adjusted for all channels to an equal degree between all 
conditions. (I+J) Quantification of nuclear YAP/TAZ on at 40KPa (I) and 0.5KPa (J) at 
20%O2 and 2%O2. Each value plotted represents the percentage of a single DAPI-
marked nucleus that is occupied by YAP/TAZ. Values are from 3 independent repeats 
with the red horizontal lines representing the mean. (K+L) mRNA expression of CTGF 
(K) and ANKRD1 (L) following 24 hours of culture at 2%O2 on 40KPa and 0.5KPa 
substrates. Values plotted are from 4 independent experiments, and are fold change 
compared to expression at 20%O2 represented by the horizontal dotted line. Mean 







5.2.6.   Hypoxia induces transcription of genes conducive for early chondro-
induction on 0.5KPa substrates and increases cartilage ECM production on 
either substrate. 
The cytoskeletal re-organisation, ROCK induction and increase in cell condensation 
observed due to hypoxia, motivated the decision to analyse expression of mRNA 
which denote mesenchymal limb bud progenitors specified down a chondrogenic cell 
fate. Hypoxia appeared to increase expression of the master chondrogenic factor, 
SOX9 on the soft substrate only. The SOX9 target, COL2A1 was induced on the 40KPa 
with a trend towards increase being induced on the 0.5KPa substrate (Fig. 5.7A).  
In addition to those ‘classic’ markers of chondrogenesis, transcription of genes which 
are expressed in condensed limb bud mesenchymal cells prior to chondrocyte 
differentiation were investigated. MSX1 is expressed within and surrounding the AER 
of the limb bud [546]. Msx1 plays an important function together with the Distal-less 
Homeobox 5/6 (Dlx5/6) set of transcription factors, in growth plate formation. This 
was shown by Vieux-Rochas et al who observed a further loss of Alcian Blue staining 
in the developing limb (E12.5) due to a combined MSX1 and Dlx5/6 deletion 
compared to loss of Dlx5/6 only [546].  Msx1 has been shown to be a key mediator 
of BMP4 signalling required for maturation of the AER [547] and in the present study, 
hypoxia inhibited MSX1 expression on the 40KPa substrate whilst not inducing any 
changes in expression on the softer surface (Fig. 5.7A).  
PRX1 encodes another transcription factors whose expression also delineates pre-
chondrogenic cells of the condensed limb bud mesenchyme. Genetic deletion 




cartilage development at the pre-chondrogenic stage, prior to cell fate commitment 
[94]. This transcription factor plays important roles during limb bud chondrogenesis 
such as the regulation of Tenascin-C which is an ECM protein required for limb bud 
progenitor condensation [49]. In this study, no significant changes in its expression 
were observed due to hypoxia on either the 40 or 0.5KPa substrates (Fig. 5.7A).  
Other markers of the pre-chondrogenic limb bud mesenchyme include genes which 
encode cell-cell adhesion proteins, shown to be required for downstream 
chondrogenesis. Expression of NCAM was induced on only the 0.5KPa substrate due 
to hypoxia (Fig. 5.7B). To validate the induction of HIF in response to hypoxia in hBM-
MSCs on either substrate, the upregulation of VEGFA and EGLN were assessed. 
Hypoxia upregulated both of these genes in hBM-MSCs cultured on either substrate 
(Fig. 5.7C).  
Long-term chondrogenesis was investigated following a 21 day period. Collagen Type 
II in the ECM appeared to be upregulated due to hypoxia on both substrates. In 
addition, hBM-MSCs on the 40KPa appearing to induce higher levels of Collagen Type 
II at both 20% and 2%O2 than observed on the soft substrate (Fig. 5.7D-5.7G). Gene 
expression at this time point was also analysed. At normoxia expression of SOX9 and 
COL2A1 mRNA were higher on the 0.5KPa substrate than on the 40KPa surface (Fig. 
5.7H). Hypoxia did not have to effect on SOX9 expression in hBM-MSCs on either 
substrate but on the 40KPa substrate, there was an increasing trend of COL2A1, 
VEGFA and EGLN expression due to hypoxia. This increase in VEGFA and EGLN 
expression due to hypoxia was not observed on the 0.5KPa substrate and a trend 




substrate. No change occurred in RUNX2 expression either in response to varying 
substrate stiffness or oxygen concentration. The involvement of ROCK in hypoxic 
induction of these gene was also analysed on TCP. The increases observed in SOX9 at 
day 1 (Fig. 5.7I), COL2A1 at day 21 (Fig. 5.7J) and HIF targets (Fig. 5.7K+5.7L) 
throughout the differentiation due to hypoxia, appeared to be reduced by ROCK 
inhibition. 
Overall, hypoxia induced early transcriptional changes that are conducive for 
chondrocyte specification, in BM-MSCs on the soft substrate only. However at day 
21, hypoxia appeared to increase chondrogenic at the mRNA level in BM-MSCs 





Figure 5.7. Hypoxia induces transcription of genes conducive for early chondro-
induction on 0.5KPa substrates but it increases Collagen Type II in the ECM 
following 21-day chondrogenic induction on either stiffness. (A-C) mRNA expression 
of SOX9, COL2A1, MSX1, PRX1 (A), NCAM, NCAD (B), VEGFA and EGLN (C) following 
24 hours of culture at 2%O2 on 40KPa and 0.5KPa substrates. Values plotted are from 
4 independent experiments, and are fold change compared to expression at 20%O2 
represented by the horizontal dotted line. Mean values are represented by grey/red 
lines. (D-G) Collagen Type II immunodetection with DAPI counterstain after 21 days 
of chondrogenic induction 40KPa (D+E) and 0.5KPa (F+G) at 20%O2 (D+F) and 2%O2 
(E+G). Brightness and contrast were adjusted for all channels to an equal degree 
between all conditions. (H) mRNA expression of SOX9, COL2A1, VEGFA and EGLN 
after 21 days of chondrogenic induction at 2%O2 on 40KPa and 0.5KPa substrates. 
Values plotted are fold change compared to expression at 20%O2 represented by the 
horizontal dotted line. [548] mRNA expression of SOX9 (I), COL2A1 (J), VEGFA (K) and 
EGLN (L) at days 1, 14 and 21 of chondrogenic induction at 20%O2, 2%O2 and 2%O2+Y-
27632 on TCP. Values plotted are fold change compared to expression at day 1, 
20%O2. Statistical analysis: *indicates significant difference compared to that at 







The regulation of pathways induced in response to mechanical stimuli during 
cartilage development, may provide new potential strategies for CTE in the repair of 
acute chondral defects. The control of these pathways by the physical parameters of 
the ECM such as substrate elasticity however, may also be subject to regulation by 
other signalling pathways. Growth factor signalling for example, has also been shown 
to play keys role in regulating the activity of mechano-signalling pathways. TGF-β1 
has been observed to induce RHOA expression and actin re-organisation via a 
SMAD2/3-dependant mechanism [549]. This study is example of that which provides 
evidence that the mechanically-stimulated pathways (specifically RhoA/ROCK-
mediated cytoskeletal tension) are themselves regulated by pathways not primarily 
associated with mechanotransducive signalling. Included in such pathways are those 
stimulated by physiological hypoxia. The plethora of pro-chondrogenic effects of 
hypoxia during MSC differentiation and evidence of its role in regulating RhoA and 
ROCK activity, suggests a role for hypoxia in regulating the mechano-transducive 
pathways involved during chondrogenesis. This therefore prompted the present 
study.  
 In summary the results in this chapter demonstrate that during BM-MSC 
chondrogenesis, hypoxic culture relative to that that observed at normoxia, induces 
cytoskeletal rearrangement, MLC phosphorylation and cell condensation. These 
hypoxia-induced changes occur on the 0.5KPa substrate however and not on the 
stiffer, 40KPa surface. These changes on the soft substrate, appear to correlate with 




likened to that observed in limb bud progenitors prior to their differentiation into 
chondrocytes which constitute the growth plate prior during limb development. In 
contrast however, latent mRNA expression occurs of chondrogenic markers due to 
hypoxia on the 40KPa substrate. This indicates that the stiff substrate is more 
conducive for hypoxia mediated-chondrogenesis following intial chondro-
specification of multipotent cells. 
The established ROCK-mediated control of cytoskeleton dynamics on soft and stiff 
substrates was observed here. Actin stress fibre formation on the 40KPa substrates 
were reduced due to ROCK inhibition which also increased formation of filopodia-like 
projections from the cell body. Inhibition of ROCK has been shown to reduce 
cytoskeletal tension [305] concomitant with the result observed here and has also 
been shown to increase formation of projections from the cell body [330].  Such a 
fillopodia-rich morphology has been suggestive to be conducive for neural 
differentiation which corresponds to studies in which reduced cytoskeletal tension 
pre-disposes multipotent progenitors down a neural lineage [304].  
In contrast to that on the stiff substrate, hBM-MSCs cultured on the 0.5KPa substrate 
adopted a small, round morphology as described previously [550]. The response of 
hBM-MSCs to ROCK inhibition on the soft substrate was also as previously described 
in which the cell area was increased in response to treatment. As described by Mih 
et al, the cytoskeletal tension of cells on a soft matrix significantly outweighs the 
strength of ECM-integrin interactions. This induces a net contraction of the 
cytoskeleton towards the centre of the cell which results in formation of an actin 




Therefore when ROCK and cytoskeletal tension are inhibited in cells which adopt this 
actin arrangement on compliant ECM, the cytoskeletal tension directed towards the 
centre of the cell is ablated. This decrease in intracellular tension combined with a 
lack of interactions between the integrins and that of the surrounding ECM, induces 
a relax response in which the cell body flows freely outwards.  
The majority evidence in the literature for the effect of hypoxia and HIF on actin-
myosin dynamics, point to their role as inducers of cytoskeletal tension. For example 
in breast cancer cells, incubation at 1%O2 induces actin stress fibre formation via 
RhoA and ROCK and was required for migration and metastasis of thesecells [372]. 
Inhibition of PHD2 in fibroblasts, which reduces HIF-1α hydroxylation, ubiquitination 
and degradation, enhanced Cofilin phosphorylation [406] which is required for F-
Actin formation and cytoskeletal tension[375]. In addition, treatment of endothelial 
cells with the PHD2 inhibitor, DMOG also induced F-Actin stress fibre formation 
which again is suggestive of a role for hypoxia and HIF in inducing cytoskeletal 
reorganisation and tension [551]. Observations here suggest that hypoxia also 
increases cytoskeletal tension in hBM-MSCs. Increased phosphorylated myosin was 
observed due to hypoxia on the soft substrate, in addition to the rearrangement of 
actin on this substrate. A limitation of this system is the lack of quantification of the 
absolute levels of cytoskeletal tension of BM-MSCs in different conditions. Methods 
utilised here, including actin stress fibre immune-detection, cell morphology and 
semi-quantification of phosphorylated MLC2 are only suggestive of increased actin-
myosin contraction. Techniques instead such as Traction Force Microscopy (TFM) 




The effect of hypoxia on the soft substrate contrasts with the apparent lack of effect 
on the actin arrangement or pMLC2 in BM-MSCs on the stiff substrate. At normoxia, 
MSCs on a stiff substrate have been shown to exhibit higher cytoskeletal tension than 
that on a softer surface [305]. Therefore, it may be expected to observe a lack of 
change at 40KPa with regards to cytoskeletal tension due to this being at a maximal 
level on this substrate [304]. Again, it is important to note the limitations of this 
experiment in which the observations provide only correlative evidence of the 
regulation of cytoskeletal tension. As described above, direct quantification of 
cytoskeletal tension is most appropriate as opposed to indirect methods. In addition, 
semi-quantification of pMLC2 by Western Blotting may be required. This, and 
techniques such as TFM to quantify cytoskeletal tension, would enable 
determination of the magnitude by which hypoxia regulates actin-myosin 
contraction. TFM may also enable subtle changes to be detected in cytoskeletal 
tension on the stiff substrate due to hypoxia, which were not detected here.  
Treatment of the carcinoma cell line- SCC-61 with Calyculin A on soft PA gels by Jerrell 
et al, resulted in an increase in cell protrusions required for ECM remodelling [552]. 
Calyculin A is a pan-phosphatase inhibitor and is used to increase MLC2 
phosphorylation and contraction [553]. In the present study therefore, the increase 
in cell protrusions and decrease in circularity on the 0.5KPa substrates due to 
hypoxia, in view of the findings by Jerrel et al, are suggestive of hypoxia-mediated 
actin-myosin contraction.  Once again, techniques such as TFM would be required to 
provide robust evidence of increased cytoskeletal tension induced by hypoxia. Based 
on observations here, it is possible to only suggest that hypoxia increases actin-




The differences in the effect of hypoxia observed between the soft and stiff 
substrates may be due to an alterations in cell attachment sites. Hypoxia has been 
established as an inducer of ECM formation both in experiments conducted here and 
in the literature. Increased expression of ECM components such as fibronectin and 
collagens are induced by hypoxia for example during hESC proliferation and 
migration [541] and during hMSC chondrogenesis [272]. An increase in mRNA 
expression of genes encoding ECM-modifying enzymes has also been demonstrated 
by fibroblasts and chondrocytes cultured under hypoxic conditions [554]. Cell 
secreted ECM components have been demonstrated to increase cell attachment and 
spreading and proliferation of hMSCs [555].  In addition, fibronectin-coated surfaces 
which were observed to provide attachment sites for other ECM proteins in addition 
to a greater number of binding sites for seeded cells [556]. The use of fibronectin-
coated surfaces here may suggest that hypoxic culture increases the number of cell 
attachment sites. This may rationalise the observation of increased cell and colony 
spreading on the 0.5KPa substrates which may not occur on the 40KPa substrate due 
to the maximal spreading already observed at normoxia on this surface.  
Despite evidence of hypoxia inducing ECM formation and hBM-MSC spreading on the 
soft substrate, this theory of increased attachment sites remains speculative. ECM 
quantification on the soft substrate would need to be conducted in combination with 
quantification of cell attachment sites in response to hypoxic incubation. The latter 
suggestion may be conducted via semi-quantification of mature focal adhesions 
following their immunodetection. To robustly validate this theory, treatment of 
integrin-blocking antibodies/inhibitors would be required at the onset of 




increases in cell adhesions are mediating MSC spreading, then these cell shape 
changes would be abolished in the presence of an integrin blocker. 
The increase in phosphorylated MLC2 observed in the present study on the 0.5KPa 
substrate, suggests an induction of RhoA/ROCK due to hypoxia. However unlike that 
previously demonstrated [372], an increase in RHOA/ROCK1/ROCK2 mRNA was not 
observed, with a trend towards an increase in ROCK1 transcription observed only. 
This suggests that hypoxia may induce its effect on MLC2 phosphorylation indirectly 
by regulating components upstream of RhoA/ROCK1/ROCK2. Indeed, reduced 
oxygen concentration has been shown to increase expression of specific integrins 
which would indirectly regulate RhoA/ROCK activity and MLC2 phosphorylation. Lee 
et al observed an increase in total expression of Integrin-β1 in human ESCs due to 
hypoxic incubation. An Integrin-β1-blocking antibody was subsequently shown to 
reduce hypoxia-mediated increases in cell attachment to cell-secreted fibronectin 
[541]. Indeed, with the use of integrin blocking molecules here, this theory can be 
investigated. Alternatively as suggested above, the upregulation of phosphorylated 
MLC2 may be due to increases in cell attachment sites which arise as a result of 
hypoxia-increased ECM. Increases in ECM ligand availability would induce integrin 
engagement and clustering followed by focal adhesion maturation and RhoA/ROCK 
activation [557].  
In addition to the differences observed in hBM-MSC area between stiff and soft 
substrates at normoxia, the increased nuclear YAP localisation observed in cells on 
the 40KPa substrate contrasts with that observed on the 0.5KPa substrate in which a 




as inducing differential activation of integrin-mediated cytoskeletal tension due to 
demonstration that YAP/TAZ nuclear localisation is controlled by this pathway [330].  
The increase in cell area and ROCK activity observed due to hypoxia on the 0.5Kpa 
substrate, prompted investigation of the oxygen-dependant regulation of YAP/TAZ. 
Interestingly, a decrease in nuclear YAP localisation occurred due to hypoxia on the 
40KPa substrate, despite no changes observed in cell shape or ROCK activity due to 
this condition. Additionally, unlike that previously described of the mechano-
regulation of YAP/TAZ, this decrease was not accompanied by an increase in cytosolic 
YAP/TAZ localisation. Rather, a decrease in global YAP/TAZ was observed due to 
hypoxia. This indicates that YAP/TAZ are not mechanosensitive in this context. This is 
also supported by lack of YAP/TAZ regulation on the soft substrate due to hypoxia, 
despite this oxygen state inducing changes in actin organization and ROCK activity on 
the soft surface. That observed may therefore be due to proteosomal degradation of 
YAP/TAZ under hypoxic conditions, which is induced by the Hippo pathway and YAP 
phosphorylation [558]. As conducted by Dupont et al, the involvement of the Hippo 
pathway may be assessed by siRNA of the Lats kinases which are responsible for 
phosphorylating YAP and targeting it for proteasomal degradation.  
Hypoxia appeared to increase the number of colonies in relation to the number of 
single cells on both the 40 and 0.5KPa substrate. The total cell number on each 
substrate demonstrated a trend towards increase, but these changes were 
insignificant and to a lesser magnitude than the increases observed of colony 
number. Together with the lack of increase in cell number per colony, this suggest 




but rather a migration together or condensation of cultures. This is also supported 
by our observation of a hypoxia-induced increase in the proportion in cells that are 
present within colonies compared to single cells, as a percentage of the total cell 
number. However, a limitation of this study is a lack direct quantification of cell 
proliferation. This may be achieved via immune-detection of cell cycle markers which 
are indicative of cell division, for example the nuclear antigen Ki67. Alternatively 
incorporation and immuno-detection of 5-bromo-2’-deoxyuridine in newly 
synthesized DNA would delineate actively-dividing cells. 
Provot et al observed that the limb bud condensations prior to chondrogenesis are 
hypoxic but that deletion of HIF-1α which was induced by this hypoxic state, did not 
inhibit formation of this condensation [262]. The observation that hypoxia induces 
HIF targets, VEGFA and EGLN in our study indicates that HIF-1α may be mediating the 
observed effects on the hBM-MSCs. This therefore, places discrepancy between that 
observed of the condensations due to hypoxia here and in the study by Provot et al. 
Therefore, we cannot rule out a HIF-1α-independent function of hypoxia during 
condensation, and the conditional knockdown of this transcription factor in the study 
by Provot et al does not take in account such mechanisms. Vogler et al observed that 
the increases in vinculin-containing focal adhesions, Integrin-β1 immunodetection 
and cell spreading due to hypoxic culture of L292 fibroblasts which were not 
abolished upon HIF-1α knockdown [559]. The involvement or not of HIF-1α in 
hypoxia-induced condensation however, is purely speculative without genetic 
manipulation or chemical inhibition of HIF-1α during this process. Such an 
experiment could be conducted by the use of Acriflavine as in the chapter 4, or via 




Despite hypoxia inducing cell-cell contact on both 40 and 0.5KPa substrates, there 
was a noticeable difference between the colonies formed on each substrate. As with 
single cells, hBM-MSC condensations on the 0.5KPa substrate exhibited a more 
compact shape than those on the stiff material with an almost ten-fold difference in 
colony area observed. As described by many studies, the compact colonies formed 
on the soft substrate may be more conducive for downstream chondrogenesis. One 
of the pioneering studies investigating this phenomenon was that by Tacchetti et al 
who observed a decrease in the chondrogenesis of chick limb bud mesenchymal 
progenitors upon their separation into single cell cultures [560].  
The condensation of hBM-MSCs here on the 0.5KPa substrate due to hypoxia and the 
more compact nature of these compared to that of the stiff surface, corresponds to 
the increase in NCAM mRNA expression. This protein is essential for cell-cell adhesion 
and subsequent chondrogenesis. Widelitz et al observed a significant reduction in 
the aggregate size of chick limb bud micromass cultures upon incubation with an anti-
NCAM antibody with a dose-dependent reduction in chondrogenesis also exhibited 
[561]. These authors also demonstrated an increase in aggregate formation due to 
NCAM overexpression, with an accompanying increase in Collagen Type II expression.  
Studies investigating the expression pattern of cell-adhesion molecules during limb 
bud chondrogenesis such as that by Tavella et al, have observed a peak in expression 
of N-Cadherin which preceded that of NCAM [562]. These authors suggested the 
requirement of N-Cadherin in initiation of limb bud condensation with NCAM 
functioning to strengthen and maintain cell-cell adhesions. The lack of increase in N-




suggests that reduced oxygen concentrations in this context does not initiate 
condensation, but acts to maintain it. A limitation of the study however, which would 
enable validation of this theory, is the lack of NCAM gene expression at time points 
following 24 hours. Latent expression of this gene would suggest the constitutive role 
of NCAM in hypoxia-induced condensations. In addition, the roles of N-Cadherin and 
NCAM, are not directly implicated in the hypoxia-induced condensations observed 
here of BM-MSCs. Blocking or genetic manipulation of these adhesion proteins would 
be required in order to confirm their role or lack thereof in these observations. 
The rationale behind examining crosstalk between the hypoxic pathways and those 
stimulated in response to changes in the mechanical microenvironment, is for 
informing interaction of these pathways during chondrogenesis. Such a study would 
contribute to the knowledge of cartilage development from the mesenchymal limb 
bud. It would also aid cartilage tissue engineering strategies which aim to combine 
the effects of an appropriate mechanical environment with an oxygen gradient which 
mimics that of physiological levels in the limb bud and growth plate. Unlike other cell 
fates in which a round cell and low basal ROCK-mediated cytoskeletal tension is 
required for their differentiation [304, 307], chondrogenesis appears to be an 
anomaly. Strong evidence exists for the requirement of higher levels of ROCK activity 
and cytoskeletal tension during chondrogenesis of stem cells in which the actin 
cytoskeleton is in a cortical configuration. For example, ROCK inhibition or ablation 
of myosin light chain contraction appears to reduce chondrogenesis of ATDC5 cells 
on a relatively soft substrate in which actin fibres adopt a cortical arrangement [355]. 
This is also supported in the investigation carried out by Ray et al, who demonstrated 




progenitors of the limb bud and for subsequent mRNA expression of SOX9 and 
COL2A1 [353].   
In the present study, hypoxic incubation of hBM-MSCs on the 0.5KPa substrate, 
appeared to express increased levels of mRNA conducive for induction. This includes 
that of SOX9, and a trend towards an increase of COL2A1, PRX1 and MSX1. Despite 
inducing COL2A1 expression, which may be also be stimulated by cell condensation 
as opposed to part of a specific differentiation program, hypoxia does not appear to 
induce expression of other early chondrogenic markers on the 40KPa substrate. 
Indeed, MSX1 expression appears to be inhibited on this stiffness by hypoxia. A 
limitation of this study is represented by the relatively few genes chosen to represent 
early chondrogenic induction, and the even fewer genes whose expression were 
significantly altered due to hypoxia. As with any cellular process, expression of SOX9 
is not enough to robustly denote chondrogenesis and requires other early markers 
to confirm commitment down a chondrogenic lineage. For example expression of 
SOX5 and SOX6 may represent other suitable candidate genes, in addition to 
osteoblastic/hypertrophic markers such as RUNX2 or COL10A1. Examination of these 
genes would enable confirmation or not of the single and specific lineage 
commitment of the BM-MSCs in hypoxic conditions. 
The trend towards a chondrogenic expression due to hypoxia on the soft substrate 
only, appears to correlate with observations in which cell area increased and cell 
circularity decreased compared to no such effect on the stiff substrate. Together with 
the upregulation of MLC2 phosphorylation on the soft substrate only, this indicates 




required for chondrogenesis in cells with a cortical actin arrangement. However it is 
important to note that this role of hypoxia is based only on correlative observations 
of cytoskeletal tension with changes in chondrogenic gene expression at the same 
time point. Therefore in order to robustly demonstrate the ability of hypoxia to 
induce chondrogenesis via increased ROCK-mediated cytoskeletal tension, it would 
be required to use chemical inhibitors of actin-myosin contraction during this 
process. Such experiments may be achieved through the use of inhibitors of both 
ROCK and myosin contraction (Y-27632 [305]) and Blebbistatin respectively during 
hBM-MSC chondrogenesis induced by hypoxia. Observation of differential 
chondrogenic mRNA when compared with that in which ROCK and myosin 
contraction are not inhibited, would enable a role to be determined of ROCK-
mediated cytoskeletal tension. 
The increase in number of compact condensations due to hypoxia on the 0.5KPa 
substrate and transcription of NCAM, suggests a mechanism behind the observed 
hypoxic-induction of SOX9. However as with suggested experiments which would 
directly implicate N-Cadherin and NCAM in hypoxia-induced condensations, it would 
be required to chemically or genetically manipulate these adhesion proteins to 
determine their role during downstream chondrogenesis. Furthermore, to enable 
demonstration of a direct relationship between cell condensation and cartilage 
differentiation, it may be required to analyse expression of early chondrogenic 
markers at time points following condensation at day 1. This may enable observation 
of a downstream, latent effect of cell condensation on chondrogenesis. This 




be determined between chondrogenesis and actin re-arrangement/ROCK activity 
induction on the soft substrate due to hypoxia.   
Results here which investigated the formation of more mature cartilage tissue 
demonstrate day 21 increases in SOX9 and COL2A1 mRNA on the 0.5KPa substrate 
compared to that on 40KPa as previously described [355, 358]. However, despite the 
greater effect of hBM-MSC chondrogenesis on the soft substrate at day 1, 21-day 
cultures exhibit greater chondrogenesis due to hypoxia on the stiff substrate. 
Hypoxia appeared to increase COL2A1 transcription on the stiff substrate whilst 
inducing a reduction of this transcript on the soft surface. This also correlated with 
that of Collagen Type II protein levels which indicates that this effect of hypoxia is 
stable enough to induce changes in cartilage ECM composition. An important caveat 
to this observation is the lack of quantification of collagen type II which would clearly 
demonstrate this suggested advantage of the stiff substrate in response to hypoxic 
incubation. Additional observations which were not taken in this study would also 
more robustly demonstrate the synergistic role of hypoxia and mechanosignalling 
during chondrogenesis. One such example would be an increase in time points prior 
to day 21 at which articular chondrogenic gene expression is analysed. This would 
enable a more detailed examination of gene expression during chondrogenic lineage 
commitment in response to the combination of soft/stiff substrates with hypoxia. In 
addition, quantification of collagen type X protein would demonstrate the advantage 
of this combination for chondrogenesis over methods which do not utilise hypoxia or 




Interestingly, hypoxia only raised levels of VEFGA and EGLN in cells on the 40KPa 
substrate only at day 21. This suggests that the signalling pathways stimulated in 
response to a stiff substrate are conducive for expression of genes which contain a 
HRE. This contrasts with that on the 0.5KPa surface at day 21 on which transcription 
of these genes by hypoxia appears to be suppressed. This is also at odds with day 1, 
at which hypoxia induced increases in VEGFA and EGLN expression on both 
substrates. This therefore suggests a change in the crosstalk between the HIF and 
mechanotransducive pathways from day 1 to day 21 of chondrogenesis which results 
in differential induction of HIF-mediated transcription and chondrogenesis. An 
improvement in the experiment design and one which would enable investigation of 
this phenomenon is the analysis of VEGFA and EGLN expression between days 1 and 
21 of chondrogenesis. This would enable determination of the point at which the soft 
substrate becomes inhibitory to hypoxia-mediated expression of HRE-containing 
genes. 
The involvement of the mechano-sensing pathways in HIF-mediated transcription 
was suggested by observations here of Y-27632 inhibiting hypoxia-mediated 
increases in COL2A1, VEGFA and EGLN mRNA in hBM-MSCs differentiated on TCP. 
This suggests that ROCK-mediated cytoskeletal tension on the stiff substrate is 
required for hypoxia-induced chondrogenic gene expression. The caveat to this 
observation is that TCP is magnitudes greater in stiffness than the 40KPa substrate 
and does not include the fibronectin-coated surface. It is therefore unable to fully 
represent the mechanically stiff substrate of 40KPa in terms of its effects on hBM-




Taken together, the evidence in this chapter points to the ability of hypoxia to 
specifically regulate cell morphology, actin dynamics, cell condensation and 
downstream chondrogenic gene expression in hBM-MSCs. Interestingly, this effect 
of hypoxia appeared to be dependent on the mechano-sensing pathways stimulated 
by specific ECM stiffness values. The early induction of a milieu conducive for 
chondrogenesis on the soft substrate only, appeared to be via a unidirectional 
mechanism in which hypoxic pathways regulate those involved in sensing of 
mechanical signals, and not vice-versa. At day 21 however, there was a trend which 
indicated the dampening of hypoxic signalling in cells cultured on the soft substrate, 
with increases in hypoxia-mediated chondrogenesis observed on the stiff biomaterial 
only. This indicates that the pathways induced by hypoxia and those by mechanical 
stimuli are tightly intertwined with each regulating the activity of the other at 
different time points throughout chondrogenesis.  
The differential effect of hypoxia on soft and stiff substrates throughout 
chondrogenesis suggests the requirement of a biomaterial system of dynamic 
stiffness is to be utilised in order to realise the potential of hypoxic signalling in CTE. 
Guvendiren and Burdick investigated the effect of hydrogels which are able to stiffen 
over a 14-day time period on the mechanosensing and lineage commitment of 
hMSCs [303]. In this study, hMSCs exhibited the characteristic features of cells on 
relative soft substrates with cortical actin arrangement, low cytoskeletal tension and 
adipogenic cell fate favoured prior to gel stiffening. This contrasted with stress fibre 
formation, increased cytoskeletal tension and osteogenesis of hMSCs following 
hydrogel stiffening via increased crosslinking of the free HA methacrylated arms. In 




methacrylated HA hydrogels to induce a cell response indicative of their culture on a 
stiff substrate compared to that exhibited on a soft material [563]. Biomaterial 
systems such as these which are able to stiffen in situ may be highly conducive for 
hypoxia-mediated chondrogenesis throughout the entire chondrogenic period. Such 
scaffolds would demonstrate the potential for hypoxia and mechano-signalling 







Taken together, the results outlines in chapters 3, 4 and 5 demonstrate the 
complexity of regulatory mechanisms which govern hypoxia/HIF signalling and the 
activity of these pathways during hBM-MSC chondrogenesis. The requirement for 
lower oxygen concentrations than 5% is suggested due to the inability of this hypoxic 
level to induce expression of HIF target genes at day 14 of chondrogenesis compared 
to 2%O2 which did so at day 1 and day 14 of culture. The literature is suggestive of 
the effect of differing oxygen concentrations on inducing differential HIF-1α 
upregulation only at a threshold hypoxic state [396]. This could be hypothesized to 
be due to a negative feedback loop in which HIF stimulation by milder hypoxic states 
is overcome by EGLN transcription and PHD2-mediated degradation of HIF-1α [411]. 
This may be investigated by utilising a hBM-MSC line in which HREs are deleted from 
the promoter of the EGLN locus [411]. The hypothesis for such a study would be that 
stimulation of HIF-mediated gene expression by 5%O2 would not be subject to 
dampening by PHD2-mediated negative feedback in these transgenic HRE-deleted 
cell line compared to that conducted with wild type hBM-MSCs.  
The mild induction of HIF by 5%O2 could be due to factors present uniquely during 
chondrogenic differentiation. For example, Ascorbate as an essential co-factor for 
PHD2 which has been shown to reduce HIF-1α compared to basal conditions [430]. 
This may therefore result in an abolishment of any mild HIF induction by 5%O2 
whereas 2%O2 is able to overcome this Ascorbate-mediated upregulation of PHD2 
activity. TGF-β signalling has been shown to also raise HIF-1α levels in normoxic 




be unable to be induced further by mild hypoxic states at later time points when 
subject to negative feedback loops.  
The effects of both Ascorbate and TGF-β on hypoxic signalling may be investigated 
by the effects of their supplementation on HIF-1α upregulation and HIF activity in the 
presence of 5%O2 and 2%O2 at later time points in chondrogenesis. The hypothesis 
in such a study would be: Ascorbate treatment downregulates HIF-1α induction by 
5%O2 and downstream HIF activity, whereas 2%O2 is able to overcome this. In terms 
of the effect of TGF-β signalling, treatment with this growth factor would be 
hypothesized to induce HIF-1α at normoxia and therefore this would be unable to be 
further induced by 5%O2 but possible by 2%O2. Together, the results here combined 
with that previously described, suggests that hypoxic signalling during BM-MSC 
chondrogenesis is not able to be easily induced by a mild lack of oxygen. Instead, 
lower oxygen levels beyond a specific threshold may be required for stimulation of 
HIF in chondrogenically-induced BM-MSCs. 
The experiments conducted in the second chapter of this thesis investigated the 
effects of varying the bio-availability of a single PHD2/FIH substrate- oxygen, on 
downstream HIF activity. However, results in the second chapter instead 
demonstrate the effect of reducing the bio-availability of different PHD2/FIH co-
factors on HIF-mediated gene expression, namely 2-OG and Fe2+. DMOG, a 2-OG 
analogue has a greater effect on HIF target gene expression than that induced by 
either chelating or competing with Fe2+ using DFX or CoCl2 respectively. These results 




mechanisms which are dependent more on 2-OG than those controlled by 
intracellular Fe2+ levels.  
The relative roles of 2-OG and Fe2+ in HIF regulation could be investigated by 
examining the effect of 2-OG and Fe2+ supplementation on HIF-1α upregulation and 
HIF-mediated transcription during chondrogenesis. The hypothesis for such an 
investigation would be as follows: 2-OG supplementation more potently inhibits 
hypoxic induction of HIF compared to that induced by Fe2+ during BM-MSC 
chondrogenesis. Alternatively, inhibitors other than DMOG, DFX or CoCl2 which 
either reduce 2-OG or Fe2+ bioavailability may be utilised. Such compounds include 
N-Oxaloylglycine (NOG), another 2-OG derivative and Ciclopirox Olamine (CPX), an 
iron chelator [564]. Observations of the effect of NOG and CPX on HIF-mediated 
transcription may enable confirmation or rejection of the hypothesis that the effects 
of DMOG, DFX and CoCl2 in this study are not specific to these compounds but rather 
are representative of the effect of reducing 2-OG or Fe2+ availability. Results from 
such a study would uncover key regulatory elements of HIF during chondrogenesis. 
The mechanisms of these 2-OG-dependant processes which regulate HIF are 
suggested by the literature. For example, DMOG has been shown to inhibit both FIH 
and PHD2-mediated hydroxylation of HIF-1α compared to inhibition of PHD2 alone 
due to DFX or CoCl2 treatment [453]. This mechanism of action of DMOG may 
mediate its potent HIF-stimulation observed in the present study and is suggested 
due to observation that siRNA knockdown of FIH and PHD2 compared to PHD2 only, 
enhances HIF-mediated transcription [451]. Therefore it is a necessity to build on 




effect of DMOG in stimulating HIF-dependent transcription during cartilage 
development compared to that induced by DFX or CoCl2. Such studies would be key 
in elucidating regulatory mechanisms of a pathway which are essential for 
chondrogenesis.  It would also provide information of the specific chemical inhibition 
required for constitutive HIF stimulation throughout chondrogenic induction of hBM-
MSCs. An initial requirement for such a study would be to identify if DMOG, 
compared to the effect of DFX or CoCl2, inhibits both FIH and PHD2 and their 
respective hydroxylating functions of asparagine and proline residues of HIF-1α. It is 
possible to identify such post-translational modifications by the use of antibodies 
which are specific for hydroxylated asparagine and proline residues [453].  
Following confirmation that DMOG inhibits both these hydroxylases compared to 
that due to DFX or CoCl2, it would be required to investigate if this mechanism is 
responsible for the potent pro-chondrogenic effect of DMOG. This may be achieved 
by PHD and FIH overexpression [565, 566] in chondrogenically-induced BM-MSCs. 
The hypothesis for such a study would be as follows: Overexpression of both PHD2 
and FIH reduces DMOG-induced HIF activity and BM-MSC chondrogenesis compared 
to that in which either hydroxylase alone, or neither, is overexpressed. 
Chapters 3 and 4 suggest the differential effects of varying hypoxic states and 
bioavailability of different PHD2/FIH substrates on HIF signalling. In addition, hypoxic 
signalling that is conducive for chondrogenesis may also be subject to regulation by 
pathways which are stimulated in response to changes in ECM stiffness. In the 
present study, at an early stage of chondrogenesis, hypoxia induced expression of 




MSCs cultured on mechanically soft substrates. This is in comparison to a lack of 
effect of hypoxia on stiffer substrates. These observations suggest that pathways 
stimulated in response to a relative low ECM mechanical stiffness, are conducive for 
hypoxia-induced chondrogenic gene expression. This is in contrast to that which 
occurs of hBM-MSCS on a stiff substrate in which hypoxia-mediated induction of 
chondrogenic gene expression is suppressed. As described previously, cells in which 
a cortical actin arrangement is exhibited, express higher levels of chondrogenic 
markers compared to cells in which a spread actin network and long stress fibres are 
observed [354]. Previous evidence in the literature suggests that ROCK-mediated 
responses to changes in ECM stiffness are required for this chondrogenic bias in cells 
of a rounded morphology [355]. This suggests the significance of findings in the 
present study, specifically the correlation on the soft substrate, between 
chondrogenic gene expression, ROCK activity and cytoskeletal rearrangement in 
hypoxic conditions.  
The observations on the soft substrate in hypoxic conditions, prompt further 
experiments to investigate the role of ROCK-mediated actin re-arrangement during 
hypoxia-induced chondrogenesis. This aim may be addressed through the use of 
inhibitors of both ROCK and myosin contraction (Y-27632 and Blebbistatin 
respectively). Observation of changes in hypoxia-induced cartilage mRNA and protein 
due to Y-27632 and Blebbistatin, would enable a role to be determined of ROCK-
mediated cytoskeletal tension during chondrogenesis in low-oxygen conditions. The 
findings of such experiments would be relevant for studies of cartilage development 
and tissue morphogenesis in which mechanotransduction and hypoxic pathways play 




the early mesenchymal limb bud stage, through to adult articular cartilage 
homeostasis [259, 262].  
Observation that hypoxia induces formation of compact colonies and mRNA 
expression of NCAM is suggestive of another mechanism by which this oxygen state 
is conducive for chondrogenesis. NCAM plays a role in maintaining cell-cell adhesion 
in the mesenchyme of the limb bud following initiation of these adhesions by N-
Cadherin [61]. Therefore, experiments which enable investigation of the role of 
hypoxia-induced NCAM expression during chondrogenesis of hBM-MSCs, would be 
informative of similar mechanisms which occur in the limb bud during cartilage 
development [567]. Such an experiment may involve siRNA knockdown of NCAM in 
hBM-MSCs which would enable observation of the role of NCAM in both 
condensation of these cultures and downstream chondrogenesis when compared to 
cells in which NCAM expression is not abolished [568]. 
Perhaps most importantly, this study informs strategies for cartilage tissue 
engineering and are suggestive of advantageous technologies for repair of acute 
chondral defects. The results from chapter 3 are suggestive of a role for either severe 
or mild hypoxia in inducing HIF-stabilisation and changes in Collagen Type II and X 
production during BM-MSC chondrogenesis. However, the potential disadvantages 
of physiological hypoxia include the induction of UPR and global inhibition of 
translation, both of which are inhibitory to stem cell differentiation. In addition, 
logistical issues may accompany incorporation of sub-atmospheric oxygen levels into 
biomaterial scaffolds for delivery into the patient injury site. Therefore, compounds 




CTE strategies in which only growth factors are used to promote chondrogenesis and 
which often result in hypertrophy and mineralisation of de novo tissue.  
Results in chapter 4 indicate the ability of DMOG for stable HIF stimulation and hBM-
MSC chondrogenesis. This demonstrates the potential for competitive 2-OG 
inhibitors in CTE. Incorporation of DMOG into a scaffold was demonstrated by Min 
et al for the purpose of increased angiogenesis in bone critical defects in a rat model 
[569]. These authors observed the sustained release of DMOG from 3D-printed 
polymer scaffolds over a 28-day period and demonstrated the ability of DMOG 
release in this manner to induce transcription of HIF target genes both at day 1 and 
14 of hBM-MSC culture.  
The potent HIF-mediated chondrogenic gene expression that was induced by DMOG 
however, was offset with the detrimental effect on Collagen Type II in the ECM of 
differentiated BM-MSCs. This was alleviated with treated of DMOG for the final third 
of the differentiating period, which also maintained expression of genes conducive 
for chondrogenesis. In order to address the requirement for late DMOG treatment in 
CTE, delayed-release scaffolds such as demonstrated by Jaklenec et al may be 
employed. These authors demonstrated the release of IGF-1 from PLGA scaffolds 
only between days 7 and 14, with no IGF-1 released prior to this time point [570]. As 
an alternative to DMOG, completion of suggested further experiments which 
examine the mechanism of action of this 2-OG analogue during chondrogenesis (e.g. 
FIH and PHD inhibition as opposed to PHD2 ablation alone), may highlight the 
usefulness of more specific inhibitors whose continuous treatment does not abolish 




The results in chapter 5 suggest a crosstalk between the hypoxic pathways and those 
activated in response to changes in mechanical stiffness. Hypoxia-induced expression 
of chondrogenic markers, ROCK activation and cytoskeletal arrangement shown to 
be conducive for chondrogenesis were only stimulated in hBM-MSCs differentiated 
on a soft substrate. Therefore, it may be critical to ensure that DMOG/HIF stimulating 
compounds are incorporated into biomaterial scaffolds of a relatively low stiffness in 
which actin adopts a cortical arrangement. This combinatorial induction of hypoxic 
pathways and those activated in response to a soft microenvironment may offer 
greater levels of chondrogenesis compared to that in which either set of pathways 
are enhanced alone. 
In order for robust conclusions to be made based on observations here and the 
described interpretations, the major experimental limitations of this study must be 
identified and addressed. The specifics of these have already been described in the 
discussion sections of each chapter, but one of the aims of this chapter is to 
summarise the caveats of the study presented here. One limitation of this study and 
one which may have omitted observations of key hypoxia-induced effects on 
chondrogenesis, are the time points chosen for analysis of gene expression. Evidence 
here suggests correlation between expression of specific gene products, such as 
SOX9 with its target, COL2A1 or RUNX2 with that of COL10A1. However in order to 
validate these correlations, It would be a requirement to utilise more frequent time 
points throughout chondrogenesis. To confirm the role of a transcription factor in 
mediating the chondrogenic effect of hypoxia/a HIF-stimulating compound, genetic 




In addition to re-evaluation of time points at which samples are harvested during 
chondrogenesis, the number of genes chosen to denote a specific cellular process 
may need to be expanded. For example, HIF activity or early chondrogenic induction 
in this study have been delineated with expression of genes which represent only a 
subset of loci that are transcriptionally-active during these processes. By selecting a 
broader range of genes, the induction of these cellular processes will be more clearly 
demonstrated if they exist. This would also be enabled by quantification of specific 
proteins as oppose to a reliance placed solely on gene expression analysis. For 
example, quantification of HIF-1α or ECM proteins would enable the respective 
processes of HIF stabilisation and articular chondrocyte function to be more robustly 
assessed. 
Another limitation to this study is represented by the nature of BM-MSCs. The 
adherence in this study to the ISCT criteria for BM-MSC characterisation, may negate 
sub-populations of cells which are adherent and capable of adipogenic, chondrogenic 
and osteogenic lineage commitment. This is due to observation by others of BM-
MSC-like characteristics exhibited by cells sorted by markers such as Stro-1 and 
CD271 [170, 571] which were not used here. This lack of uniformity within the BM-
MSC field in terms of the markers which define BM-MSCs, may suggest that the 
observations here are not representative of a true BM-MSC population. Such a 
population which would be viable for CTE or study of mesenchymal development, 
may consist of subgroups of cells defined by different subsets of markers. This 
represents a limitation of this study as each of these subgroups may exhibit different 




 Finally, the use of BM-MSCs from a single donor also represents a limitation of this 
study. This is due to the differential phenotype of BM-MSCs isolated from young/old 
patients, male/female or OA patients for example, and their potential differential 
response to hypoxia-mediated chondrogenic induction [572]. This is particularly 
important due to the requirement for harvesting autologous BM-MSCs for repair of 
chondral defects or for treatment of cartilage-related diseases. By discounting the 
effect of the experimental conditions used here on BM-MSCs derived from differing 
population groups such as age or sex, we may also omit key differences in their 












The purpose of the research presented here was to investigate the potential role of 
hypoxia and its downstream signalling factor, HIF in CTE strategies for repair of acute 
chondral defects. The data here demonstrates, in the broadest sense, the complexity 
with which HIF/hypoxic signalling is regulated during chondrogenesis. By 
understanding this complexity, it may be possible to develop technologies which 
enable greater levels of HIF stimulation and downstream chondrogenesis. For 
example, it is important to understand the type of chemical inhibition required to 
achieve maximal HIF-mediated transcription, in addition to the mechanical 
environment that is conducive for HIF-mediated signalling.  
Additionally, this study provides evidence for the multitude of effects of hypoxia 
which are beneficial for articular cartilage, be it chondrogenic induction of stem cells, 
collagen maturation, or inhibition of hypertrophy.  Such insights may not only 
improve stem cell chondrogenesis in CTE, but may also inform the development of 
other cartilage-related treatments. For example, stimulation of ECM formation by 
articular chondrocytes may improve ACI/MACI-based strategies. Alternatively, work 
such as that presented here provide insights into HIF-related therapies for treatment 
of diseases such as OA in which cartilage is remodeled and degenerated. Finally, by 
taking the studies here forward and dissecting the mechanisms behind HIF-mediated 
chondrogenesis, it may be possible to further refine therapeutic strategies for 
damaged cartilage. This may be via stimulation of specific HIF-mediated effects, as 




















96 0.34 5.1x104 0.2 1.02x104 3.0x104 
24 2 6.0x104 1.0 6.0x104 3.0x104 
12 3.8 5.7x104 2.0 1.146.0x105 3.0x104 
6 9 9.0x104 3.0 2.706.0x105 3.0x104 
 
Appendix figure 1. Concentrations of cell suspensions made from master stock prior 


















Appendix figure 3. Cell number throughout chondrogenesis in control conditions, 
utilising the PicoGreen Assay. Values plotted represent the mean from 3 independent 
experiments and are a percentage of the cell number at day 0. Error bars show the 















Appendix figure 4. Comparison of TGF-β1 and TGF-β3 for inducing presence of GAGs 
in ECM. Alcian Blue, Picosirius Red and Haemotoxylin staining of hBM-MSCs and 
Bovine Chondrocyte pellets in presence of TGF-β1/TGF-β3-containing chondrogenic 
media. A+B: hBM-MSCs at day 21 of culture in expansion conditions. C+D: hBM-MSCs 
at day 21 of chondrogenic induction in presence of TGF-β1 (C) and TGF-β3 (D). E+F: 
Bovine chondrocyte cultures at day 14 of culture in chondrogenic media consisting 
of TGF-β1 (E) and TGF-β3 (F). G+H: Bovine chondrocyte cultures at day 21 of culture in 








Appendix figure 5. Histological processing of hBM-MSC and bovine chondrocyte 
pellets.  
  
Chemical processing of cell pellets for wax embedding 
Solution Treatment time 
  70% (v/v) IMS 15 minutes 
  90% (v/v) IMS 15 minutes 
100% (v/v) IMS            15 minutes 
100% (v/v) IMS            15 minutes 
100% (v/v) IMS            15 minutes 
100% (v/v) IMS            15 minutes 
Xylene 15 minutes 
Xylene 15 minutes 
Xylene 15 minutes 
Ultraplast Wax 15 minutes 
Ultraplast Wax 15 minutes 




Solution Treatment time 
Histoclear 2 x 10 minutes 
100% (v/v) IMS 2 minutes 
90% (v/v) IMS 2 minutes 
70% (v/v) IMS 2 minutes 
50% (v/v) IMS 2 minutes 
Deionised water 2 minutes 
Alcian Blue pH 1 10 minutes 
Drain and blot dry   
Deionised water Quick rinse 
Ehrlich’s Haematoxylin 2 minutes 
Running water 10 minutes 
Deionised water Quick rinse 
Phosphomolybdic acid (2.5% (v/v)) 10 minutes 
Deionised water Quick rinse 
Sirius Red F3B (0.5% (w/v) in saturated 
picric acid) 
1 hour 
Acetic acid 0.5% (v/v) 2x Quick rinse 
Drain and blot dry   
100% IMS 3 x 5 minutes 
Histoclear 2 x 5 minutes 
 
Appendix figure 6. Alcian Blue, Picosirius Red and Haemotoxylin staining protocol 

















No. Cycles Cycle Duration Temperature 
1 3 mins 95○C 
39 5 secs 95○C 





Forward Primer Sequence Reverse Primer Sequence Concentration 
(nM) 
VEGFA AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA 250 
PGK1 TGGACGTTAAAGGGAAGCGG GCTCATAAGGACTACCGACTTGG 250 
EGLN AGGCGATAAGATCACCTGGAT TTCGTCCGGCCATTGATTTTG 250 
SOX9 AGCGAACGCACATCAAGAC CTGTAGGCGATCTGTTGGGG 250 
COL2A1 CCAGATGACCTTCCTACGCC TTCAGGGCAGTGTACGTGAAC 500 
ACAN GTGCCTATCAGGACAAGGTCT GATGCCTTTCACCACGACTTC 500 
RUNX2 TGGTTACTGTCATGGCGGGTA TCTCAGATCGTTGAACCTTGCTA 250 
COL10A1 GGGGCTAAGGGTGAAAGGG GGTCCTCCAACTCCAGGATCA 250 
MMP13 ACTGAGAGGCTCCGAGAAATG GAACCCCGCATCTTGGCTT 500 
P4HA1 AGTACAGCGACAAAAGATCCAG CTCCAACTCACTCCACTCAGTA 250 
LOX CGGCGGAGGAAAACTGTCT TCGGCTGGGTAAGAAATCTGA 250 
DKK1 ATAGCACCTTGGATGGGTATTCC CTGATGACCGGAGACAAACAG 250 
GREM1 CGGAGCGCAAATACCTGAAG GGTTGATGATGGTGCGACTGT 250 
IHH AGACCGCGACCGCAATAAG GCCTTTGACTCGTAATACACCCA 250 
PTHRP AAGGTGGAGACGTACAAAGAGC CAGAGCGAGTTCGCCGTTT 250 
LEF1 TGCCAAATATGAATAACGACCCA GAGAAAAGTGCTCGTCACTGT 500 
AXIN2 AGCCAAAGCGATCTACAAAAGG AAGTCAAAAACATCTGGTAGGCA 500 
RHOA AGCCTGTGGAAAGACATGCTT TCAAACACTGTGGGCACATAC 500 
ROCK1 AACATGCTGCTGGATAAATCTGG TGTATCACATCGTACCATGCCT 250 
ROCK2 TCAGAGGTCTACAGATGAAGGC CCAGGGGCTATTGGCAAAGG 500 
CTGF AAAAGTGCATCCGTACTCCCA CCGTCGGTACATACTCCACAG 500 
ANKRD1 GCCTACGTTTCTGAAGGCTG GTGGATTCAAGCATATCACGGAA 250 
PRX1 TGATGCTTTTGTGCGAGAAGA AGGGAAGCGTTTTTATTGGCT 500 
MSX1 CTCCGCAAACACAAGACGAAC   CACATGGGCCGTGTAGAGTC 250 
NCAD TCAGGCGTCTGTAGAGGCTT ATGCACATCCTTCGATAAGACTG 250 
NCAM GGCATTTACAAGTGTGTGGTTAC TTGGCGCATTCTTGAACATGA 500 
RPL13A GCCATCGTGGCTAAACAGGTA GTTGGTGTTCATCCGCTTGC 250 
 
Appendix figure 7. qPCR reaction conditions and primer sequences. A: qPCR 









Target Protein Antibody Species Dilution Detection 
Ab/Method 
HIF-1α h206 (Santa Cruz) Rabbit 1:100 ab150077 
Collagen Type II ab34712 (Abcam) Rabbit 1:200 ab150077 
Collagen Type X ab49945 (Abcam) Mouse 1:250 Strep/Biotin 
YAP sc101199 (Santa Cruz) Mouse 1:100 Strep/Biotin 
pMLC2 3671S [573] Rabbit 1:100 ab150077 
 
B 
1○ Antibody Target Culture substrate Dilution 
HIF-1α TCP 1:200 
Collagen Type II TCP 1:1000 
Collagen Type II PA Gels 1:500 
pMLC2 PA Gels 1:500 
 
Appendix figure 8. Primary and secondary antibody details. A: Primary antibodies. 
B: α-Rabbit secondary antibody (ab150077) dilutions for conjugation to each primary 








Appendix Figure 9. During BM-MSC chondrogenesis, CoCl2, DFX and DMOG induce 
changes in the mRNA of genes whose products are involved in the Bone 
Morphogenetic Protein, Wnt and Indian Hedgehog signalling pathways. mRNA 
expression of DKK1 (A), GREM1 (B), AXIN2 (C), LEF1 (D), IHH (E) and PTHRP (F) 
throughout chondrogenesis. Values plotted are from 4 independent experiments and 
are fold change compared to the untreated control which is represented by the 
horizontal dotted line. The solid coloured lines representing the mean for each 
condition.  
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Appendix figure 10. A:  Volume of reagents used for synthesis of PA gels. B: 
Classification of colonies and single cells on PA gels. Single cells are outlined in white 
and colonies outlined in yellow. 
  
Acrylamide (μl) Bis acrylamide 
(μl) 
PBS (μl) APS (μl) TEMED 
(μl) 
E (kPa) 
75 30 895 10 1 0.5 
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